PPARγ connects energy metabolism to the integrity of the white adipose tissue by Anghel Ramond, Ioana Silvia et al.
UNIVERSITE DE GENEVE 
 
Département de Zoologie et FACULTE DES SCIENCES  
Biologie animale Professeur Denis Duboule 
 
 
UNIVERSITE DE LAUSANNE 
 
Centre Intégratif de Génomique FACULTE DE BIOLOGIE ET 
DE MEDECINE 
 Professeur Walter Wahli 
 
________________________________________________________________ 
 
 
 
 
PPARγ connects energy metabolism to the integrity of the white 
adipose tissue 
 
 
 
 
THESE 
 
présentée à la Faculté des sciences de l’Université de Genève 
 
pour obtenir le grade de Docteur ès sciences, mention biologique 
 
 
 
par 
 
 
Ioana Silvia Anghel Ramond 
 
de 
 
Montréal (Canada) 
 
 
 
 
Thèse n° 3865 
 
 
Lausanne, 2007 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Jury : 
 
Directeur de thèse : Professeur Walter Wahli  
Co-Directeur de thèse : Professeur Denis Duboule 
Membre du jury : Professeur Luc Tappy 
Membre du jury : Professeur Bernard Thorens 
 
 
 
 
 
 
 
 
                                                                           
   
 
 
 
 
 
 
 
 
  
 
 
 
 
 1 
Remerciements 
 
Remerciements 
 
Je tiens en tout premier à remercier le Professeur Walter Wahli de m’avoir accueilli dans son 
laboratoire au sein du Centre Intégratif de Génomique (CIG) et de m’avoir permis d’effectuer mon 
travail de thèse. Par l’intérêt et l’implication que vous avez apportés à mon sujet  de thèse vous 
m’avez permis d’évoluer et faire avancer ce projet. Je vous suis également reconnaissante pour la 
liberté que vous m’avez accordée tant dans les choix expérimentaux que dans les collaborations que 
j’ai pu établir, grâce à vous, avec plusieurs laboratoire de Suisse et d’ailleurs.  
Je remercie tout particulièrement, les Professeurs Luc Tappy et  Bernard Thorens d’avoir 
accepté de faire partie du jury d’évaluation de ce travail.  
Je remercie également, la Professeure Béatrice Desvergne pour ses nombreux conseils avisés 
dans le vaste domaine du métabolisme. Son aide m’a été précieuse.  
Tous mes remerciements à l’ensemble des membres des laboratoires Wahli et Desvergne, qui 
ont aidé à ce travail par leurs conseils. Une pensée toute particulière pour Elodie, Laurent, Liliane, 
Jérôme et Caroline pour leur aide précieuse et leur amitié. Grâce à toi Elodie, je comprends mieux 
maintenant que le métabolisme est truffé de gris, le noir et le blanc existent rarement ! Merci 
également à Alexandra Krauskof pour son aide précieuse lors de la préparation de ce manuscrit. 
J’adresse également mes remerciements au Professeur Didier Trono et aux membres de son 
laboratoire de l‘Ecole Polytechnique de Lausanne, à Céline Delucinge, Mylène Docquier et 
Christelle Barraclough de la Platforme Génomique de Genève. Sans leur collaboration, une partie ce 
travail de thèse n’aurait pas pu voir le jour. Merci également à Armelle Bauduret et Patrick Gouet et 
leurs équipes qui ont participé à ces projets.  
J’exprime également mes remerciements à l’égard du Pôle de Recherche National « Frontiers 
in Genetics »  qui m’a octroyé le financement de ma thèse et surtout, m’a permis, par les nombreux 
cours et séminaires, de  m’ouvrir encore plus à ce monde de la science. Un grand merci au Dr 
Stéphane Barges pour son aide avec tous les tracas administratifs et pour tous ses conseils.  
Enfin, je remercie ma famille de m’avoir soutenu et suivi dans ce choix, pas toujours si 
facile. Leur aide et soutien ont été déterminants pour mener à bien ce travail.      
 
 2 
Résumé 
 
Résumé  
 
Chez les mammifères, il existe plusieurs dépôts de tissus adipeux qui constituent dans 
l’ensemble ce que l’on pourrait nommer « l’organe adipeux ». En, effet on peut qualifier le tissu 
adipeux d’organe d’une part parce qu’il a une fonction métabolique bien connue, le stockage et 
la mise à disposition des graisses, et d’autre part car ce tissu possède une fonction endocrine 
importante. Plusieurs types cellulaires assurent la spécificité de ce tissu. Il est composé 
premièrement de cellules adipocytaires matures, puis des précurseurs de ces adipocytes appelées 
préadipocytes, et finalement de cellules faisant partie de la fraction stromacale vasculaire telles 
que les cellules sanguines, endothéliales et les macrophages. Seuls les adipocytes ont un rôle 
métabolique de stockage des lipides, alors que l’ensemble des ces cellules participent à la 
réponse endocrine du tissu adipeux. De part sa fonction endocrinienne, une communication 
efficace s’établit entre le tissu adipeux et d’autres organes, et le tissu participe ainsi, non 
seulement à la régulation métabolique et énergétique, mais aussi à la fonction immunitaire de 
l’organisme. 
Les pathologies reliées à un dysfonctionnement du tissu adipeux blanc (TAB1) font 
l’objet d’enjeux socio-économiques importants. En effet, l’obésité, par exemple, est souvent 
associée à des problèmes proinflammatoires, d’hypertension, de dyslipidemie, d’hyperglycémie, 
de résistance à l’insuline et de diabète de type 2. L’Organisation Mondiale de la Santé estime que 
plus de 300 millions de personnes dans le monde souffrent de ces maladies reliées à l’état du 
tissu adipeux. Ces maladies sont regroupées sous l’appellation de syndrome métabolique, et leur 
nombre ne fait qu’augmenter, particulièrement chez les enfants. 
  L’obésité et la lipodystrophie, toutes deux associées à un dysfonctionnement du TAB, 
conduisant à des maladies reliées au syndrome métabolique. Lorsque l’apport d’énergie est 
supérieur aux besoins de l’organisme, le TAB stocke cet excès sous forme de lipides, dans le 
cytoplasme des adipocytes. Le TAB devient alors hypertrophique, puis hyperplasique, lorsque 
les adipocytes atteignent leur taille critique et commencent donc à augmenter en nombre. Les 
adipocytes, les macrophages et les cellules stromacales qui composent le tissu de sujet obèse 
secrètent alors toute une série d’hormones, appelées adipokines, qui stimulent l’infiltration de 
cellules inflammatoires. A contrario, en période de grande restriction énergétique, ou lorsque les 
stocks de graisses sont épuisés, de part leur mauvaise distribution ou leur perte (lipoatrophie ou  
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lipodystrophie), le tissu adipeux restant secrète également toute une série d’adipokines. On peut 
citer la résistine, le TNF-α ou le MCP1. D’une part, les adipokines fournissent aux organes qui 
contrôlent l’homéostasie énergétique, tels que le foie, le muscle squelettique et le cerveau, des 
informations sur l’intégrité du TAB. D’autre part, leur production, provoque une infiltration de 
cellules inflammatoires notamment des macrophages, et induit un état inflammatoire général. Ce 
dernier étant d’ailleurs la signature des maladies du syndrome métabolique telles que le diabète 
de type 2, l’hypertension et les maladies cardiovasculaires. 
Comme mentionné plus haut, le tissu adipeux blanc est divisé en plusieurs dépôts qui, 
selon leur emplacement, peuvent jouer un rôle métabolique et endocrinien différent. Pendant la 
différenciation adipocytaire, la batterie de gènes exprimés dans le TAB, peut donner naissance à 
des tissus ayant une morphologie et une fonction différente, principalement le tissu viscéral 
(vis2) et le tissu sous-cutané (sc3). Les dépôts sc sont ceux qui possèdent la plus grande élasticité, 
pouvant s’élargir ou se rétrécir facilement sans affecter vraiment l’activité métabolique ou la 
sensibilité à l’insuline du tissu. Les dépôts vis participent de façon importante à la régulation du 
métabolisme énergétique car leur réduction améliore la sensibilité à l’insuline du tissu. En effet, 
une corrélation directe a été établie entre la réduction des dépôts vis et l’amélioration des 
pathologies reliées au dysfonctionnement du TAB telles que la résistance à l’insuline, 
l’hypertension ou les concentrations plasmatiques de cholestérol. L’élasticité du TAB est définie 
par la capacité de stockage de lipides dans le cytoplasme des adipocytes matures, et dépend ainsi 
du nombre d’adipocytes matures présents dans le tissu. La différenciation adipocytaire est donc 
intimement associée aux pathologies reliées au TAB. 
Le facteur de transcription PPARγ joue un rôle primordial dans la différenciation 
adipocytaire puisqu’il participe à la dernière étape de la différenciation en stimulant l’expression 
des gènes impliqués dans la régulation lipidique. Il appartient à la famille des récepteurs 
nucléaires PPARs (Peroxisome Proliferator-Activated Receptors4), composés de trois isotypes 
différents (PPARα, β/δ and γ). PPARα, a été découvert en premier comme la cible moléculaire 
de la prolifération peroxisomale chez les rongeurs. Depuis, les trois isotypes PPARs ont été 
reliés à des rôles uniques dans la régulation de l’énergie métabolique, des fonctions cellulaires et 
systémiques, cependant en contrôlant de façon concomitante l’expression des gènes régulant  
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l’homéostasie lipidique. Le pattern d’expression des trois isotypes est différent : PPARα est 
principalement exprimé dans des tissus impliqués dans l’oxydation des acides gras, tels que le 
foie et le muscle alors que PPARβ/δ a une expression ubiquitaire, exprimé dans tout 
l’organisme. Finalement, PPARγ est exprimé principalement dans le TAB où il contrôle 
l’expression des gènes de la différenciation adipocytaire, de l’intégrité tissulaire ainsi que de la 
fonction de stockage des graisses.  
PPARγ est exprimé sous forme de deux isoformes, PPARγ1 et PPARγ2. PPARγ1 est 
exprimé de manière ubiquitaire dans tous les tissus exprimant PPARγ, tels que le TAB, le tissu 
adipeux brun, les macrophages, le foie, le muscle squelettique, les reins, le colon, le pancréas et 
d’autres. En revanche PPARγ2, qui possède chez l’humain une extension de 30 résidus (ou 28 
résidus chez la souris) dans sa partie N-terminale, est exprimé principalement dans le TAB. 
En accord avec la structure des autres récepteurs nucléaires, PPARγ  possède une 
structure modulaire composée de plusieurs domaines fonctionnels. Dans la partie N-terminale, le 
domaine A/B possède une fonction de transactivation indépendante du ligand (AF-1). Le 
domaine C contient une séquence permettant la liaison à l’ADN  (DBD, DNA Binding Domain) 
qui permet la reconnaissance des séquences spécifiques, les Peroxisome Proliferator Response 
Elements (PPRE), se trouvant dans le promoteur des gènes cibles. PPARγ est aussi composé 
d’un domaine charnière D et finalement du domaine E, qui contient une fonction de 
transactivation dépendante du ligand (AF-2) ainsi qu’un site de fixation du ligand (LBD, Ligand 
Binding Domain).  
L’activité transcriptionelle de PPARγ résulte d’une combinaison très complexe entre 
l’hétérodimérisation du récepteur avec son partenaire le Retinoic X Receptor (RXR), la liaison 
aux éléments de réponse présents dans la région promotrice des gènes cibles et l’activation par 
les ligands spécifiques. Pour la plupart, ces ligands naturels sont des acides gras insaturés 
généralement des eicosanoides derivés de l’acide arachidonique tels que les leukotriènes et les 
prostaglandines. La «15-deoxy-D12,14-prostaglandin J2 » a été démontrée comme un des 
ligands spécifiques et naturels de PPΑRγ. D’autres ligands synthétiques ont été développés, 
principalement comme molécules thérapeutiques pour lutter contre les maladies reliées au 
syndrome métabolique, comme le diabète de type 2. Il s’agit principalement des agonistes totaux 
faisant partie de la classe des  «15-deoxy- D12,14-prostaglandin J2 » a été démontrée comme un  
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des ligands spécifiques et naturels de PPΑRγ. D’autres ligands synthétiques ont été développés, 
principalement comme molécules thérapeutiques pour lutter contre les maladies reliées au 
syndrome métabolique, comme le diabète de type 2. Il s’agit principalement des agonistes totaux 
faisant partie de la classe des  Thiazolidinediones (TZDs5) comme la Rosiglitazone (Rosi6) et la 
Pioglitazone (Pio7). D’autres ligands synthétiques de PPARγ, des agonistes partiels (les 
«selective PPARγ modulators», SPARγMs) ou certains antagonistes sont également en 
développement. Ces agonistes partiels et antagonistes sont censés être dépourvus d’effets 
secondaires lors des traitements des maladies reliées au syndrome métabolique et ont comme but 
de remplacer l’utilisation des TZDs qui ont démontrés certains effet secondaires lors de leur 
utilisation.  
L’implication de PPARγ dans la différenciation adipocytaire a été intensivement 
démontrée. Son ablation chez la souris est létale due à des problèmes de développement 
placentaires. Lorsqu’on contourne ces problèmes, en exprimant PPARγ seulement dans le 
placenta, on obtient des souris gravement atteintes de lipodystrophie, de résistance à l’insuline et 
d’hypotension. De manière surprenante, les souris PPARγ +/- bien qu’elles ne soient pas 
lipodystrophiques, ont moins de tissu adipeux dû à un défaut d’accumulation des lipides dans les 
cellules adipeuses. De plus, ces souris ne présentent pas de défauts métaboliques majeurs, 
excepté un retard de croissance qui est certainement dû à une dérégulation dans la signalisation 
de l’hormone de croissance (GH). En revanche, lorsqu’elles sont nourries avec une diète riche en 
lipides (HFD), elles sont protégées contre la prise de poids et ne développent pas la résistance à 
l’insuline observée chez les souris sauvages. De plus, sous un régime alimentaire HFD, les souris 
PPARγ +/- ne développent pas la stéatose hépatique attendue puisque la consommation en acides 
gras est augmentée dans le foie.  
Une étude montre que la délétion spécifique de PPARγ dans le TA, s’accompagne non 
seulement d’une lipodystrophie, mais aussi d’une résistance à l’insuline et d’une augmentation 
de la gluconéogenèse hépatique. Le même phénotype lipodystrophique a également été observé 
dans un autre modèle de souris pour lequel l’expression de PPARγ a été spécifiquement inhibé 
dans le TA (PPARγ hyp/hyp). Les animaux sont alors plus sensibles au pouvoir insulino-résistant  
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provoqué par des régimes HFD, comme il l’a été aussi montré dans un modèle de souris 
transgéniques exprimant un dominant négatif de PPARγ, le PPARγL466A. Une autre étude 
suggère cependant, que la délétion spécifique de PPARγ dans le TAB ne s’accompagne pas de 
cette insulino-résistance en raison d’une augmentation du métabolisme hépatique du glucose.  
Finalement, une troisième étude montre que lorsque la délétion de PPARγ ne se fait que 
dans les adipocytes matures, cela induit la nécrose des adipocytes et provoque une infiltration de 
cellules inflammatoires dans le TAB. Cette observation, est en accord avec le rôle de PPARγ 
dans le développement mais également le maintien de l’intégrité de l’adipocyte. L’étude du rôle 
de PPARγ dans le TAB a permis de relier la perte de l’intégrité de tissu à un état inflammatoire 
et à la résistance à l’insuline.  
Ces résultats, chez la souris, mettent en évidence le rôle important de PPARγ dans la 
différenciation adipocytaire en premier mais également dans l’intégrité du TAB. L’étude du rôle 
de PPARγ dans le TAB a donc permis de relier la perte de l’intégrité de ce tissu à un état 
inflammatoire et à la résistance à l’insuline. Le rôle important de PPARγ a également été 
démontré chez l’humain où plusieurs mutations ponctuelles se soldant par une perte d’activité 
transcriptionnelle du récepteur se caractérisent par une lipodystrophie partielle, une résistance à 
l’insuline ainsi qu’à un état inflammatoire systémique.  
L’activation de PPARγ par l’utilisation des agonistes totaux, comme les TZDs 
(Rosiglitazone et Pioglitazone), améliore le profile lipidique, les paramètres cardiovasculaires, la 
sensibilité à l’insuline et diminue le niveau systémique des marqueurs inflammatoires chez les 
patients atteints de syndrome métabolique. La Pioglitazone, permet une redistribution des lipides 
des dépôts vis vers les dépôts sc, ce qui conduit à des complications métaboliques moindres. 
Cependant, il a été démontré que les TZDs peuvent avoir des effets secondaires provoquant la 
rétention de l’eau et des problèmes cardiaques. Pour palier à ces effets secondaires, et au vue des 
résultats obtenus avec les souris PPARγ +/-, un concept relativement récent préconise 
l’utilisation d’antagonistes de PPARγ comme molécules thérapeutiques dans la lutte contre les 
maladies reliées au syndrome métabolique. Cependant, le traitement des souris avec des 
antagonistes PPARγ ne semble pas améliorer la sensibilité à l’insuline. De plus, comme 
démontré plus haut, il diminue l’activité de PPARγ et par conséquence la quantité de TAB dans 
l’organisme, créant ainsi un effet contraire à celui désiré, spécialement dans le cas où le 
syndrome métabolique est déjà instauré.  
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L’émergence de nouvelles molécules, agonistes partiels de PPARγ, semble de loin une meilleure 
alternative.  
L’utilité de PPARγ comme cible de choix dans le traitement des maladies reliées au 
syndrome métabolique n’est plus à faire. En revanche, plusieurs questions restent ouvertes. Le 
but de ce travail était de comprendre le paradoxe suivant : Les souris PPARγ +/- sont résistantes 
à une diète riche en gras et sont plus sensibles à l’insuline que les souris sauvages nourries au 
même régime. Leur niveau de sensibilité à l’insuline est comparable à celui obtenu chez les 
souris sauvages traitées avec l’agoniste PPARγ, la Rosiglitazone. Notre but a été donc, de mettre 
en évidence des nouvelles fonctions de ce récepteur nucléaire qui pourraient expliquer ce 
paradoxe. Il est possible que l’utilisation des diètes riches en gras exacerbe la fonction de 
stockage des graisses au détriment de toute autre fonction. Nous avons donc décidé d’étudier le 
rôle de PPARγ chez des jeunes souris mâles, traitées avec une diète standard (SD). 
Nos analyses démontrent des niveaux plasmatiques d’insuline et glucose normaux 
lorsque les souris ont libre accès à une nourriture standard. En condition de jeûne, en revanche, 
le niveau de glucose n’est pas aussi efficacement régulé chez les souris PPARγ +/- que chez les 
souris sauvages, ce qui suggère une altération du contrôle glycémique. Egalement, le bilan 
lipidique, spécialement les niveaux d’acides gras libres et la concentration de glycérol 
plasmatique, plus faibles à jeun, suggèrent également une dérégulation de la lipolyse. 
L’oxydation hépatique incomplète des acides gras est la source plasmatique de corps cétoniques; 
la concentration plasmatique des corps cétoniques des souris PPARγ +/- est également diminuée, 
en lien avec le taux circulant d’acides gras plus faible. Donc nos observations désignent 
fortement le tissu adipeux comme le tissu principalement responsable de dérégulations dans la 
mise à disposition des lipides lorsque PPARγ est moins exprimé dans l’organisme.  
Nous avons vérifié l’implication du foie, et du muscle squelettique, deux organes qui 
participent activement au métabolisme énergétique et qui expriment aussi, de manière plus 
faible, PPARγ. Pour se faire, nous avons mesuré le profil d’expression génique de ces deux 
tissus, et nos résultats montrent que ni le profil du foie, ni le profil du muscle squelettique n’est 
modifié chez les souris hétérozygotes pour PPARγ. Par exemple, aucune modification du niveau 
d’expression des gènes impliqués dans la glycolyse, l’oxydation des acides gras ainsi que la 
gluconéogenèse n’a été mis en évidence dans le foie. Egalement, l’expression des gènes 
impliqués dans la glycogénolyse, la glycolyse et l’oxydation des acides gras n’est pas modifiée 
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dans le muscle squelettique. L’ensemble suggère qu’aucun de ces deux tissus n’est impliqué 
dans la dérégulation systémique observée chez les souris mutantes.  
En revanche, la délétion d’un allèle PPARγ a des effets importants et inattendus sur 
l’expression des gènes dans le TAB, et particulièrement concernant les gènes impliqués dans la 
croissance et la production d’énergie cellulaire. D’une part, des gènes impliqués dans la cascade 
de signalisation cellulaire de l’insuline, qui est un activateur important de la glycolyse et de la 
lipogenèse, sont significativement plus faiblement exprimés dans le TAB des souris PPARγ +/- 
par rapport à des souris de type sauvage. En accord avec ces observations, le transport basal de 
glucose ainsi que la glycolyse sont eux aussi diminués. L’utilisation du glucose dans l’adipocyte 
participe à la fois à la synthèse de novo des acides gras et à leur processus d’estérification et de 
stockage sous forme de triglycérides, mais aussi représente une source d’ATP non négligeable, et 
nécessaire pour la survie des adipocytes. Et de façon cohérente, notre étude montre que 
l’expression des gènes contrôlant la synthèse des acides gras et leur stockage est diminuée dans 
le TAB des souris PPARγ +/-. Cette diminution de l’utilisation cellulaire du glucose pourrait 
expliqué le faible niveau d’ATP dans le TAB des souris PPARγ +/-, en comparaison avec les 
souris sauvages. D’ailleurs nos résultats sont en accord avec des données démontrant que 
l’ablation de PPARγ dans les adipocytes matures provoque une nécrose des adipocytes due à une 
diminution de la fourniture en ATP. En plus de la dérégulation métabolique, les adipocytes 
PPARγ +/- souffrent également d’une dérégulation au niveau des gènes impliqués dans le stress 
cellulaire, le programme de détoxification et les réactions inflammatoires, conduisant ainsi à une 
perte de l’intégrité adipocytaire. Il est probable que le déficit énergétique observé dans le TAB 
des souris PPARγ +/- soit responsable de la dérégulation de voies de détoxification et 
d’inflammation.  
Nos travaux montrent aussi que l’ensemble de ces dérégulations géniques entraînent des 
modifications du métabolisme in vivo au niveau systémique, puisque les souris PPARγ +/- ont 
une activité métabolique et une activité physique réduites. On peut émettre l’hypothèse que cette 
diminution de la dépense énergétique totale, permet aux souris de prolonger la période de temps 
pendant laquelle les réserves énergétiques peuvent palier aux besoins métaboliques. 
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En conclusion de cette partie de mes travaux, en utilisant comme modèle d’étude les 
souris PPARγ +/- nourries avec un régime SD, nous avons déterminé qu’une activité normale de 
PPARγ est importante pour l’intégrité métabolique et physique du TAB. Son rôle ne se limite pas 
à la différenciation adipocytaire et le stockage des lipides, mais il régule également les processus 
énergétiques tels que la glycolyse, la lipogenèse, mais aussi la lipolyse. La dysrégulation de ces 
voies métaboliques affecte l’intégrité du TAB comme démontré par la dérégulation des voies de 
détoxification et par l’augmentation des réactions inflammatoires. Par ailleurs, la perte de cette 
intégrité au niveau du TAB, affecte de manière plus surprenante l’activité métabolique et 
physique des souris, alors que l’expression génique dans le foie et le muscle n’est pas modifiée.  
Dans une second partie de mes travaux, et pour mieux étudier les effets de PPARs, 
notamment PPARβ et PPARγ, au niveau cellulaire nous avons mis au point une technique 
permettant une modulation simple de leur niveaux d’expression in vitro. Nous avons retenus à 
cet effet, la technique de « small interference RNA » (siRNA8) exprimés de manière constitutive 
à l’aide d’un système lentiviral. Les siRNAs font parti d’un mécanisme naturel chez les 
eucaryotes permettant la régulation transcriptionelle et traductionnelle des gènes cibles. Leur 
expression assure une diminution spécifique de l’expression des gènes cible sans affecter le 
niveau d’expression d’autres protéines de la même famille.  
Leur utilisation comme outil biotechnologique est particulièrement intéressante dans les 
cas où les modèles cellulaires dans lesquels la délétion spécifique stable d’un gène donné 
n’existent pas. 
 En utilisant cette technique, nous avons crées des siRNA reconnaissant spécifiquement 
les transcrits PPARβ et PPARγ chez l’humain, le rat et la souris. Ces siRNAs (siPPARβ et 
siPPARγ) permettent la suppression spécifique de PPARβ et PPARγ chez les trois espèces 
mentionnées ci haut. En utilisant les vecteurs lentiviraux comme souce d’expression des 
siPPARβ et siPPARγ, nous avons infecté de manière stable et avec une bonne efficacité 
plusieurs types de cellules (lignée et primaires), provenant de l’humain, du rat et de la souris.  
Ce système d’expression des siRNAs à l’aide des vecteurs lentiviraux nous a permis de 
déchiffrer avec succès, le rôle de PPARβ dans la mort embryogénique observée dans les souris 
PPARβ -/-. En effet, il est connu que la délétion de PPARβ affecte de manière importante le 
développement placentaire conduisant souvent vers une mort embryogénique. Chez les rongeurs, 
les cellules trophoblastiques sont essentielles au bon développement de l’embryon. Ces cellules 
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 se différencient dans des cellules appelées « giant cells » et participent au développement 
placentaire en secrétant différentes hormones telles que la prolactine, le lactogène I et la 
proliférine. Le bon fonctionnement de ces cellules est donc critique au bon développement 
embryogénique. L’analyse histologiques des placentas provenant des souris PPARβ -/- a 
démontré une diminution du nombre de giant cells, suggérant l’implication de ce récepteur dans 
leur différenciation. En utilisant notre construction siPPARβ nous avons infecté une lignée 
trophoblastique de rat. La supression de l’expression de PPARβ dans ces cellules empêche leur 
différenciation en « giant cells » demontrant ainsi le role primordial de PPARβ dans leur 
differenciation en giant cells. Par ailleurs, grâce à ce système, nous avons pu explorer les 
mécanismes affectés par l’inhibition de l’expression de siPPARβ dans les cellules 
trophoblastiques et que la perte de différenciation est due à une dérégulation de la voie Akt et de 
l’expression de la protéine appelées « adipose differentiation related protein ».  
En utilisant le même système lenitivral nous avons introduit un siPPARγ dans les cellules 
murines 3T3L1. Ces cellules sont utilisées comme un modèle de différenciation adipocytaire. En 
présence d’un cocktail adipogéniques elles sont capables de se différencier de fibroblastes en 
adipocytes. A l’aide de ce modèle cellulaire nous avons démontré que les phthalates, molécules 
se trouvant dans les plastiques industriels utilisés lors de l’emballage de différents produits 
alimentaires ou sanitaires ont un effet adipogenique sur la differenciation des cellules 3T3L1. En 
utilisant le système d’expression de siPPARγ à l’aide du vecteur lentiviral nous avons également 
été en mesure de démontrer que l’effet adipogenique de ces molécules s’effectue via l’activation 
de PPRAγ. En effet, leur effet adipogenique est inhibé par la suppression spécifique de 
l’expression de PPRAγ dans ces cellules.  
Le syndrome métabolique regroupe dans une seule entité la résistance à l’insuline et 
d’autres maladies associées telles que les risques cardiovasculaires, le diabète de type 2, 
l’hypertension, la dyslipidémie et l’obésité. Plusieurs hypothèses tentent d’expliquer les 
interactions génétiques et les facteurs environnementaux pouvant conduire à ce syndrome. 
Dernièrement, l’intérêt s’est porté sur le rôle du tissu adipeux blanc dans cette pathologie.  
Le TAB n’est plus regardé comme un simple réservoir de lipides. Plusieurs études ont 
démontré dans les dernières années son importance dans la régulation de l’homéostasie lipidique 
et son implication dans le syndrome métabolique. En plus de stoker les lipides, le TAB est 
capable de produire de l’énergie pour sa survie et pour l’organisme, et de produire et sécréter des 
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adipokines qui peuvent réguler le métabolisme non seulement au niveau du TAB mais également 
dans le foie, le muscle squelettique, le cerveau et dans bien d’autres organes. Une dérégulation 
dans leur expression est observée dans les cas d’obésité et lipodystrophie produisant un état 
inflammatoire responsable des maladies reliées au syndrome métabolique.  
PPARγ est important dans le développement et la survie du TAB. De plus, l’utilisation 
des agonistes PPARγ est le traitement de choix dans le cas des maladies reliées au syndrome 
métabolique. Une diminution de son expression dans le TAB détruit l’intégrité de ce tissu et 
affecte, en plus de l’intégrité énergétique et physique de ce tissu, l’activité métabolique et 
physique de l’animal.  
En vue de nos résultats, nous pouvons conclure que l’expression de PPARγ dans le TAB 
joue un rôle primordial pour l’intégrité physique et métabolico-énergétique de ce tissu. La 
dérégulation de son expression peut engendrer des conséquences néfastes au niveau systémique 
de l’animal, questionnant ainsi la possibilité d’utiliser des antagonistes PPARγ dans le traitement 
des maladies métaboliques. Ces résultats suggèrent également, que le traitement des patients 
souffrant des mutations diminuant l’activité transcriptionelle du récepteur avec des agonistes 
PPARγ pourrait être bénéfique. Les souris PPARγ +/- représentent une excellent modèle pour 
étudier le mécanisme d’action des nouvelles molécules dans le traitement de la lipodystrophie.  
A l’aide de notre modèle siRNA exprimé par le vecteur lentiviral nous espérons mieux 
comprendre le rôle de la faible expression de PPARγ mais également des autres membres de 
cette famille dans d’autres types cellulaires tels que les cellules intestinales, musculaires, 
hépatiques ou du cerveau. 
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In mammals, the ensemble of fat tissues constitutes a multi-depot adipose organ that is 
highly innervated and rich in blood vessels. It serves metabolic and endocrine functions, which are 
of key importance for the whole physiology of the body. This organ is not only composed of lipid-
laden mature adipocytes and adipocyte precursors called preadipocytes, but also comprises a stromal 
vascular fraction (SVF), which includes blood cells, endothelial cells and macrophages. Adipocytes 
participate to the metabolic functions of the adipose tissue whereas, adipocytes as well as the SVF 
cells participate to the endocrine function of the tissue. This knowledge has contributed to a better 
understanding of the intense cross-talk between the different components of fat tissue, and has led to 
stimulating speculations about the initiation of pathological conditions. As part of this interactive 
and integrated network, the adipose tissue per se is involved in the coordination of diverse processes 
including not only energy metabolism, but also endocrine and immune regulatory functions. Both 
adipose tissue deficiency (lipodystrophy, lipoatrophy) and adipose tissue excess (obesity) have 
deleterious effects and constitute major medical problems and socioeconomic burdens all around the 
world today. Obesity, in particular, is associated with prothrombic and proinflammation states, 
hypertension, dyslipidemia, hyperglycemia, insulin resistance, degenerative diseases, and some 
cancers. The World Health Organization estimates that over 300 million people are clinically obese, 
and the dramatic increase in obesity among children underscores the urgent need for increased 
knowledge on adipocytes as regulators of energy balance, which will hopefully contribute to 
ameliorating the serious public health problem created by obesity. 
Mature adipose cells, whose differentiation is controlled by a cascade of specific 
transcription factors, represent the major component of the adipose tissue (WAT). During the 
differentiation process, morphologically and functionally diverse tissues give birth to the sc and vis 
adipose tissues. Each of them has a different metabolic activity reflected in a different sensitivity to 
insulin. Among these different tissues, the sc deposits are those that undergo the more conspicuous 
enlargements and retractions without noticeable effects on insulin sensitivity, glucose metabolism, 
and metabolic profile. Vis fat is distinct from other adipose regions since it is drained by the portal 
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vein, and therefore has a unique direct connection with the liver. Reduction of vis deposits promotes 
insulin sensitivity and glucose metabolism. In fact, vis fat mass correlates positively with glucose 
intolerance, alteration of plasma lipoprotein lipid levels, increased triglyceride and cholesterol 
concentrations, hypertension, and dyslipidemia. Moreover, insulin signaling analyses in human vis 
and sc fat show that the vis adipose tissue expresses higher levels of specific insulin-signaling 
proteins and an earlier and greater response to insulin than the sc WAT. In short, vis fat is more 
affected by weight reduction than sc fat, is more active metabolically, has a higher lipolytic rate, and 
produces more adipokines. These different characteristics of the two fat depots with respect to 
morphological structure, metabolic activity, and hormonal control suggest a specific role distribution 
between vis and sc WAT in whole body energy homeostasis and an impact on insulin sensitivity in 
skeletal muscle and liver.  
One of the primary functions of WAT is to store excess energy as lipids, which are then 
mobilized to other tissues in response to metabolic needs during periods of food scarcity. The 
adipose tissue also participates in the regulation of glucose homeostasis, which depends on the 
action of other organs as well (pancreas, muscle, liver, and brain). The WAT, by being involved in 
the regulation of lipid and glucose metabolism, not only in adipocytes, but also in the whole body, 
plays an important integrative role in energy homeostasis especially in extreme conditions when 
food is available on a very irregular basis and/or is of variable nutritional quality. 
WAT has finally emerged as a bona fide endocrine gland able to integrate hormonal signals 
from different parts of the body and respond by secreting its own signaling polypeptides called 
adipokines. These mediators have an impact on multiple target organs, such as the liver and skeletal 
muscle, and directly participate in the general control of the energy balance. Several of these 
adipokines, such as leptine and adiponectin, mediate some of their effect through activation of 
neuronal circuits in the hypothalamus and other brain areas with an impact on systemic regulation of 
energy expenditure and lipid catabolism. Besides the production of these adipokines, WAT, under 
stress conditions, also secretes pro- or anti-inflammatory cytokines, with autocrine or/and paracrine 
effector functions contributing to the control of energy homeostasis. Both the production and 
secretion of adipokines and pro- or anti-inflammatory cytokines by the WAT are regulated by the 
overall WAT mass (obesity or lipodystrophy) and the physiological status of the organism. 
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From the above, it has already become obvious that balanced amounts of adipose tissue are 
critical for an optimal regulation of lipid and glucose metabolism. Excess adiposity contributes to 
the development of insulin resistance, dyslipidemia, inflammation, hypertension, and cardiovascular 
diseases, while selective loss of WAT, called lipodystrophy, also predisposes to the same 
complications. Thus, adipocyte differentiation is intimately associated with the pathologies linked to 
WAT.  
Peroxisome proliferator-activated receptors (PPARs) compose a subgroup of three receptors, 
belonging to the nuclear hormone receptor family, and acting as lipid sensors to modulate gene 
expression. PPARγ, which is highly expressed in WAT, is a pivotal coordinator of adipocyte 
differentiation and fatty acid uptake and storage.  
Studies on the role of PPARγ in WAT have been stimulated by the finding that TZDs, now 
used to treat patients suffering from type 2 diabetes, are specific ligands of PPARγ. Most of the 
present knowledge on PPARγ functions in energy homeostasis and its deregulations derives from 
the use of animal models and the investigation of patients bearing variant forms of the PPARγ gene. 
General ablation of the PPARγ gene in mice is lethal due to placental malformation. In a model of 
generalized PPARγ ablation, which prevents embryonic lethality by preserving PPARγ expression in 
trophoblasts, severe lipodystrophy, insulin resistance and hypotension probably due to increased 
vascular relaxation, were observed. Specific deletion of PPARγ in WAT has led to a better 
understanding of pathologies linked directly to PPARγ dysfunction in this tissue. Three different 
laboratories performed this specific genetic manipulation. In a first study, using mutant animals on a 
standard diet, adipocyte hypocellularity and hypertrophy were observed, which were accompanied 
by increased hepatic gluconeogenesis and insulin resistance. These animals were more susceptible to 
HFD-induced steatosis, hyperinsulinemia and associated insulin resistance. A similar phenotype was 
observed in a “knock in” mouse model using the dominant negative mutant PPARγL466A, which 
again showed the relationship between PPARγ function, adipose tissue and typical metabolic 
syndrome pathologies. In a second ablation study, mutant mice lacking PPARγ in adipose tissue 
were fed HFD, following which they presented diminished weight but, in contrast to the first study, 
did not develop systemic insulin resistance or glucose intolerance. Furthermore, the mice exhibited  
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diminished glucose uptake in the skeletal muscle, which suggests insulin resistance in this tissue. 
However, the liver did compensate for this insulin resistance by increasing glucose uptake and 
utilization, thereby improving the overall systemic insulin sensitivity. This improvement coincided 
with an increased expression of PPARγ in the liver, where it might have had a protective effect 
under these conditions. In the third study, ablation of PPARγ was induced selectively in adipocytes 
after the animals had reached adulthood. PPARγ-null adipocytes died within a few days after 
invalidation of the gene thus demonstrating that, in addition to its role in adipose differentiation, 
PPARγ is essential for the survival of mature adipocytes. On the contrary, the PPARγ +/- 
heterozygous animals are viable and do not present any major defects except a decrease in the WAT 
size. The PPARγ +/- mice have normal insulin sensitivity under a standard diet (SD). However, 
when on a high fat diet (HFD) and compared to wild type animals, they are protected against fat 
mass increase, which is reflected in smaller adipocytes. Furthermore, they do not develop insulin 
resistance or liver steatosis, and display a substantial increase in FA oxidation in the liver and in 
skeletal muscle.  
The results obtained from these different mouse models underscore the link between 
adipogenesis and the metabolic syndrome, and highlight the crucial role of PPARγ for the 
development, integrity and well-functioning of the WAT. Adipocytes communicate with 
preadipocytes, monocytes/macrophages and endothelial cells within the adipose tissue and with the 
liver, skeletal muscle, pancreas and brain at the systemic level. Most importantly, it shows that 
deregulation of the WAT function and integrity, which often interferes with the production of 
secreted adipokines and other signaling proteins by the different cell types comprised in the WAT, 
ultimately affects the homeostasis of the whole body. A disturbance of this balance contributes to 
the development of the metabolic syndrome and associated risks. 
The mutations found in the human PPARγ receptor show that in general, as in mice, the level 
of PPARγ activity correlates with adiposity. Loss of PPARγ function is linked to partial 
lipodystrophy, which in turn is associated with severe metabolic dysfunctions. This connection 
highlights once more the role of PPARγ in the control of both lipid and glucose metabolism.   
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Before even being identified formally as PPARγ ligands, TZDs were shown to stimulate 
adipogenesis and to improve insulin sensitivity. It is only more recently that TZDs were described as 
selective ligands for the receptor, bridging the gap between PPARγ and insulin sensitivity. The 
effects of the TZD Rosiglitazone were investigated in acquired or genetic lipodystrophies, including 
those caused by mutations in the PPARγ gene. In patients with inherited or HIV-induced 
lipodystrophies, treatment with Rosiglitazone increases the sc fat mass, and augments insulin 
sensitivity and adipokine secretion, probably by increasing the lipogenic program in WAT. With 
respect to type 2 diabetes, several drugs have been introduced during the past decade, which are 
effective in lowering blood glucose and in reducing diabetes-related end-organ diseases. The two 
TZDs, Rosiglitazone and Pioglitazone, currently approved as anti-diabetic drugs, are selective 
PPARγ agonists. In addition to improving insulin signaling, Rosiglitazone and Pioglitazone improve 
cardiovascular parameters, such as lipids, blood pressure, inflammatory biomarkers, endothelial 
function, and fibrinolytic status. Furthermore, Pioglitazone treatment shifts fat from the visceral to 
the subcutaneous compartment in obese patients, a fat redistribution thought to improve insulin 
sensitivity since sc WAT confers less insulin resistance than vis WAT. Despite the efficacy and 
beneficial effects of TZDs, a number of undesired side effects have been noted, including increased 
weight gain due to both increased adiposity and fluid retention.  
As mentioned above, PPARγ activation reduces insulin resistance, but also increases fat mass 
by promoting adipocyte hypertrophy and hyperplasia. Since lasting enhanced adiposity is associated 
with increased insulin resistance, it was hypothesized that reducing PPARγ activity would result in 
less fat mass and improved insulin sensitivity. In fact, mice treated with PPARγ partial antagonists 
had no effect on insulin sensitivity. Several lines of evidence discussed above suggest that WAT 
dysfunctions resulting from lipodystrophies or experimentally induced loss of adiposity in animal 
models can also be linked to insulin resistance, possibly due to excessive levels of circulating FFA 
that could be lipotoxic for the liver, skeletal muscle and even for the pancreas (by affecting beta cell 
action). It would appear, therefore, that the use PPARγ antagonists over long periods of time might 
interfere with the integrity of the adipose tissue and trigger unexpected and undesired effects on 
whole body metabolism, including insulin sensitivity. 
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To overcome side effects associated with the use of TZDs, a novel approach consists in 
developing new PPARγ ligands that have insulin-sensitizing properties, via selective action on 
beneficial pathways, without exacerbating fluid retention and obesity. Such compounds are called 
“selective PPARγ-modulators” (SPARγMs). SPARγMs would separate the effects of PPARγ on 
lipid and glucose metabolisms as well as on different organ systems (gastrointestinal, immune, and 
cardiovascular). The selective action of such compounds is thought to depend on different structural 
configurations induced in the ligand-binding domain by their interaction with the receptor, allowing 
recruitment of different complexes of cofactors that impact on the activation or repression of 
specific sets of target genes in different tissues.  
Taking advantage of our PPARγ +/- mouse model, we aimed at understanding how deletion 
of one allele of PPARγ, which significantly reduces the activity of the receptor via a gene dosage 
effect, would affect WAT function and whole body metabolism, when the mice are fed with a 
standard diet (SD), a condition which does not exacerbate the lipid storage function of the WAT. 
Furthermore, we were interested in exploring the interaction between PPARγ and other signaling 
pathways in the white adipose tissue. Moreover, we set up an in vitro siRNA lentivirus mediated 
system allowing the flexible modulation of the expression of PPARs in different cellular types. We 
aimed towards a better understanding of their role in controlling different metabolic pathways in 
adipocytes but also in other cellular types.  
The results reported herein show that deletion of one PPARγ allele affects specifically the 
expression of genes associated with metabolic pathways in the WAT. These effects are not seen in 
the liver or skeletal muscle, where PPARγ expression is normally much lower. In addition to genes 
involved in lipid storage, genes involved in glycolysis, de novo fatty acid synthesis, and in lipolysis 
were also down-regulated in the PPARγ heterozygous mice, creating a strong energy deficit in these 
animals. These defects in WAT functions correlated with a lowering of the metabolic rate of the 
whole body and were accompanied by a reduction in physical activity. These results cast doubt on a 
potential long term use of PPARγ antagonists for the treatment of type 2 diabetes.  
Furthermore, our results showed that deletion of one PPARγ allele affects the integrity of the 
WAT. Beside the delay in the adipocyte differentiation, several key proteins involved in the 
detoxification pathway were deregulated in the mutated WAT. This deregulation was accompanied  
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by an increase inflammatory reaction. Proteins involved in the inflammatory reactions as well as in 
the macrophage activation were up-regulated in the PPARγ +/- WAT. Surprisingly the expression of 
some of this adipokines and chemokines was shown to be stimulated by fasting. This was an 
interesting observation since it makes the link between the inflammatory status of the mutant WAT 
and its energetic deficiency that we explored above.  
In a second part of my work, we took advantage of the lentivirus mediated small interference 
RNA technique as a valuable tool for the down-regulation of different target genes such as PPARβ 
and PPARγ.  
The expression of siRNA ensures an efficient and relatively easy knock-down of target genes 
without having any effect on other related proteins. Their use is particularly valuable in the absence 
of available knock-out cellular models or of specific inhibitors against the target protein. By their 
expression through lentivirus vectors, siRNAs can be used as first step tools in the investigation of 
the role of a target protein in different pathways and cellular types.  
By the use of lentivirus vectors, we were able to transduce several cell types from different 
species such as mouse, human and finally rat with the siPPARβ and siPPARγ. This is of high 
interest in our laboratory since very often experiments are conducted in at least two of the species 
mentioned above, giving us flexibility in the choice of experimental models. Besides their tropism 
and high diversity in their ability to transduce different animal species, the lentivirus vectors ensure 
the permanent integration of siRNAs in the host genome, facilitating the creation of siRNA 
expressing cell lines. Moreover, the expression of GFP proteins under the EF1α promoter by the 
same vector expressing the siRNAs, ensure the tracing of infected cells, their sorting when 
convenient and the measurement of the percentage of infected cells in a given populations. 
Furthermore, in contrast of other viral vectors, the lentivirus vectors were shown to be devoid of 
immunogenic potential for the host cells or organisms.  
We successfully used siPPARβ to decipher the role of this receptor in the embryonic death 
observed in the PPARβ-/- mice. siPPARβ lentivirus mediated expression allowed an efficient 
infection of the rat Rcho-1 trophoblast. Their infection with siPPARβ inhibited their differentiation 
into giant cells, which are involved in placental development. Moreover, the use of this cellular 
model allowed the exploration of the pathway by which PPARβ is involved in their differentiation.  
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We were able to show that PPARβ is involved in the control of the activity of several proteins from 
the Akt pathway as well as the expression of adipose differentiation related protein important for the 
lipid droplet accumulation in giant cells.  
The use of siPPARγ in 3T3L1 cells proved that the adipogenic effect of phthalate plasticizers 
(such as Mono Ethyl Hexyl Phthalate and of its active metabolite Di Mono Ethyl Hexyl Phthalate) 
was PPARγ specific, since knock-down of this receptor blocked the adipocyte differentiation.   
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FPLD:  Familial Partial Lipodystrophy Dunningam-type 
FRET:  Fluorescence Resonance Energy Transfer Imaging 
 
G 
G:  Glycine 
Gadd45γ: Growth Arrest And DNA Damage Inducible Gene 45γ 
GDH:   Glucose 1 Dehydrogenase 
GFP:  Green Fluorescent Protein 
GH:  Growth Hormone 
GH-R:  Growth Hormone Receptor 
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Glut 1,4: Glucose Transporter 1, 4 
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JNK:  c-Jun Kinase 
IR:  Insulin Receptor 
IRS-1:  Insulin Receptor Substrate 1 
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L:  Lysine 
LBD:  Ligand Binding Domain 
LDL:  Low Density Lipoprotein 
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LMW:  Low Molecular Weight 
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Mgst3:  Microsomal Glutathione S-Transferase 3 
Mkrn 1: Makorin 1 
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p65:  Transformation Related Protein 63 
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PAI 1:  Plasminogen Activator Inhibitor 1 
PBP:  PPAR Binding Protein 
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PDK1:  Phosphoinositide Dependent Protein Kinase 1  
PDE3B:  Phosphodiesterase 3B 
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Q 
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R 
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Rcn 1:  Reticulocalbin 1 
Redd1: Regulated in Development And Damage Response 1 
RELMs: Resitin Like Molecules 
RER:  Respiratory Exchange Ratio 
RIP140: Nuclear Receptor Interacting Protein 140 
RISC:  RNA-Induced Silencing Complex 
RNA:  Ribonucleic Acid 
ROS:  Reactive Oxygen Species 
RT-PCR: Real Time Polymerase Chain Reaction 
RXR:  Retinoic X Receptor 
 
S 
S:  Serine 
sc:  Subcutaneous Fat 
SD:  Standard Diet 
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SOCS-2: Suppressor Of Cytokine Signaling 2 
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U 
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V 
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WAT :  White Adipose Tissue 
wt:  Wild type 
 
Z 
ZDF:  Zucker Diabetic Fatty  
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I. Introductive remarks  
 
In mammals, the ensemble of fat tissues constitutes a multi-depot adipose organ that is 
highly innervated and rich in blood vessels. It serves metabolic and endocrine functions, which are 
of key importance for the integrative physiology of the body. This organ is not only composed of 
lipid-laden mature adipocytes and adipocyte precursors called preadipocytes, but also comprises a 
stromal vascular fraction (SVF), which includes blood cells, endothelial cells and macrophages. 
Although adipocytes have been recognized as secretory cells with endocrine functions for some 
time, the importance of macrophages and stromal vascular cells within the adipose tissue of obese 
animals and humans is now well accepted. This knowledge has contributed to a better understanding 
of the intense cross-talk between the different components of fat tissue, and has led to stimulating 
speculations about the initiation of pathological conditions. Furthermore, analysis of the sympathetic 
and parasympathetic innervations of adipose tissue revealed that the autonomic nervous system 
modulates the fat cell number and other processes, such as adipokine expression levels, 
lipogenesis/lipolysis, fatty acid uptake, and local insulin sensitivity to glucose uptake. These recent 
findings underscore the integrative role of the brain in long-term energy balance (1). As part of this 
interactive and integrated network, the adipose tissue per se is involved in the coordination of 
diverse processes including not only energy metabolism, but also endocrine and immune regulatory 
functions. Both adipose tissue deficiency (lipodystrophy, lipoatrophy) and adipose tissue excess 
(obesity) have deleterious effects and constitute major medical problems and socioeconomic 
burdens all around the world today. Obesity, in particular, is associated with prothrombic and 
proinflammation states, hypertension, dyslipidemia, hyperglycemia, insulin resistance, degenerative 
diseases, and some cancers (2). The World Health Organization estimates that over 300 million 
people are clinically obese, and the dramatic increase in obesity among children underscores the 
urgent need for increased knowledge on adipocytes as regulators of energy balance, which will 
hopefully contribute to ameliorating the serious public health problem created by obesity. 
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II. Adipose tissue: the organ and its functions 
 
The adipose tissue has two main functions. Firstly, it plays an important role in the storage 
and release of lipids (3), thus  managing the energy reserve of the body according to supply and 
need. Secondly, it is a bona fide endocrine organ synthesizing and secreting a large variety of 
molecules called adipokines, which act both at the local (autocrine/paracrine) and systemic 
(endocrine) levels, and have an influence on all major organs involved in the physiology of the body 
(4-6).  
There are several visceral (vis) and subcutaneous (sc) fat depots, each playing a specific role 
(Fig 1) (7). Some parts of these depots are predominantly white, and thus they form the white 
adipose tissue (WAT), while a few depots are predominantly brown, due to a more dense irrigation 
and high numbers of mitochondria, and these correspond to the brown adipose tissue (BAT). WAT 
and BAT perform complementary functions in vivo. WAT essentially accumulates excess energy as 
fat and therefore constitutes the largest energy reservoir in mammals as a guard against times of 
food shortage. In contrast, BAT is highly specialized in non-shivering adaptive thermogenesis. 
Although the role of BAT in rodents and neonates of other mammalian species, including humans, 
has been extensively studied, the persistence and importance of BAT in adult humans is currently 
under intense investigation and putative functions remain to be elucidated (8,9). In brief, the brown 
and white adipose tissues closely collaborate in partitioning the energy contained in lipids between 
thermogenesis and the other metabolic functions, respectively. This introduction will concentrate on 
the latter only.  
  
II.1. White adipose tissue subtypes 
 
Mature adipose cells, whose differentiation is controlled by a cascade of specific 
transcription factors, represent the major component of the adipose tissue. During the differentiation 
process, morphologically and functionally diverse tissues give birth to the sc and vis adipose tissues 
(10-14). Each of them has a different metabolic activity reflected in a different sensitivity to insulin 
(10,15,16). Different expression profiles in sc and vis WAT of several genes involved in embryonic 
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development and pattern specification suggest different genetically determined developmental 
programs in preadipocytes for the formation of each depot with its specific functional characteristics 
(17). In addition to the main sc and vis depots, WAT is found in small amounts around other organs, 
such as the heart, kidney and genitalia. 
Among these different tissues, the sc deposits are those that undergo the more conspicuous 
enlargements and retractions without noticeable effects on insulin sensitivity, glucose metabolism, 
and metabolic profile (18,19). In humans, the sc adipose tissue can be subdivided into two distinct 
layers: the superficial and the deep layers. There is a gender dimorphism in the amount of deep layer 
sc WAT. 51% of a woman’s sc WAT is found in this layer, whereas in a man it comprises 66% of 
the sc WAT. It appears that obesity is associated with a preferential increase in the deep layer, and 
weight loss in obese people also impacts more on the deep layer, suggesting that the deep layer is 
metabolically more active than the superficial one (20). 
The vis fat is found in both the intraperitoneal and retroperitoneal compartments. 
Intraperitoneal fat is itself composed of omental, mesenteric, and in rodents perigonadal 
(epididymal) adipose tissues, the latter being largely used as an experimental model for vis fat. The 
delimitation between the intraperitoneal and retroperitoneal fat is along the ventral surface of the 
kidney and the dorsal borderline of the intestines. In humans, the retroperitoneal fat is minor as it 
represents only 25% of the total visceral part (16). Vis fat is distinct from other adipose regions 
since it is drained by the portal vein, and therefore has a unique direct connection with the liver. 
Reduction of vis deposits promotes insulin sensitivity and glucose metabolism. In fact, vis fat mass 
correlates positively with glucose intolerance, alteration of plasma lipoprotein lipid levels, increased 
triglyceride and cholesterol concentrations, hypertension, and dyslipidemia (21,22). Moreover, 
insulin signaling analysis in human vis and sc fat shows that the vis adipose tissue expresses higher 
levels of specific insulin-signaling proteins and an earlier and greater response to insulin than the sc 
WAT (23). In short, vis fat is more affected by weight reduction than sc fat, is more active 
metabolically, has a higher lipolytic rate, and produces more adipokines (Fig 1) (16,24).  
These different characteristics of the two fat depots with respect to morphological structure, 
metabolic activity, and hormonal control suggest a specific role distribution between vis and sc 
WAT in whole body energy homeostasis and an impact on insulin sensitivity in skeletal muscle and 
liver. These functions will not be discussed further since the information is already available in two 
reviews (16,25). 
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Figure 1. Schematic representation of the human adipose organ, main adipose subtypes and 
functions. The rodent perigonadal fat, which has no relevance in humans, is depicted here only as a 
reminder of its broad use as an experimental model of vis fat. Different processes and adipokine 
expression are indicated with respect to their prevalence in sc WAT or vis WAT. * enhances insulin 
sensitivity; ** enhances insulin resistance. 
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II.2. WAT and energy homeostasis 
 
One of the primary functions of WAT is to store excess energy as lipids, which are then 
mobilized to other tissues in response to metabolic needs during periods of food scarcity (9).  
After copious meals, and in periods of food abundance, the adipose tissue stores the energy 
ingested in excess as triglycerides (TG) (Fig 2A). The adipocyte is able to accumulate astonishingly 
high amounts of TG, which can be stored anhydrously within intracellular lipid droplets coated with 
proteins called perilipins, without causing cellular lipotoxicity (26,27). 
Starvation induces the breakdown of these TG into free fatty acids (FFA) and glycerol, 
which are released into the circulation (Fig 2B). FFA then serves as fuel for metabolically active 
tissues such as the skeletal muscle where their oxidation to carbon dioxide and water generates ATP. 
In the liver, most of the acetyl CoA produced by FFA oxidation is used to synthesize ketone bodies 
(acetoacetate; β-hydroxybutyrate) released into the circulation and used as fuels by the peripheral 
tissues. The glycerol generated by TG hydrolysis serves for the synthesis of glucose, which is 
reserved for cells depending on it as an energy source (neurons, red blood cells), or participates in 
the hepatic production of TG (28). These TG are then packaged within very low density lipoproteins 
(VLDL) and released into the circulation from where they can return to WAT. Regulation of the TG 
stocks is crucial for survival, since without WAT and its lipid reserve, animals would have to eat 
continuously, which is obviously not possible. For well-known reasons, food intake occurs only in 
distinct episodes underscoring the importance of a control of lipid production or intake, storage, and 
utilization. 
Regulation of lipid metabolism in adipocytes is controlled at three levels: fatty acid uptake, 
lipogenesis and lipolysis. Each of these processes is controlled by extracellular stimuli including 
insulin, corticoids, catecholamines, natriuretic peptides, and cytokines such as TNF-α, whose levels 
depend on conditions such as age, gender, physical activity, and nutritional factors (29). In addition, 
there are marked differences between the vis and sc adipose tissues in the regulation and levels of 
lipid metabolic activities. For instance, nearly 80% of fat is in the sc tissue, but the lipolytic effect of 
catecholamines is more pronounced in the vis fat whereas the antilipolytic effect of insulin is 
stronger in the sc fat (22).  
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The adipose tissue participates in the regulation of glucose homeostasis, which 
depends on the action of other organs as well (pancreas, liver, brain) (29). Firstly, it is 
involved in glucose disposal, which provides the substrate for the de novo synthesis of 
fatty acids and glycerol, and thus of lipogenesis, via the glycolytic pathway. Too little or 
too much adiposity are associated with hyperglycemia and insulin resistance. Not 
surprisingly, by liberating FFA into the circulation, the adipose tissue influences insulin 
sensitivity and thus glucose metabolism, in the muscles and liver. Furthermore, among 
other functions FFA serve as a substrate for lipoprotein assembly in the liver, regulate 
insulin production in the pancreas, and bind to and activate the transcription factors 
Peroxisome Proliferator Activated Receptors (PPARs) in all tissues, which in turn results 
in gene expression changes and their consequences (see below) (11,29-31). Thus WAT, 
by being involved in the regulation of lipid and glucose metabolism, not only in 
adipocytes, but also in the whole body, plays an important integrative role in energy 
homeostasis especially in extreme conditions when food is available on a very irregular 
basis and/or is of variable nutritional quality.  
In mammals, when excess energy is not directed correctly into sc fat, it will 
preferentially accumulate in vis WAT, with deleterious effects, a condition often 
associated with a genetic susceptibility to visceral fat obesity, and/or an endocrine-related 
maladaptive response to stress or smoking (32). 
When the adipose tissue is deficient, for instance because it is insulin resistant, or 
is abnormally distributed (lipodystrophy), the extra TG will be deposited ectopically in 
muscle, liver and heart, and to some extent also in the pancreas, which will be detrimental 
to the normal functioning of these now abnormally lipid-loaded tissues. This will impact 
on whole body metabolism with the development of metabolic syndrome features as a 
consequence (Fig 3) (32).  
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A                                                                 
 
 
Figure 2. Role of the white adipose tissue (WAT) and peripheral organs in postprandial (A) 
and fasting (B) states. A) In the postprandial state, the ingested nutrients reach the circulation in the 
form of triglycerides (in chylomicrons as very low density lipoproteins (VLDL), glucose and amino 
acids. In this state the main metabolic activities are the oxidation of glucose for the production of 
ATP in most cells, and the storage of excess fuel molecules in adipocytes as triglycerides, in 
hepatocytes as proteins, glycogen and triglycerides, and in skeletal muscle fibers as proteins and 
glycogen. In fuel excess conditions, amino acid oxidation increases in proportion to increments in 
protein intake, regardless of carbohydrate and fat substrate availability. 
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B               
 
 
Figure 2. Role of the white adipose tissue (WAT) and peripheral organs in postprandial (A) 
and fasting (B) states. B) Fasting induces breakdown of the triglycerides from WAT into free fatty 
acids and glycerol, both released into the circulation. Free fatty acids can be directly oxidized by 
skeletal muscle fibers for the production of ATP. Hepatocytes use glycerol for gluconeogenesis, and 
free fatty acids for ketone body synthesis. Both glucose and ketone bodies are important fuel 
molecules for the peripheral organs. In fuel shortage conditions, the extent to which amino acid 
oxidation rises above the minimum required rate depends on the proportion of the energy needs, 
which is covered by free fatty acids (FFA), glucose and ketone body oxidation. Stored molecules 
(Triglycerides, Glycogen, Proteins are in indicated in bold capitals.) Adapted in part from (33). 
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II.3 WAT as an endocrine gland 
 
For long regarded as a mere inert fat store for metabolic demands associated with fasting or 
exercise, WAT has finally emerged as a bona fide endocrine gland able to integrate hormonal 
signals from different parts of the body and respond by secreting its own signaling polypeptides 
called adipokines. These mediators have an impact on multiple target organs, such as the liver and 
skeletal muscle, and directly participate in the general control of the energy balance. Several of these 
adipokines, such as leptine and adiponectin, mediate some of their effect through activation of 
neuronal circuits in the hypothalamus and other brain areas with an impact on systemic regulation of 
energy expenditure and lipid catabolism (34). Besides the production of these adipokines, WAT, 
under stress conditions, also secretes pro- or anti-inflammatory cytokines, with autocrine or/and 
paracrine effector functions contributing to the control of energy homeostasis. Both the production 
and secretion of adipokines and pro- or anti-inflammatory cytokines by the WAT are regulated by 
the overall WAT mass (obesity or lipodystrophy) and the physiological status of the organism (35).  
Below, only a few major adipokines will be considered further, namely those which have 
been implicated in the direct modulation of metabolism, as well as pro/anti-inflammatory cytokines, 
which are produced under stress conditions and indirectly affect energy homeostasis. 
II.3.1 Adipokines directly involved in energy homeostasis 
 
As mentioned previously, adipocytes have a high capacity to produce and secrete adipokines, 
which act in an autocrine, paracrine or endocrine fashion to control several functions including lipid 
and glucose metabolism, and insulin secretion. Deregulation of these processes contributes to the 
development of the metabolic syndrome. Although several adipokines involved in energy 
homeostasis were discovered in recent years, the so far most studied ones are leptin, adiponectin, 
resistin, angiopoietin-like protein 4, and preadipocyte factor 1, on which this section will 
concentrate. In addition, information on other adipokines is given in Table 1 and Fig 4 or can be 
found in several review articles (27,36-40).  
Leptin (from the Greek leptos, meaning thin) is a small 16 kDa polypeptide of 167 amino 
acids produced mainly by adipocytes, in direct proportion to adipose tissue mass. Its production is  
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Figure 3. Obesity and lipodystrophy alterations of the WAT induce activation of the 
innate immune system, which is responsible for a low grade inflammation of the tissue, 
as well as an increased expression of several deleterious adipokines. Therefore, the 
plasma levels of adipokines, free fatty acids (FFA), triglycerides (TG), and glucose are 
increased. Ectopic fat accumulation in the liver, skeletal muscle or the pancreatic beta cells 
will alter their functioning and in consequence will affect the whole body energetic balance 
and promote the development of the metabolic syndrome.   
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increased by estrogens, glucocorticoids, insulin,TNF-α, and C/EBPα, and decreased by PPARγ 
agonists, FFA, growth hormone, androgens, and β3-adrenergic activity. It is secreted in higher 
amounts by sc compared to vis fat (Fig 1). It reduces food intake through a direct effect on the 
hypothalamus (41). These observations contributed to viewing leptin as an antiobesity hormone, but 
it is now thought that it serves primarily as an energy sufficiency signal, whose levels decrease with 
weight loss or caloric restriction. Reduction in leptin levels during starvation is associated with 
adaptive responses including decreased energy expenditure and increased appetite.  In several 
obesity models, the role of leptin is less obvious since there was no improvement in spite of high 
endogenous leptin levels, or treatment with exogenous leptin. Evidently, the target tissues have 
become resistant to leptin action, but the mechanism of this resistance remains unknown (42). 
However, hyperleptinemia induced by over-nutrition prevents ectopic lipid deposition by acting on 
appetite via the hypothalamus, thereby limiting energy surplus storage in the available adipocytes. 
Furthermore, ectopic lipid deposition is minimized by increasing fatty acid oxidation and decreasing 
lipogenesis in peripheral tissues (43). In addition, the WAT itself has a leptin receptor-mediated 
energy regulating system, which is turned-off during overnutrition allowing the storage of excess 
calories and thereby diet-induced weight gain. This down-regulation of the regulatory mechanism 
protects the whole organism against toxic ectopic lipid accumulation by permitting lipid 
accumulation in WAT (44). 
The organism appears most leptin sensitive in a range between low levels of the adipokine in 
situations of food restriction and its increasing levels during re-feeding, rather than in its 
supraphysiological concentrations such as those occurring in obesity (45). Exogenous leptin 
improves glucose homeostasis in ob/ob and lipodystrophic mice (46,47). It also improves glucose 
homeostasis in humans with congenital leptin deficiency or lipodystrophy, but has little effect on 
classic obesity (48-50). In addition to its role in energy homeostasis, leptin has important endocrine 
functions including the regulation of the hypothalamic-pituitary-adrenal and gonadal axes, bone 
development, immune response, angiogenesis and hematopoiesis (51,52). 
Adiponectin, (or AdipoQ, adipocyte complement-related protein (Acrp30), GBP28, apM1) 
(53), is a mature adipocyte-specific secretory protein with a molecular weight of approximately 30 
kDa, which shares homology with complement C1q, and types VIII and X collagen. Its expression is 
higher in sc than in vis fat (Fig 1), and post-translational hydroxylation and glycosylation produce 
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multiple isoforms. It circulates in serum at high concentrations (several micrograms per ml) as a 
hexamer of relatively low molecular weight (LMW), and a larger multimeric structure of high 
molecular weight (HMW, 12-18 subunits). Its biological effects depend both on the circulating 
concentrations and properties of the different isoforms, and on the tissue-specific expression of the 
two adiponectin receptors (AdipoR1 and AdipoR2) distantly related to the G protein-coupled 
receptor (53). In some cells, T-cadherin may function as a coreceptor to transmit adiponectin 
metabolic signals (54). Experimental data suggest that adiponectin has anti-diabetic, anti-
inflammatory and anti-atherogenic effects (39,55). Only the former are summarized here, since they 
play important roles in energy homeostasis, obesity, and insulin sensitivity. In mice, decreased 
adiponectin is involved in the development of insulin resistance in models of both obesity and 
lipoatrophy (56). Adiponectin stimulates phosphorylation and activation of the 5’-AMP-activated 
protein kinase in skeletal muscle and the liver, thereby regulating insulin sensitivity and glucose 
metabolism (57). In muscle, adiponectin stimulates fatty acid oxidation and glucose catabolism, and 
in the liver, it reduces glucose output and FFA influx, and increases fatty acid oxidation and insulin 
sensitivity. In Rhesus monkeys, plasma levels of adiponectin were shown to decrease parallel with 
reduced insulin sensitivity even before the onset of type 2 diabetes (58), and in Japanese men with 
type 2 diabetes, hypoadiponectinemia was found to be associated with visceral fat accumulation and 
insulin resistance (59). In contrast, an increase in adiponectin levels is observed after administration 
of TZDs, angiotensin-converting enzyme inhibitors (ACEIs), and the angiotensin II receptor blocker 
(ARB), after weight loss, renal failure, heart failure or after intake of soy protein or oils (53). Other 
effects on monocytes/macrophages, angiogenesis and nitric oxide production are not discussed here. 
 Resistin (resistance to insulin, also called FIZZ3 or ADSF), is another small protein (12.5 
kDa) and a member of the hormone family of cysteine-rich resistin-like molecules (RELMs) (60), 
which is mainly produced and secreted by WAT and appears to increase glucose production in the 
liver by a specific insulin antagonizing action (61). In rodents, it is expressed 15 times more in vis 
compared to sc fat (Fig.1) and it is highly up-regulated in models of diet-induced obesity, as well as 
in genetic models of obesity and diabetes. Resistin circulates in multimeric forms, probably 
corresponding to trimers and hexamers, the conversion of the latter to the trimeric form most likely 
representing an obligatory step towards activation (62). Mice treated with recombinant resistin 
develop insulin resistance and glucose intolerance, while cultured adipocytes receiving the same 
treatment are impaired in insulin-stimulated glucose uptake, suggesting that resistin affects insulin  
 44
INTRODUCTION-Adipose tissue : the organ and its functions 
 
action. Resistin-null mice have similar fat mass and weight as wild-type mice and 
improved glucose homeostasis associated with a decrease in hepatic gluconeogenesis (63-
65). In addition, resistin appears to be a pro-inflammatory cytokine. There are substantial 
inter-species differences between the sites of resistin production, occurring for example, 
in adipocytes in rodents, and most likely non-fat cells, macrophages or other stromal cells 
present in the adipose tissue in humans (66-69). The role of resistin in humans is not well 
established, since clinical studies do not show a clear link between obesity and insulin 
resistance versus resistin levels (70,71). 
 Angiopoietin-like proteins (ANGPTLs) are also involved in the regulation of 
energy homeostasis (72). One of them, the fasting-induced adipose factor (FIAF), also 
called ANGPTL4, HFARP and PGAR (73-76) is most highly expressed in the adipose 
tissue and secreted into the circulation where it is found associated with plasma 
lipoproteins. Adenovirus-mediated overexpression of FIAF was found to improve 
hyperinsulinemia, hyperglycemia and glucose tolerance (77). Yet it is a powerful 
signaling molecule that inhibits plasma TG clearance and thus fat storage, and promotes 
TG mobilization by stimulating adipose tissue lipolysis possibly by the inhibition of 
lipoprotein lipase activity (78). Thus, FIAF is efficient in both reducing blood glucose 
and improving insulin sensitivity, while simultaneously promoting hyperlipidemia and 
fatty liver. Although much remains to be discovered about this intriguing dual function of 
FIAF, one can speculate that it connects adipose tissue to the modulation of the levels of 
plasma lipids. Modification of FIAF production and signaling may contribute to the 
development of dyslipidemia and possibly type 2 diabetes (78). 
Lastly, proteolytic cleavage of the transmembrane protein preadipocyte factor 1 
(Pref-1), highly expressed in preadipocytes, but not in adipocytes where it plays the role 
of an inhibitor of adipogenesis, gives birth to two soluble proteins of 50 and 25 kDa. In 
transgenic mice, overexpression of Pref-1 specifically in WAT reduces the expression of 
adipocyte proteins such as leptin and adiponectin, and produces substantial loss of WAT, 
while these mice suffer from hypertriglycemia, impaired glucose tolerance and decreased 
insulin sensitivity. These findings demonstrate that Pref-1-induced impairment of 
adipocyte functions in vivo leads to the development of metabolic abnormalities (79). 
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II.3.2. Adipokines, chemokines, and vascular proteins involved in pro/anti inflammatory 
reactions 
 
Several molecules involved in inflammatory processes are produced by the adipose tissue in 
situations of stress, such as in obesity or lipodystrophy. Some of these adipokines are synthesized by 
adipocytes, whereas others are produced by the haematopoietic cell fraction of the WAT (in 
macrophages, T-cells, B-cells, natural killer cells), or cells from the stromal vascular fraction (SVF) 
(38,80,81). A large number of studies suggest that adipose tissue inflammation is associated with 
metabolic diseases, such as insulin resistance and other obesity-related complications, and 
lipodystrophy (82-87) (reviewed in (88)). Most of the better-defined adipokines, which are involved 
in inflammation, are discussed briefly in this section, while a more exhaustive list is given in Table 2 
and Fig 4. 
The plasmatic levels of TNF-α, which is a 26-kDa transmembrane protein that is cleaved to a 
17-kDa biologically active polypeptide, are relatively low in general. Within WAT, it is expressed in 
adipocytes and stromal vascular cells at higher levels in sc compared to vis adipose tissue (Fig 1) 
(89). Although there is no clear correlation between obesity and insulin resistance versus levels of 
plasmatic TNF-α, expression of this cytokine in WAT correlates with these two pathologies (90,91). 
Chronic exposure of mice to TNF-α induces insulin resistance, decreases the expression of genes 
involved in adipogenesis and lipogenesis in WAT and promotes lipolysis, while deletion of the 
TNF-α gene improves circulating FFA and insulin sensitivity in mouse obesity (92). Besides its role 
in WAT, TNF-α increases the expression of genes involved in the de novo synthesis of FA, and 
decreases that of genes involved in FA oxidation in liver. The autocrine and paracrine effects of 
TNF-α are responsible for the insulin resistance observed in humans and rats to whom this cytokine 
has been administrated (93-95). TNF-α also regulates the expression of other adipokines in WAT. 
For instance, it down-regulates the expression of adiponectin and increases the expression of IL-6, 
another cytokine involved in the endocrine role of WAT (see below) (96). 
IL-6 is found at high levels in the plasma in multiple glycosylated forms ranging from 22 to 
27-kDa a third of which is produced by adipocytes. Its synthesis and secretion are approximately 3 
times greater in vis compared to sc adipose tissue. The plasma levels of IL-6 positively correlate 
with fat mass, obesity, impaired glucose tolerance and insulin resistance, and thus they predict the  
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Name Cell type and 
expression 
Metabolic effects References 
Leptin 
 
 
 
Adiponecti
n 
(Acrp30) 
 
Resistin 
(FIZZ3, 
ADSF) 
 
Visfatin 
(PBEF) 
 
Adipsin 
 
RBP4 
 
Vaspin 
 
ANGPTL4/
FIAF 
 
Omentin 
 
Apelin 
 
 
Pref-1 
adipocytes 
 
 
 
adipocytes 
 
 
adipocytes 
 
 
 
adipocytes 
 
 
adipocytes 
 
adipocytes 
 
adipocytes 
 
adipocytes 
 
 
SVC 
 
adipose tissue 
(adipocytes, SVC) 
 
preadipocytes 
Satiety signal with direct effects on the hypothalamus; stimulates lipolysis; inhibits lipogenesis; improves insulin 
sensitivity; increases glucose metabolism; stimulates fatty acid oxidation; (increased leptin plasma concentrations 
in obese subjects – leptin resistance) 
 
Increases fatty acid oxidation with reduction in plasma fatty acid levels; decreases plasma glucose levels; 
increases insulin sensitivity; anti-inflammatory, anti-atherogenic; (decreased adiponectin plasma concentrations 
associated with IR) 
 
Recombinant resistin promotes systemic IR in mice; induces severe hepatic IR – increased rate of glucose 
production, in rat  
(increased resistin plasma concentrations in diet induce obese mice, but reduced mRNA levels in WAT of obese 
rodents; stimulates lipolysis); function controversial in humans 
 
Insulin-mimetic effects; hypoglycaemic effects by stimulating glucose uptake; promotes insulin sensitivity; pro-
adipogenic and lipogenic action; (increased visfatin plasmatic concentration in obesity linked to IR.) 
 
Stimulates TG storage, inhibits lipolysis 
 
Promotes IR; (increased RBP4 plasma concentrations in obesity) 
 
Improves insulin sensitivity; suppresses the production of resistin, leptin and TNFα 
 
Hypertriglyceridemic effect by LPL inhibition, improves glucose tolerance, induces hepatic steatosis, induces 
lipolysis; 
(lower ANGPTL4/FIAF plasma concentrations in type 2 diabetes patients) 
 
Enhances insulin-stimulated glucose transport in sc as well as om adipocytes, modulation of insulin action 
 
Reduces food intake (?), inhibits glucose-induced insulin secretion; (increased plasma levels in obesity associated 
with IR and hyperinsulinemia) 
 
Inhibits adipogenesis, overexpression in WAT affects the glucose tolerance and insulin sensitivity, and induces 
hypertriglyceridemia 
 
(41,47) 
 
 
 
(39,55,56) 
 
 
(64,65,97) 
 
 
 
(98) 
 
 
(99) 
 
(100) 
 
(101) 
 
(75,77,78) 
 
 
(102) 
 
(103,104) 
 
 
(79) 
 
 
Table 1: Adipokines involved in energy balance/metabolism. insulin resistance (IR), triglycerides (TG), pre-B-cell colony-enhancing 
factor (PBEF), visceral adipose-tissue-derived serine protease inhibitor (Vaspin), lipoprotein lipase (LPL), fasting-induced adipose factor 
(FIAF), angiopoietin-like protein 4 (ANGPTL4), retinol binding protein 4 (RBP4), subcutaneous (sc), omental (om), stromal vascular 
cells (SVC), APJ endogenous ligand (Apelin), adipocyte complement-related protein 30 (Acrp30),  found in inflammatory zone (FIZZ3), 
adipose tissue-specific secretory factor (ADSF) 
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development of type 2 diabetes and cardiovascular diseases (6,105). IL-6, like TNF-α, modulates 
the insulin sensitivity of the liver and of skeletal muscle thereby supporting the notion that cytokines 
produced by the adipose tissue influence whole body insulin sensitivity. It is thought that IL-6 
decreases the expression of both insulin receptor signaling components and Socs-3 (inducing-
suppressor of cytokine signaling-3) that negatively regulates insulin and leptin signaling. Central 
administration of this cytokine in rodents decreases body fat by increasing energy expenditure. In 
line with this effect, transgenic mice overexpressing IL-6 have reduced fat pad and body weights, 
which are associated with a growth defect (106-108). 
 In humans, the circulating levels of the Tumor Growth Factor-β1(TGF-β), a homodimer 
composed of two 12.5-kDa subunits, correlate positively with the body mass index (BMI) (109). 
This correlation also exists between the BMI and TGF-β production in WAT, a feature which holds 
especially for the vis WAT that produces more than two-fold more TGF-β compared to the sc WAT 
in humans (110,111). However, the adipocytes are not the main producers of WAT TGF-β, as the 
non-fat cells in the adipose tissue release more than 90% of it, production of which can be inhibited 
by TNF-α as well as by IL-1 (110). In addition to its association with adipogenesis, TGF-β has 
multiple functions in a wide range of tissues, which will not be discussed here. 
Mature Monocyte Chemotactic Protein 1 (MCP1) is a non-glycosylated 76 amino acid 
polypeptide (8.7-kDa) usually found at low levels, but IL-1, TNF-α or LPS rapidly induce its 
expression and secretion. MCP1 expression in WAT, and MCP1 circulating levels are increased in 
obesity (rodents and humans). Conversely, its circulating levels are reduced parallel to weight loss 
(112). In vis WAT especially, MCP1 is not only produced by the infiltrated macrophages, but also 
by adipocytes (113). In adipocytes, MCP1 influences lipid metabolism by down-regulating PPARγ 
which regulates lipid accumulation in these cells (the roles of PPARγ will be further discussed later). 
Moreover, MCP1 also stimulates leptin secretion and decreases insulin-stimulated glucose uptake in 
adipocytes. Transgenic animals over-expressing MCP1 in WAT only, develop a normal adipose 
depot mass, but the tissue is infiltrated by an increased number of macrophages and produces 
elevated amounts of TNF-α and IL-6. Furthermore, the plasmatic levels of FFA in these animals are 
increased, most likely reflecting an increased lipolysis. In addition, the overexpression of MCP1 in  
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Name Cell type expression Effects related to the metabolic syndrome       References 
Pro-inflammatory 
adipokines 
TNF-α  
 
IL-1 
 
IL-6 
 
Anti-inflammatory 
adipokines 
TGF-β 
 
IL-1Ra 
 
IL-10 
 
Inflammatory 
chemokines 
MCP1 
 
 
IL-8 
 
RANTES 
 
IP10 
 
Vascular proteins 
PAI1 
 
TF 
 
Angiotensinogen/Angiot
ensin II 
 
 
macrophages 
 
 
macrophages 
 
adipocytes 
 
 
 
adipocytes/macrophages
 
not clearly defined 
 
adipocytes/macrophages
 
 
 
adipocytes/macrophages
 
 
non adipose cells from 
WAT 
T cells 
 
adipocytes 
 
 
adipocytes 
 
not clearly defined 
 
adipocytes 
 
 
 
Induces insulin IR and increases lipolysis in adipocytes; decreases adiponectin and 
IL-6 expression; (increased expression in obese WAT) 
 
Increased expression in obese WAT 
 
Decreases insulin and leptin signaling; linked to IR; (increased plasma 
concentrations in obesity)  
 
 
Iincreased circulating levels in obesity 
 
Produced in response to stress; (increased plasma concentrations in IR) 
 
Increased circulating levels in obesity 
 
 
 
Increases lipolysis and leptin secretion, decreases insulin-stimulated glucose uptake; 
(increased plasma concentrations in obesity; disturbs insulin sensitivity) 
 
Increased expression in vis WAT in obesity 
 
Increased expression linked to development of type 2 diabetes 
 
Increased plasma concentrations in early stages of diabetes 
 
 
Increased circulating levels in obesity; linked to IR 
 
Increased expression in obese WAT; involved in vascular development in WAT (?) 
 
Linked to vascular inflammation; (increased plasma levels in obesity) 
 
(91,93) 
 
 
(114) 
 
(6,108) 
 
 
 
(110) 
 
(110,115) 
 
(38) 
 
 
(112,116,117) 
 
 
(118) 
 
(119) 
 
(120) 
 
 
(121) 
 
(122) 
 
(123-125) 
Table 2: Adipokines, Chemokines and Vascular proteins produced in WAT and involved in the inflammatory reactions. insulin 
resistance (IR), tumor necrosis factor alpha (TNF-α), interleukin 1 (IL-1), interleukin 6 (IL-6), transforming growth factor beta (TGF-β); 
interleukin 1 receptor antagonist (IL-1Ra); interleukin 10 (IL-10), monocyte chemotactic protein 1 (MCP1), interleukin 8 (IL-8), 
regulated upon activation, normally T-expressed, and presumably secreted (RANTES), interferon gamma inducible protein 10 (IP10), 
plasminogen activator inhibitor 1 (PAI1), tissue factor (TF) 
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WAT influences insulin sensitivity in the liver and especially in skeletal muscle, where it 
disturbs the insulin signaling pathway (116,126,127). Consistently, these mice become 
insulin resistant and glucose intolerant. These observations indicate that deregulation of 
cytokine expression in WAT can affect the overall metabolism of the body, particularly 
its insulin sensitivity (116,117). Furthermore, it suggests that MCP1-mediated 
macrophage infiltration of fat might contribute to metabolic deregulations associated with 
insulin resistance and obesity. In rodent obesity, increased circulating levels of MCP1 
positively correlate with increased monocytes, a phenotype also seen after peripheral 
administration of MCP1 to mice. In these animals, accumulation of monocytes in 
collateral arteries, and enhanced neointimal formation might implicate MCP1 in the 
development of atherosclerosis. 
At least two proteins, plasminogen activator inhibitor-1 (PAI1, 45-kDa), and 
tissue factor (TF, 47-kDa), which are involved in the fibrinolytic system and vascular 
haemostasis, are secreted by the WAT. PAI1 is a serine protease inhibitor protein (serpin) 
that is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), 
which activate plasminogen and hence the physiological breakdown of blood clots 
(fribrinolysis). This protein is expressed and secreted in the WAT of rodents (higher in 
vis compared to sc adipose tissue) and humans, where its expression is regulated by TNF-
α and TGF-β, themselves produced by WAT (111,128). The circulating levels of PAI1 
are correlated with obesity and insulin resistance, and thus predict future risk of type 2 
diabetes and cardiovascular disease (121,129). The adipose tissue is thought to be an 
important contributor to the elevated plasmatic PAI1 concentrations in obesity (130,131), 
but the mechanism underlying the association between PAI1 levels and the disturbances 
found in the metabolic syndrome are not well understood. However, inhibition of 
fibrinolysis by PAI1 might be responsible for the high incidence of cardiovascular 
diseases, which is a feature of this syndrome (132).  
TF is a protein released from damaged tissue that triggers the clotting cascade. It 
acts as a cell-surface receptor for the activation of factor VII. Its expression is up-
regulated in the WAT of ob/ob mice (133). Besides its role in coagulation, TF is thought  
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Figure 4. Schematic representation of the cell types that constitute the white adipose 
tissue and the adipokines, chemokines and vascular proteins secreted by each cell 
type, as well as their beneficial and deleterious effects on whole body homeostasis.   
 
to be involved in vascular development and integrity (122). In obesity, where the adipose 
mass is greatly increased, the need for oxygen supply is dramatically augmented. In this 
condition, it is likely that TF is involved in the angiogenesis associated with fat mass 
expansion.  
Several proteins of the classic renin angiotensin system (RAS) are synthesized in 
the WAT. Adipose tissue RAS is considered to be a potential link between hypertension 
and obesity. The intimate relationship between WAT and RAS may also have a role in 
the pathophysiology of type 2 diabetes, especially in obese individuals. These points have 
been addressed in different review articles (45,134,135). Finally, the adipose tissue also 
expresses a variety of enzymes implicated in the activation, inter-conversion and 
inactivation of steroid hormones that are also involved in the regulation of metabolic 
pathways. This role will not be discussed here as it has been reviewed recently (136). 
Similarly, the role of adipokine in the interaction between adipose tissue and immunity 
has been summarized recently and will not be presented here (36,80). 
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II.4. Pathologies of the white adipose tissue 
 
From the above, it has already become obvious that balanced amounts of adipose tissue are 
critical for an optimal regulation of lipid and glucose metabolism. Excess adiposity contributes to 
the development of insulin resistance, dyslipidemia, inflammation, hypertension, and cardiovascular 
diseases, while selective loss of WAT, called lipodystrophy, also predisposes to the same 
complications (Fig 3). Both branches of these deregulations, obesity and lipodystrophy, are 
addressed below. 
II.4.1. Obesity 
 
When the energy balance is positive, as often occurs with western diet, the adipose tissue 
becomes hypertrophic and subsequently hyperplastic. Since the adipocytes cannot expand beyond a 
“critical size”, which is thought to be genetically established for each depot type, the adipocyte  
number is increased when this critical point is reached (137,138). Combined together, cell size and 
cell number increase leads to an expansion of the adipose tissue, which ultimately results in obesity 
(7).  
Obesity produces what is called a “low grade” inflammatory reaction in the adipose tissue by 
a mechanism that remains largely unknown (139). As presented in a former section, autocrine, 
paracrine and endocrine signals from adipocytes, together with increased adipose tissue mass 
stimulate the synthesis and secretion of adipokines that trigger macrophage infiltration in the WAT. 
As already mentioned, there is a positive correlation between the adipocyte size and BMI, and the 
increase in adipokine expression in WAT (112,140-143). This low grade inflammation is thought to 
result from a chronic activation of the innate immune system (86). The involvement of obesity in 
this process was suggested by the decrease of inflammation in the WAT of obese patients after 
weight loss (112,144). Low grade inflammation in WAT impairs its ability to control plasmatic 
FFA, promotes its deleterious endocrine function, and ultimately leads to insulin resistance, 
impaired glucose tolerance, and may result in diabetes and cardiovascular diseases (Fig 3).  
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It was shown in models of obese rodents as well as in humans, that obesity is linked to an 
increase in adipocyte size. This hyperplasia is associated with an increased number of necrotic-like 
dead adipocytes surrounded by infiltrated macrophages, and the progressive up-regulation of 
inflammatory genes, such as TNF-α within the WAT. Moreover, this up-regulation precedes the 
dramatic increase in the circulating insulin levels suggesting that the inflammatory reaction in the 
WAT is responsible for systemic insulin resistance. In addition, the persistence of WAT 
inflammation is responsible for the maintenance of insulin resistance in obese models 
(87,126,142,145-147). 
The genetics of human obesity unveiled the key role of leptin and melanocortin pathways, 
but only in rare cases. In fact, it is more a myriad of polymorphisms in genes and candidate regions, 
which defines the susceptibility of an individual to weight gain, a susceptibility that is accentuated 
by a permissive environment (diet, sedentarity) (148). 
 
II.4.2. Lipodystrophy 
 
Lipodystrophies are characterized by the absence of fat store development, the altered 
distribution of these reserves or their loss with, as a consequence, an excess accumulation of lipids 
in the liver, skeletal muscle and other organs, along with the emergence of insulin resistance (Fig 3) 
(149). It was demonstrated recently in mice that the membrane-anchored metalloproteinase MT1-
MMP is required for WAT development and function. In its absence, the animals are lipodystrophic. 
MT1-MMP governs the interaction between the adipocyte and the extracellular matrix, and hence 
acts as a 3-dimensional-specific adipogenic factor (150).  
The different human lipodystrophic syndromes are defined by an altered quantity and/or 
distribution of adipose tissue (lipoatrophic peripheral sc fat and increased vis fat). In humans, the 
classification of lipodystrophies is usually according to their origin, either genetic or acquired. 
Among the inherited lipodistrophies, some are better characterized, among which are the familial 
partial lipodystrophy Dunnigan-type (FPLD) and the familial generalized lipoatrophy known as 
Berardinelli-Seip congenital lipodystrophy (BSCL). FPLD is characterized by a loss of sc fat, while 
the inter- and intra-muscular fats as well as the abdominal fat are preserved. In adult patients, insulin 
resistance and type 2 diabetes correlate with an increase in plasmatic TG and  
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FFA concentrations, as well as the presence of C-reactive protein (CRP). Several FPLD patients also 
suffer from dyslipidemia and hypertension. In 50 % of the FPLD families there is a link between 
FPLD and the LMNA (lamin A) gene also associated with premature forms of aging, which codes 
for the nuclear envelope protein lamin A/C (151). Different mutations in this gene have been 
identified as culprits for lipodystrophy, but the mechanism by which it occurs is not known (152-
154). Mutations in the LMNA gene are linked to a decrease in the plasmatic concentrations of 
adiponectin and leptin, and an increase in circulating TNF-α concentrations, which may cause the 
insulin resistance observed in FPLD patients (155). Another gene involved in FPLD encodes 
PPARγ, a transcription factor involved in adipogenesis.  
BSCL is a generalized lipoatrophy characterized by the total loss of WAT, which is 
associated with insulin resistance and increased plasmatic TG levels. It is caused by mutations in 
two genes independently linked to this pathology. These genes encode seipin, a protein of unknown 
function, and 1-acylglycerol-3-phosphate-acyl transferase, which is involved in TG synthesis 
(156,157). 
Among the acquired lipodystrophies, the most common is the one associated with the 
antiretroviral treatments in HIV–infected patients. 50% of these patients suffer from lipoatrophy, 
often associated with dyslipidemia, impaired glucose tolerance and diabetes. Interestingly, treatment 
of the patients with protease inhibitors (which are a part of the pharmacopoeia of HIV treatment) 
markedly alters the expression and secretion of adipokines from WAT. While adiponectin 
expression and secretion are decreased, IL-6 and TNF-α expression is up-regulated in these patients. 
In WAT, increase in the production of these inflammatory cytokines is correlated to a decrease in 
adipocyte size, an increase in fibrosis, and infiltration of macrophages (158-161). 
Altered metabolism due to the loss of WAT is also observed in mouse models of 
lipodystrophy. Induced fat-cell apoptosis through targeted activation of caspase 8 causes WAT 
distrophy, glucose intolerance, and signs of inflammation (84). The same phenotype of adipocyte 
apoptosis, WAT fibrosis, macrophage infiltration, and increased inflammation is seen in mice with 
PPARγ specifically deleted from WAT in adult animals (see below) (162).  
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In conclusion, the study of lipodystrophy resulting from an impaired development of body 
fat or, alternatively, its altered distribution, revealed a link between this pathology and deregulation 
of lipid and glucose metabolism with insulin resistance. Therefore, lipodystrophic patients, 
independent of the origin of lipodystrophy, either genetic or acquired, suffer from major 
complications with a prevalence of diabetes, cardiovascular diseases, pancreatitis, and liver steatosis 
with an evolution towards cirrhosis. Treatments with hypoglycemic and hypolipidemic drugs are 
beneficial therapeutic options for these patients, and for those with very low leptin levels, leptin 
treatment provides a major improvement (163,164).  
 
III. Role of the Peroxisome Proliferator-Activated Receptor γ (PPARγ) in white adipose tissue 
 
Adipocyte differentiation is intimately associated with the pathologies linked to WAT such 
as obesity, lipodystrophy and inflammation, as described above. Peroxisome proliferator- 
activated receptors (PPARs) compose a subgroup of three receptors, belonging to the nuclear 
hormone receptor family, and acting as lipid sensors to modulate gene expression (165,166). They 
are implicated in both major metabolic regulations, and processes controlling cellular fate (167). In 
this part of the introduction, we will concentrate on one of the three PPAR isotypes, PPARγ, which 
is a pivotal coordinator of adipocyte differentiation and fatty acid uptake and storage (Fig 5). 
 
III.1. PPARγ is a member of the superfamily of nuclear receptors 
 
The PPARs form a subfamily of the nuclear receptor superfamily. Three isotypes, encoded 
by three different genes, have been identified: PPARα (NR1C1), PPARβ/δ (NR1C2; PPARβ) and 
PPARγ (NR1C3) (168).  
PPARα was the first isotype discovered as the molecular target of hepatic peroxisome 
proliferating agents in rodents. Since then, these receptors were linked to an extensive range of 
cellular and systemic functions far beyond their role in the peroxisome proliferation (167). The  
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Figure 5. The main functions of PPARγ in the white adipose tissue are given with respect to 
adipocyte differentiation, lipid storage, pathologies induced by its ill functioning or as a target of 
TZDs. 
 
three PPAR family members have distinct pattern distributions. PPARα and PPARγ are mostly 
expressed in liver and adipose tissue respectively whereas PPARβ is abundantly expressed 
throughout the body. Consistent with their expression profiles, the PPARs carry out unique 
functions in the regulation of the energy metabolism (167).  
By their role as lipid sensors, binding numerous fatty acid and their derivatives such as 
eicosanoids and prostaglandins (see below), the PPARs are able to modulate the expression of 
several genes involved in metabolism. Particularly, PPARγ which is mostly expressed in the adipose 
tissue plays an important role in the development, maintenance and metabolism of this tissue. 
Deregulation of its transcriptional activity accounts for several pathologies of the adipose  
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tissues such as obesity and lipodystrophy having as a consequence the development of metabolic 
related diseases (169). Thus, it is not surprising that PPARγ is one of the primary targets of synthetic 
compound used as successful treatment of metabolic related diseases such as type 2 diabetes (170).   
 
III.2. PPARγ and its expression pattern 
 
Alternative promoters give rise to two PPARγ isoforms. PPARγ1 is the ubiquitous isoform 
found in all PPARγ expressing tissues such as WAT, BAT, macrophages, liver, skeletal muscle, 
kidney, colon, pancreas, vascular endothelium and others (171-173). PPARγ2, which has an 30 
residues (29 in humans) N-terminal extension over that of PPARγ1, is expressed primarily in WAT 
(Fig 6A) (174,175).  
Interestingly, the expression of the two PPARγ isoforms is regulated by the energetic status 
of the body. The expression of PPARγ2 in WAT and BAT is down-regulated by fasting whereas the 
expression of  PPARγ1 is only modestly down-regulated (172). Exposure of mice to a high fat diet 
increases the adipose expression of PPARγ1,2  and induces the expression of  PPARγ2 in liver of 
obese mice (176).  
 
III.3. PPARγ and its structure  
 
PPARγ, like other nuclear receptors, posses a modular structure composed of several 
functional domains (177). The N-terminal A/B domain harbours a ligand-independent 
transactivation function called AF-1 (178). The C domain contains the DNA Binding Domain 
(DBD) that consist of two zinc finger motif allowing the receptor binding to specific sequences 
called Peroxisome Proliferator Receptor Elements (PPRE) found in the regulatory regions of PPAR-
responsive genes. Following the hinge region found in the D domain, the E domain contains the 
Ligand Binding Domain (LBD) which harbours a ligand dependent transactivation function called 
AF-2, (Fig 6A). This region is intimately involved in the generation of the receptor-cofactor binding  
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surface. The LBD reveals a structure composed of 12 helices and a small β-sheet of four strands 
creating a large hydrophobic pocket. Its large size accommodates binding of a high variety of 
structurally different fatty acids and their derivatives, (see below), (179). In this structure, helix 12 
covers the predicted ligand binding pocket creating a binding surface for cofactors (180). 
Stabilisation of helix 12 by agonist binding is critical to the transactivation properties of the receptor 
(181). 
 
III.4. PPARγ and its mode of action: heterodimerization and DNA binding  
 
Unlike steroid hormone receptors, which function as  homodimers, PPARs in general, form 
heterodimers with the retinoid X receptor (RXR, NR2B) (182). Like PPARs, RXR exists as three 
distinct isoforms: RXRα, β, and γ, all of which are activated by the endogenous agonist 9-cis 
retinoic acid (183). All are able to heterodimerize with PPARγ and their different interactions affect 
the recognition of target promoters (184). Recently, our team showed that the PPAR/RXR 
heterodimerization does not require ligand nor DNA binding (185). 
The PPARγ/RXR heterodimers activate transcription by binding to specific sequences, 
PPREs, found in the promoter region of PPARγ target genes. The PPREs are direct repeats (DR-1) 
elements consisting of two hexanucleotides with the consensus sequence AGGTCA, separated by a 
single nucleotide spacer (186). Cis elements adjacent to the PPRE core site, especially in 5’, play a 
role in defining the binding selectivity of the response elements (184).   
 
III.5. Mechanism of transcriptional regulation  
 
PPAR mediated transactivation results from a combination of its heterodimerization, binding 
to PPRE and its ligand activation. The conformational changes induced by the ligand binding or by 
other activation process such as phosphorylation, ubiquitination or sumoylation of the receptor allow 
interaction with proteins called cofactors, see below. This interaction transduces regulatory action to 
the basal transcriptional machinery, (Fig 6B)  (11).  
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Other regulatory mechanisms can influence the transcriptional activity of the receptor such 
as the ligand independent activation trough the AF-1 but also AF-2 as well as the non genomic 
actions of the receptor. However, for space reasons these points are not discussed here. Detailed 
information on this subject can be found in the recent review by Feige and colleagues (167).  
 
III.5.1. Ligand/PPARγ complex 
 
PPARs are ligand-dependent transcription factors. Activation of their transcriptional activity 
and subsequent activation of their target genes depends essentially on the nature of the ligand bound 
to the receptor. Some ligands are shared by the three PPAR isotypes, such as polyunsaturated fatty 
acids and several others are specific or have higher affinity for one of the isotypes. Here we will 
resume our knowledge on the natural and synthetic PPARγ compounds (11,75).    
 
III.5.1.1. Natural PPARγ ligand 
 
Cell based transactivation assays and direct binding studies allowed identification of several 
natural and synthetic PPARγ ligands. A large variety of unsaturated fatty acids (PUFAs) such as 
linoleic acid, linolenic acid, arachidonic acid, and eicosanoid derivatives such as prostaglandins, 
bind and activate PPARγ at micromolar concentrations (187). The affinity of the receptor for these 
compounds is in line with their plasmatic concentrations, however their intracellular concentration is 
unknown. Conversion of arachidonic acid via the cyclooxygenase pathway provides to PPARγ its 
specific agonist the 15-deoxy-∆12,14-prostaglandin J2 (15d-PGJ2) (11).  
Recently, natural PPARγ ligands such as 15d-PGJ2, 15-ketoprostaglandin F2α and 15- 
ketoprostaglandin E2, were shown for the first time to share a common structure, the α,β-
unsaturated ketone. Through this structure, they are able to bind covalently to PPARγLBD, and this 
specific binding is required for PPARγ activation. The covalent binding enables the receptors to 
accumulate under an active form, allowing ligands with low concentrations to function as PPARγ  
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Figure 6. A. Schematic linear representations of PPARγ1 and PPARγ2.  The A/B domain, which 
contains 30 additional N-terminal residues in the PPARγ2 isoform, harbours a weak ligand 
independent transactivation function 1 (AF-1). The C domain binds DNA trough a two zinc finger 
motif (DBD). The D domain is a hinge region, whereas the E domain contains the ligand binding 
domain (LBD) as well as a ligand dependent transactivation function 2 (AF-2). Moreover, the E 
domain is responsible of interactions with cofactors. B. Classical model of target gene activation 
by PPAR/RXR heterodimers. The ligand activated (red dot) PPAR:RXR complex binds to the 
PPRE producing a change in chromatin structure indicated by the histone release. PPRE-
PPAR:RXR complex targets coactivator complexes to the promoter. The promoter chromatin at the 
transcription initiation site region is modified by the acetyl transferase activity of coactivators 
producing a transcriptionally competent structure. Additional transcription factors and the basal 
transcriptional machinery are recruited to the accessible promoter and transcription is initiated.  
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in vivo. The covalent binding is specific to natural PPARγ ligands since mutations of residues 
responsible for these interaction does not affect the activity of synthetic ligands such as 
Rosiglitazone (188).  
III.5.1.2.Synthetic PPARγ ligands: agonists and antagonists 
 
A variety of specific synthetic PPARγ agonists have been developed such as the 
Thiazolidinediones (TZDs). Rosiglitazone and Pioglitazone, which are TZDs compounds, are                           
currently being used clinically in the treatment of metabolic related diseases. A thorough 
examination of their pharmacological effects is available at section Introduction III.9.1.  
Specific synthetic PPARγ antagonists such as SR202, GW9662 or BADGE (bisphenol A 
diacylycidyl ether) were developed as an alternative to the undesirable side effects observed with the 
synthetic full agonists, which will be described in section Introduction III.9.2. Their development 
was based on the observation that PPARγ heterozygous mice (PPARγ +/-) have a better resistance to 
a high fat diet (HFD) induced obesity and have a better insulin sensitivity then their wt counterparts 
on the same high fat diet (189). Thus, it was thought that activation or inhibition of PPARγ 
transcriptional activity has a beneficial outcome on the treatment of metabolic related diseases such 
as type 2 diabetes. However, their long term use was shown to have more deleterious side effects 
than full PPARγ agonists (section Introduction III.9.2.). 
III.5.1.3. Selective PPARγ modulators 
 
One can divide PPARγ agonists into two groups, classical full agonists such as the TZDs 
(section Introduction III.5.1.2. and III.9.1.), and newer “partial agonists”, which were developed as 
an alternative to the side effects observed with the full agonists (section Introduction III.9.2.). Partial 
agonists also called “selective PPARγ-modulators” (SPPARγMs) are compounds that, at saturating 
concentrations, produce transcriptional activity below that of saturating concentrations of  full 
PPARγ agonists (190). Besides their different affinity to the receptor, which influences their overall 
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transcriptional activity, SPPARγMs also interact with cofactors in a tissue specific manner. This 
feature is thought to be responsible for their lack of side effects and is at the basis of the SPPARγMs 
concept. More information on SPPARγMs and their pharmacological effects are available at section 
Introduction III.9.3.   
III.5.2.  Cofactors interaction 
 
Several cofactors proteins (coactivators and corepressors) that mediates the ability of PPARγ 
to initiate or suppress the transcriptional process were identified. Their mode of action often 
involves modulation of the chromatin compaction. Chromatin compaction and histone deacetylation 
were shown to repress gene activation whereas histone acetylation and methylation were shown to 
activate transcription. A brief summary of the mechanisms of action of several coactivators and 
corepressors are given in the next sections. For more details on the subject, the readers are 
encouraged to consult the review written by Feige and colleagues (167).  
 
III.5.2.1. Coactivators 
 
The interaction between PPARγ and coactivators depends on the nature of the ligand bound 
to the receptor. The natural ligand 15d-PGJ2 does not recruit the same set of coactivators as the 
synthetic agonist Troglitazone. This observation shows the importance of the structure of the 
PPARγ-ligand complex for the receptor-coactivator interaction and the further activation of target 
genes (191).  
Coactivators are able to remodel chromatin and reposition nucleosomes via their histone 
acetyltransferase (HAT) and methyltransferase (HMT) functions. These modifications, allow 
binding of the pre-initiation complex and of other transcription factors to the regulatory region of 
activated genes (192).  
Coactivators interact with PPARγ in a agonist dependent-manner through a conserved 
LXXLL motif (where X is any amino acid) (193). This motif is formed by residues within the helix 
3 and 12 of the LBD (194). Several coactivators, including CBP/p300 and steroid receptor  
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coactivator-1 (SRC-1) posses HAT activity that can remodel chromatin structure (11). As mentioned 
above, SPPARγMs binding to PPARγ was shown to be responsible of a less efficient interaction 
between the receptor and these coactivators (section Introduction III.5.1.3.; (195)).   
The protein arginine methyltransferase 2 (PRMT-2) was shown to interact directly with 
PPARγ and to enhance its transcriptional activity via its HMT activity (196). However, its 
mechanism of action remains largely unknown.  
Other coactivators such as PPAR binding protein (PBP/TRAP220) and PPARγ coactivator 1 
(PGC-1) form a bridge between the nuclear receptor and the basal transcriptional machinery 
favouring the transcriptional activation (197,198).  
 
III.5.2.2. Corepressors 
 
Corepressor activity is mediated essentially through recruitment of histone 
deacetytransferases (HDACs) although interactions with basal transcription  machinery  might also 
play a role (195,199,200). 
The interaction of PPARγ with the nuclear receptor corepressor (NCoR) and the silencing 
mediator of retinoid and thyroid receptors (SMRT) was documented by direct interaction in in vitro 
interaction assays  (201,202). Both repress the activity of the receptor in the absence of ligand or 
upon antagonist treatment (192). Interestingly, their action was demonstrated to be  promoter 
specific since NCoR and SMRT were associated to PPARγ on glycerol kinase and oxidized LDL 
receptor 1 promoters but not on the aP2 promoter (203).  
In contrast to NCoR and SMART which interact with PPARγ in the absence of ligand or 
presence of an antagonist, the receptor interacting protein 140 (RIP140) and the retinoblastoma 
protein (Rb) interacts with the receptor in presence of an agonist (204,205). It is possible that 
RIP140 and Rb constitute a functional negative feedback loop that limits activation of the receptor 
in the continued presence of an agonist.   
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III.5.3.  Phosphorylation 
 
Modulation of PPARγ activity by phosphorylation allows the receptor to integrate signals 
coming from the plasma membrane. Besides the classical ligand-dependent control, several studies 
have reported the modulation of PPARγ activity by phosphorylation. The transcriptional activity of 
the receptor is not only modulated by the receptor phosphorylation but also by the phosphorylation 
of the kinase or of cofactors interacting with the receptor (206,207). Because of space limitations, 
we will only summarize our knowledge on the modulation of PPARγ activity by its phosphorylation. 
For further information on this subject please refer to the review written by Gelman and colleagues 
(208).  
The effects of phosphorylation on the PPARγ activity depends largely on the affinity of the 
ligand bound to the receptor, the nature of the bound cofactors, the stimulus and the activated 
kinase, the phosphorylated residue, the cell type and the target promoter. For instance, the 
phosphorylation of serine 112 found in the A/B domain can decrease the activity of the receptor or 
can increase it depending on the cellular type (209-211). Phosphorylation of the A/B domain 
modulates the AF-1 function but it can also have a repercussion on the ligand binding potential of 
the E domain. This interference between the N-and C-terminal domains seems to be reciprocal as 
treatment of PPARγ1 with an agonist reduces the phosphorylation of  the serine 82 from the A/B 
domain by MAPKs (210). The specific relationship between kinases and PPARγ is illustrated by the 
fact that the extracellular signal-regulated kinase 2 (ERK2) and the Jun NH2-terminal kinase (JNK), 
but not p38 kinase can phoshorylate the receptor (211,212).  
 
III.5.4.Ubiquitination 
 
Ubiquitin is a small protein that binds covalently to proteins to target them to degradation by 
the 26S proteasome. Ubiquitin-dependent degradation of the activated PPARγ is another regulatory 
mechanism by which the receptor modulates its transcriptional activity. Upon agonist binding, the 
receptor is ubiquitinated on lysine residues prior to its degradation by the proteasome. However, 
authors demonstrated that it is not the transcriptional activity of the receptor which stimulates its  
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degradation, but rather the conformational changes induced by the agonist binding (213). Moreover, 
PPARγ1 serine phosphorylation status was shown to protect the receptor against the ubiquitin-
dependent degradation (214).  
 
III.5.5. Sumoylation 
 
Small ubiquitin-like modifiers (SUMO) compose a family of proteins homologous to 
ubiquitin. They can be reversibly conjugated to target proteins through covalent binding. Their 
binding regulates several cellular mechanisms including transcriptional repression. Sumoylation of 
PPARγ occurs on lysine residues within the AF-1 domain, and was shown to repress its 
transcriptional activity. Moreover, agonist treatment reduces the sumoylation of the receptor (215). 
Studies with phosphorylation-defectif PPARγ mutants suggest that phosphorylation of serine 112 
promotes sumoylation of the receptor (216). 
A recent report showed a link between sumoylation and ubiquitination of PPARγ. Ligand-
dependent sumoylation of the receptor promotes the binding of corepressor complexes such as 
NCoR/HDAC3 to PPARγ. Τhe subsequent binding of this new formed complex on the promoter 
region of target genes suppresses their transcription. This in turns prevents recruitment of the 
ubiquitylation/proteasome machinery that normally degrades these complexes. As a result, NCoR 
complexes are not removed from the promoter and target genes are maintained in a repressed state 
(217).  
 
III.6. PPARγ and adipocyte differentiation at the cellular level 
 
Both adipocyte number and adipocyte size are major contributors to adipose tissue mass. 
Therefore, adipocyte differentiation is crucial in the maintenance of adipose tissue integrity. 
Adipocytes are either derived from resident differentiated preadipocytes or from progenitor cells 
(218,219). PPARγ is a key player in this process (Fig 5). It was recently shown that activated 
PPARγ not only stimulates differentiation to adipocytes of resident adipose tissue preadipocytes,  
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but it also promotes the mobilization of bone marrow-derived circulating progenitor cells to WAT 
and their subsequent differentiation into adipocytes (220,221). These results add an unexpected 
dimension to the field since they demonstrate, for the first time, that cells which reside outside the 
adipose tissue can influence and contribute to its fate.  
The role of PPARγ1 and PPARγ2, as key regulators of adipocyte differentiation from 
preadipocytes was shown by several groups (175,222,223). Based on cellular studies, the 
differentiation of preadipocytes to adipocytes can be divided into four steps. First, the preadipocytes 
are withdrawn from the cell cycle, and genes responsible for the “preadipocyte phenotype” are 
down-regulated. The second step, called the “mitotic clonal expansion”, allows a last round of cell 
division. Next, 48 hours after the initiation of differentiation, the cells start to acquire the “early 
adipocyte phenotype”, which represents the third step. Fourth, in the “differentiated adipocytes”, 
genes already expressed at low levels in the early adipocyte phenotype, are now at their maximal 
expression levels, especially genes involved in energy storage and fat metabolism, such as C/EBPβ 
and PPARγ (224,225). 3T3L1 cells, frequently used as adipocyte differentiation models, which have 
been manipulated to express small interference RNA (siRNA) against PPARγ or embryonic stem 
cells (ES cells) deficient for PPARγ (PPARγ -/-), are unable to differentiate into adipocytes. These 
defects in PPARγ expression reveal the important involvement of the receptor in this differentiation 
process, especially in the transition between the “mitotic clonal expansion” and the acquisition of 
the “early adipocyte phenotype” (226,227). Conversely, experiments on gain of function, using 
retroviral expression of PPARγ in cultured fibroblasts , as well as treatment of fibroblasts with 
PPARγ agonists, were shown to stimulate adipogenesis (228).  
Obviously, PPARγ is not the only transcription factor controlling the differentiation of 
mesenchymal cells to adipocytes, but is a major player in a sophisticated network of transcription 
factors and their co-repressors and co-activators, which respond to specific stimuli to repress or 
stimulate adipocyte formation. The elegant cascade of transcription factor signaling in the regulation 
of adiposeness has been reviewed recently (229), and therefore will not be discussed further here. 
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III.7. PPARγ and lipid storage 
 
 In addition of being involved in the differentiation of adipocytes, PPARγ participates in the 
function of the mature cells. Indeed, PPARγ is the major regulator of lipid storage in WAT  
(230). It promotes the release of FFA from circulating lipoproteins by regulating lipoprotein lipase 
expression (LPL) (231), and stimulates their uptake by enhancing the expression of the fatty acid 
translocase CD36, and of the fatty acid transport protein FATP1 (232-234). Furthermore, PPARγ 
regulates the intracellular retention/transport of FFA by controlling the expression of fatty acid 
binding proteins (FABPs) (235). It also promotes the esterification of FFA into TG and their storage 
by regulating the expression of enzymes such as phosphoenol pyruvate carboxykinase, glycerol 
phosphate dehydrogenase, and diacylglycerol O acyltransferase. Perilipin, which is the predominant 
protein associated with adipocyte lipid droplets and has a key function in regulating adipocyte lipid 
storage and body fat accumulation, is stimulated, too (234,236-241). Finally, PPARγ participate in 
the de novo FFA synthesis by regulating directly or indirectly the expression of enzymes such as 
fatty acid synthase, acetyl CoA synthetase, and stearoyl CoA desaturase 1 (Fig 5) 
(230,233,234,242). 
 
III.8. Ablation of PPARγ expression and activity in WAT: lessons from mouse models and 
human genetics 
 
Studies on the role of PPARγ in WAT have been stimulated by the finding that TZDs, now 
used to treat patients suffering from type 2 diabetes, are specific ligands of PPARγ. Most of the 
present knowledge on PPARγ functions in energy homeostasis and its deregulations derive from the 
use of animal models and the investigation of patients bearing variant forms of the PPARγ gene (Fig 
5). 
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III.8.1. Mouse models 
 
General ablation of the PPARγ gene in mice is lethal due to placental malformation (243). In 
a model of generalized PPARγ ablation, which prevents embryonic lethality by preserving PPARγ 
expression in trophoblasts, severe lipodystrophy, insulin resistance and hypotension probably due to 
increased vascular relaxation, were observed (244). On the contrary, the PPARγ +/- heterozygous 
animals are viable and do not present any major defects except growth retardation in males, possibly 
due to a deregulation of growth hormone signaling in the WAT (245). The PPARγ +/- mice have 
normal insulin sensitivity under a standard diet (SD). However, when on a high fat diet (HFD) and 
compared to wild type animals, they are protected against fat mass increase, which is reflected in 
smaller adipocytes. Furthermore, they do not develop insulin resistance or liver steatosis, and 
display a substantial increase in FA oxidation in the liver and in skeletal muscle (189,246,247). 
Specific deletion of PPARγ in WAT has led to a better understanding of pathologies linked 
directly to PPARγ dysfunction in this tissue. Three different laboratories performed this specific 
genetic manipulation. In a first study, using mutant animals on a standard diet, adipocyte 
hypocellularity and hypertrophy were observed, involving an increase of the levels of plasma TG 
and FFA, and a decrease in leptin and adiponectin levels, which were accompanied by increased 
hepatic gluconeogenesis and insulin resistance. This latter was reversed by TZD treatment that, 
however, failed to lower circulating FFA. These animals were more susceptible to HFD-induced 
steatosis, hyperinsulinemia and associated insulin resistance (248). A similar phenotype was 
observed in a “knock in” mouse model using the dominant negative mutant PPARγL466A, which 
again showed the relationship between PPARγ function, adipose tissue and typical metabolic 
syndrome pathologies. Homozygous PPARγL466A mice died in utero, similarly to PPARγ -/- mice 
(249). 
In a second ablation study, mutant mice lacking PPARγ in adipose tissue were fed HFD, 
following which they presented diminished weight gain and plasma levels of adiponectin and leptin 
but, in contrast to the first study, did not develop systemic insulin resistance or glucose intolerance. 
Furthermore, the mice exhibited diminished glucose uptake in the skeletal muscle,  
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which suggests insulin resistance in this tissue. However, the liver did compensate for this insulin 
resistance by increasing glucose uptake and utilization, thereby improving the overall systemic 
insulin sensitivity. This improvement coincided with an increased expression of PPARγ in the liver, 
where it might have had a protective effect under these conditions (250). The reason for the 
difference in insulin resistance between the two studies remains unclear, but different feeding 
protocols might be the cause. These studies also showed that several genes involved in lipid uptake 
and lipogenesis were down-regulated. The resulting diminution of fat accumulation in the  
WAT of these animals most likely contributed to the plasmatic increase in FFA and TG 
concentrations as well as to hepatic steatosis. (248,250).  
In the third study, ablation of PPARγ was induced selectively in adipocytes after the animals 
had reached adulthood. PPARγ-null adipocytes died within a few days after invalidation of the gene 
thus demonstrating that, in addition to its role in adipose differentiation, PPARγ is essential for the 
survival of mature adipocytes (162). In the studies discussed above, both isoforms PPARγ1 and 
PPARγ2 were deleted. When PPARγ2 alone is selectively disrupted, the mutant mice develop 
normally and are viable. However, they display a reduced WAT mass with smaller and 
heterogeneous-in-size adipocytes reflecting less lipid accumulation, well in line with a decreased 
expression of lipogenic genes. However, there was no liver steatosis, and insulin resistance was 
observed in male mice only. It was corrected by TZD treatment, probably by the effect of this drug 
on the remaining PPARγ1 in WAT, liver, and skeletal muscle. This model underscores again that the 
integrity of the adipose tissue is primordial for a good whole body energy balance as well as for 
systemic insulin sensitivity. In addition, it shows that PPARγ1 alone can sustain development in 
general and drive adipose tissue formation in particular (251). 
 Another model in which the expression of PPARγ2 and γ1 is blunted in WAT, without 
affecting PPARγ1 expression in the liver and skeletal muscle, but in which PPARγ1 was found to 
increase in BAT, was called the PPARγ hypomorphic mouse (PPARγhyp/hyp) (252). PPARγ hyp/hyp 
mice present a severe lipodystrophic syndrome and a relatively high neonatal mortality. Even if the 
surviving mice develop a hyperlipidemia, they present only limited metabolic consequences of the 
severe WAT lipodistrophy most likely because of compensation, particularly by muscles (252).  
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The site of action of TZDs has been long debated and although not fully clarified yet, 
significant knowledge has come from the use of the A-ZIP/F1 fatless mouse that lacks WAT. These 
mice present a phenotype similar to that of humans with lipoatrophic diabetes, fatty liver, 
hyperlipidemia, and hyperglycemia and insulin resistance. Treatment of these animals with 
Rosiglitazone and Troglitazone (two PPARγ agonists), (see section Introduction III.9.1.) showed 
that adipose tissue is required for the antidiabetic, but not for the hypolipidemic effect of TZDs 
(253). Using the same model it was shown that Rosiglitazone enhances insulin action in skeletal  
muscle by a distribution of fat away from this organ, contributing at least in part to liver steatosis. 
Ablation of liver PPARγ in the A-ZIP/F1 mice, while reducing steatosis, aggravates triglyceride 
clearance, hyperlipidemia and, as a consequence, muscle insulin resistance (254,255). 
The results obtained from these different mouse models underscore the link between 
adipogenesis and the metabolic syndrome (256), and highlight the crucial role of  PPARγ for the 
development, integrity and well-functioning of the WAT. Adipocytes communicate with 
preadipocytes, monocytes/macrophages and endothelial cells within the adipose tissue and with the 
liver, skeletal muscle, pancreas and brain at the systemic level. Most importantly, it shows that 
deregulation of the WAT function and integrity, which often interferes with the production of 
secreted adipokines and other signaling proteins by the different cell types comprised in the WAT, 
ultimately affects the homeostasis of the whole body. A disturbance of this balance contributes to 
the development of the metabolic syndrome and associated risks (32). 
 
III.8.2. Human genetic studies 
 
 As highlighted by the animal models, PPARγ is a determining factor for fat-related 
pathologies. Similarly, arrays of polymorphisms and mutations have been identified in the human 
PPARγ gene, which are linked to metabolic phenotypes. Only mutations particularly informative on 
the role of PPARγ in WAT will be discussed below, with regard to adipose mass (obesity and 
lipodystrophy), energy balance, insulin resistance, and low-grade inflammation. 
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III.8.2.1. PPARγ loss of function mutations 
 
  Familial partial lipodystrophy (FPL) is associated in a few patients with mutations in the 
PPARγgene. This partial lipodystrophy affects limbs and buttocks, but spares abdominal sc fat that 
might be increased, causing insulin resistance, diabetes, high plasmatic TG levels, hypertension and 
in some cases liver steatosis and polycystic ovarian syndrome.  
  A study of the PPARγ gene in seven FPL patients revealed a heterozygous change of the 
highly conserved arginine 425 to cysteine, in exon 6, in one of the patients, a non-Hispanic white  
woman who developed type 2 diabetes and hypertriglyceridemia, and later lipodystrophy, of the 
extremities and face, while sc truncal fat was slightly increased (164). Since arginine 425 might be 
involved in a salt bridge that maintains the PPARγ protein in a proper configuration, it was 
speculated that this PPARγR425C mutation represents the molecular basis of one of the FPL 
phenotypes. 
  Another mutation, PPARγP467L, was found in two adult patients (man and woman) as well 
as a PPARγV290M mutation in a female patient. These adults also suffered from lipodystrophy at 
the extremities, elevated plasmatic TG concentrations, hyperinsulinemia and fat accumulation in the 
liver. However, there was no difference in the circulating levels of leptin and TNF-α but a decrease 
in adiponectin levels in the two PPARγP467L patients (257). In vitro studies of both mutations 
suggest a destabilization of the PPARγ configuration more favorable for receptor-corepressor 
interactions with dominant negative properties. Interestingly, a PPARγ ligand stabilizes the receptor 
structure in the active conformation and promotes corepressor release, which most likely explains 
the improvement of these patients’ condition after thiazolidinedione (TZD) treatment (258).  
 In addition, four members of a same family were identified, who suffered from a 
transactivation deficient mutant PPARγ, namely PPARγF388L, which changes a highly conserved 
residue of helix 8 of the ligand-binding pocket (259). All four patients were heterozygous carriers 
and presented partial lipodystrophy as well as hyperinsulinemia. In addition, the older patients 
suffered from type 2 diabetes and hypertension. In transactivation assays, the basal transcriptional 
activity of the mutant receptor was three-fold lower compared to the wild type molecule in the  
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absence of an exogenous ligand. However, in the presence of TZD, its activity increased, 
comparable to the wild type receptor only at high Rosiglitazone concentrations. It is noteworthy that 
the proband, when treated with pharmacological doses of Rosiglitazone, in combination with 
metformin, had a good glycemic control (259). 
 Another well studied variant is the PPARγ2P12A (73,76,260,261). This is the only well-
described change found so far in the N-terminal domain of PPARγ2. The initial study of Finnish and 
second-generation Japanese populations concluded that the less common 12A allele promoted 
insulin sensitivity and conferred protection against type 2 diabetes (73,76,260,261). In vitro studies 
showed that this allele reduces PPARγ DNA binding affinity and transcriptional activity 
(73,76,260,261). Although some additional studies did not support a statistically significant role for 
the PPARγ2P12A polymorphism in the etiology of type 2 diabetes (262-264), a more recent meta-
analysis of all published data, comprising more than 25 000 cases of diabetes, showed an association 
of P12A with type 2 diabetes (265). The large population that was necessary in order to demonstrate 
the association between P12A and type 2 diabetes is due to the weak effect of the risk allele, since 
individuals that are homozygous for the higher risk P12 allele have only a 25% increase in diabetes 
risk. However, because the frequency of the P12 allele is high in Europeans, it has a substantial 
effect at the level of this population, since the disease would be reduced significantly if the risk 
factor were not present (265). Data from a recent study support the idea that additional PPARγ 
variants, besides the one just described, most likely contribute to PPARγ effects on metabolic traits 
in African-Americans and whites (237). 
 In brief, the mutations found in the human PPARγ receptor show that in general, as in mice, 
the level of PPARγ activity correlates with adiposity. Loss of PPARγ function is linked to partial 
lipodystrophy, which in turn is associated with severe metabolic dysfunctions. This connection 
highlights once more the role of PPARγ in the control of both lipid and glucose metabolism. 
Interestingly, a mild reduction in PPARγ activity, as seen above with the 12A in humans, or with a 
partial antagonist in mice, promotes insulin sensitivity. In mice it also decreases fat depots, and 
brings the metabolic parameters to the levels seen in PPARγ heterozygous mice (245,247,266). 
These heterozygous mice are partially protected from high-fat diet or mono sodium glutamate-
induced weight gain and insulin resistance. It is not known if treatment of human diabetic patients 
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with a partial PPARγ antagonist would inhibit TG accumulation in fat tissue without redistribution 
to muscle and liver, thus promoting insulin sensitivity (267). 
III.8.2.2. PPARγ gain of function mutations 
 
 The PPARγP115Q mutation, which was found in four unrelated patients, is the only one in 
humans that was found to increase PPARγ activity. Q115 prevents the adjacent S114 from being 
phosphorylated (phosphorylation of this residue inactivates the receptor). All four patients were 
severely obese, lending additional support to the notion that increased PPARγ activity promotes 
increase in fat mass. It is noteworthy that in a nation-wide German epidemiological field survey no 
individual homozygote or heterozygote for the 115Q allele was found, showing that this mutation is 
unlikely to have a significant epidemiological impact on morbid obesity (268). However, it certainly 
contributes to a better understanding of the role of PPARγ activity on fat mass in humans. 
Taken together, data from the mouse models and human genetic studies underscore a direct 
and positive correlation between PPARγ and adiposity. Such a correlation appears less obvious 
between PPARγ activity and insulin sensitivity. It may suggest that insulin sensitivity is achieved 
mainly by a modulation of PPARγ activity within the WAT, possibly through its transcriptional 
effects on adipokine expression and secretion, as well as on lipogenic gene expression. Maintaining 
the integrity of the adipose tissue may fulfill this function. In fact, obese and lipodystrophic animals 
and humans both develop insulin resistance and associated pathologies. 
 
III.9. PPARγ as a therapeutic target in fat related diseases 
 
Before even being identified formally as PPARγ ligands, TZDs were shown to stimulate 
adipogenesis and to improve insulin sensitivity (269,270). It is only more recently that TZDs  
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were described as selective ligands for the receptor, bridging the gap between PPARγ and insulin 
sensitivity (Fig 5) (271,272). 
Supraphysiological activation of PPARγ by TZDs stimulates adipogenesis by increasing the 
number of newly differentiated adipocytes, especially in the sc WAT. Increasing the storage 
capacity of WAT decreases ectopic lipid accumulation. The result is a decrease in liver and skeletal 
muscle TG content and an amelioration of insulin sensitivity at the expense of increased sc WAT 
mass. However, TZD amelioration of insulin sensitization in skeletal muscle appears to be 
independent of the lipid profile of this organ, since the TZD treatment was shown to increase lipid 
accumulation in skeletal muscle (273). Lessons learned from the PPARγ +/- mouse model, as 
mentioned above, as well as from clinical observations of obese patients after weight loss, which 
correlated with reduced PPARγ levels, suggest that a moderate decrease in PPARγ activity might 
have beneficial effects on the TG content of WAT, liver and skeletal muscle. In fact, diminution of 
PPARγ transcriptional activity reduces the expression of the lipogenic program and promotes the β-
oxidation pathway in the liver and muscle, with an improvement of plasma lipidic parameters, as 
well as insulin sensitivity (246,274,275). 
 
III.9.1. Use of synthetic PPARγ agonists in the treatment of lipodystrophies and type 2 
diabetes 
 
The effects of the TZD Rosiglitazone were investigated in acquired or genetic 
lipodystrophies, including those caused by mutations in the PPARγ gene (see above). In patients 
with inherited or HIV-induced lipodystrophies, treatment with Rosiglitazone increases the sc fat 
mass, and augments insulin sensitivity and adipokine secretion, probably by increasing the lipogenic 
program in WAT (242,276,277). 
With respect to type 2 diabetes, several drugs have been introduced during the past decade, 
which are effective in lowering blood glucose and in reducing diabetes-related end-organ diseases. 
The two TZDs, Rosiglitazone and Pioglitazone, currently approved as anti-diabetic drugs, are 
selective PPARγ agonists. Troglitazone, the first agent of this class, effective in controlling 
glycaemia, was removed from the market because of serious liver toxicity.  
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In addition to improving insulin signaling, Rosiglitazone and Pioglitazone improve 
cardiovascular parameters, such as lipids (increase in sc WAT, influx of FFA), blood pressure, 
inflammatory biomarkers (inhibition of adipokine expression and action), endothelial function, and 
fibrinolytic status (278-280). Furthermore, Pioglitazone treatment shifts fat from the visceral to the 
subcutaneous compartment in obese patients, a fat redistribution thought to improve insulin 
sensitivity since sc WAT confers less insulin resistance than vis WAT (274). These observations are 
consistent with recent data from a report on the treatment of male rats with a PPARγ agonist. 
Redistribution of fat by stimulation of the potential for lipid uptake and esterification in sc WAT 
was obtained, but only a minimal effect on uptake was achieved in vis WAT. More significantly,  
energy expenditure was strongly increased in vis fat with a consequent reduction in fat accumulation 
(281). 
Despite the efficacy and beneficial effects of TZDs, a number of undesired side effects have 
been noted, including increased weight gain due to both increased adiposity and fluid retention 
(edema) (282,283). The latter, which can be explained by PPARγ stimulation of ENaC-mediated 
renal salt absorption (284)  might be the cause of an increased incidence of congestive heart failure 
(285), an outcome also observed in rats where Rosiglitazone treatment is associated with increased 
post-myocardial infarction mortality (286). However, this issue is still under debate as The 
Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive) showed recently that 
treatment of type 2 diabetic patients with Pioglitazone, another TZD drug, improved their 
cardiovascular outcome (287).  
At the present time, substantial effort has been concentrated on generating novel selective 
PPARγ modulators that retain the beneficial clinical effects while avoiding the unwanted side 
effects. 
 
III.9.2. Use of synthetic PPARγ antagonists as therapy drug for obesity and type 2 diabetes  
 
As mentioned above, PPARγ activation reduces insulin resistance, but also increases fat mass 
by promoting adipocyte hypertrophy and hyperplasia. Since lasting enhanced adiposity is associated 
with increased insulin resistance, it was hypothesized that reducing PPARγ activity  
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would result in less fat mass and improved insulin sensitivity. In fact, mice treated with PPARγ 
partial antagonists such as SR202, GW9662, or BADGE (bisphenol A diacylycidyl ether) showed 
decreased TG content in WAT, liver and skeletal muscle, decreased adipocyte size, increased 
resistance to HFD-induced obesity, and decreased expression and secretion of leptin and TNF-α. 
However, insulin sensitivity under HFD conditions depends on the type of antagonist which was 
administrated to the animals. SR202- and BADGE-treated mice presented an increased sensitivity to 
insulin, whereas GW9662 had no effect on insulin sensitivity (288). Especially for SR202, the effect 
is comparable to the improved sensitivity recorded in untreated PPARγ +/- mice, in which PPARγ 
levels were reduced by half compared with wild-type animals (213,288-290).  
Several lines of evidence discussed above suggest that WAT dysfunctions resulting from 
lipodystrophies or experimentally induced loss of adiposity in animal models can also be linked to 
insulin resistance, possibly due to excessive levels of circulating FFA that could be lipotoxic for the 
liver, skeletal muscle and even for the pancreas (by affecting beta cell action). In addition, 
experimental disruption of the WAT in mice induces a low-grade inflammation, as in obese patients. 
Associated with adipokine and pro-inflammatory cytokine expression and secretion from the 
dysfunctional WAT, this inflammatory condition may affect insulin sensitivity. In line with this 
possibility, treatment of PPARγ +/- mice (where the activity of the receptor is decreased by half) 
with the PPARγ antagonist BADGE causes re-emergence of the lipotoxic effect of TG in liver and 
skeletal muscle, and insulin resistance (290). 
 It would appear, therefore, that the use PPARγ antagonists over long periods of time might 
interfere with the integrity of the adipose tissue and trigger unexpected and undesired effects on 
whole body metabolism, including insulin sensitivity. 
 
III.9.3. Selective PPARγ modulators as an alternative treatment 
 
To overcome side effects associated with the use of TZDs, a novel approach consists in 
developing new PPARγ ligands that have insulin-sensitizing properties, via selective action on 
beneficial pathways, without exacerbating fluid retention and obesity. Such compounds are called 
“selective PPARγ-modulators” (SPPARγMs) analogous to selective estrogen receptor (ER)  
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modulators such as raloxifen, which spares the uterus functions, but acts as a partial ER agonist in 
bones (291). SPPARγMs would separate the effects of PPARγ on lipid and glucose metabolisms as 
well as on different organ systems (gastrointestinal, immune, cardiovascular). The selective action 
of such compounds is thought to depend on different structural configurations induced in the ligand-
binding domain by their interaction with the receptor, allowing recruitment of different complexes 
of cofactors that impact on the activation or repression of specific sets of target genes in different 
tissues (167,183,211,284,292-295). 
A variety of such new PPARγ ligands with differential pharmacological affinities for PPARγ 
have been reported in recent years. One of the first SPPARγMs that was tested, and which validated 
this idea, is FMOC-L-Leucine (F-L-Leu), which separates insulin sensitivity from adipogenesis in 
vivo (200). 
The non-TZD-selective PPARγ modulator (nTZDpa) was also shown to alter the 
conformational stability of the receptor when compared to TZDs. Chronic treatment of fat-fed 
C57BL/6J mice with nTZDpa improved hyperglycemia and hyperinsulinemia and promoted 
reductions in weight gain and adipose depot size, without causing cardiac hypertrophy. In WAT, 
nTZDpa produced a different in vivo expression pattern of a panel of PPARγ target genes when 
compared to a full agonist (211). Similarly, a series of metabolically robust N-benzyl-indole partial 
PPARγ agonists, with either a 3-benzoyl or 3-benzisoxazoyl moiety, also produced potent glucose 
reduction in db/db mice and attenuated increases in heart weight and brown adipose tissue mass, 
which are typically observed in rodents upon treatment with PPARγ full agonists (296,297). In 
addition, halofenate, one of the recently discovered SPPARγMs, displays the characteristics of an 
optimized modulator, retaining an insulin sensitization potential with minimal adipogenic activity in 
vitro and with less weight gain in vivo (ob/ob mouse and fa/fa Zucker rat models). At the molecular 
level, the partial agonism of halofenic acid may be explained in part by effective displacement of the 
corepressors NCoR and SMRT, coupled with inefficient recruitment of co-activators, such as p300, 
CBP, and TRAP 220 (195). Further characterization of SPPARγMs will most likely yield novel 
agents for the treatment of type 2 diabetes, which are as effective as current pharmacological 
compounds but without their side effects. These findings should encourage mechanism-based 
screens (291), which would capitalize on a still very incomplete knowledge of the ensemble of  
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PPARγ coactivators and corepressors and their expression profile in tissues that are pivotal for 
PPARγ action.  
At this point, is worth mentioning the emergence of novel potential therapeutic targets for the 
treatment of metabolic-related diseases, among which is the cofactor sirutin 1 (SIRT1), which is a 
protein lysine deacectylase and 11-β-Hydroxysteroid dehydrogenase type 1 (Hsd11β1) which allows 
local conversion of inactive to active cortisol. The human SIRT1 regulates several transcription 
factors that govern metabolism among which is PPARγ. SIRT1 is induced by fasting in several 
tissues, such as the WAT where it represses PPARγ activity thus decreasing the amount of fat 
storage. Its activation by resveratrol was shown to improve mitochondrial function and to protect 
against metabolic related diseases (200,298-300). Glucocorticoids are important regulators of 
glucose, lipid and protein metabolism, acting mainly in the liver, adipose tissue and muscle. Chronic 
glucocorticoid excess is associated with clinical features, such as insulin resistance, visceral obesity, 
hypertension, and dyslipidemia, which represent the classical hallmarks of the metabolic syndrome. 
Hsd11β1, a key intracellular enzyme which catalyses the conversion of inactive to active cortisol, 
has been implicated in the development of the metabolic syndrome. The shift of this reaction 
towards active cortisol generation may lead to tissutal overexposure to glucocorticoids even with 
normal circulating cortisol levels. The most robust evidence in support of a pathogenic role of this 
enzyme in the development of the metabolic syndrome has been reported in experimental animals 
where specific expression of this enzyme in WAT mediates critical features of the metabolic 
syndrome (301). Further, Hsd11β1 knockout mice are protected from these metabolic abnormalities 
(301). Moreover, treatment of diet-induced obese mice with Hsd11β1 inhibitors reduces their food 
intake and weight gain but maintains energy expenditure (302).  
 
As illustrated in the introduction, the white adipose tissue plays an important role in the 
pathologies related to the metabolic syndrome. Deregulation of its functions, either in obesity or 
lipodystrophy affects not only its metabolism but also the systemic metabolism. We showed in the 
previous chapter that PPARγ is one of the key factors involved in the adipose tissue development, 
maintenance and metabolism. Besides, it is also one of the most important  
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pharmacological targets in the treatment of several metabolic related diseases such as type 2 
diabetes.  
Large amounts of publications in the last years underline the involvement of PPARγ in the 
treatment of metabolic related diseases, namely its mechanism of action principally in the white 
adipose tissues where it is highly expressed. However, several questions remain open. We therefore, 
aimed to (i) study the role of PPARγ in the metabolism and integrity of the adipose tissue; 
questioning the established dogma of PPARγ being involved solely in lipid metabolism, and (ii) set 
up a lentivirus derived small interference RNA (siRNA) expression system allowing modulation of 
the expression of PPARγ and its partners in different cellular models related to metabolic functions, 
specially preadipocytes and adipocytes. 
  Although the homozygous deletion of PPARγ in a mouse model was shown to be embryonic 
lethal, the survival of PPARγ -/- mice by inactivation of PPARγ in all tissues except the trophoblasts 
was successful. These animals suffered from lipodystrophy, insulin resistance and hypotension, 
most likely due to blood vessel relaxation (244). Specific deletion of PPARγ in the white adipose 
tissue also induces a clear lipodystrophy of the tissue (248,250). Because of the lipodystrophic 
phenotype, we choose to address these questions in the context of a mouse model where only one of 
the PPARγ alleles was deleted (PPARγ +/-). Although PPARγ +/- mice had lower amount of WAT, 
they were not lipodystrophic (245). Diminution by half of the normal PPARγ in the context of the 
PPARγ +/- mice should already have an effect on its transcriptional program. Furthermore, this 
model allows a better separation between the effects of its deletion in WAT and the pathways 
triggered in this tissue by the accumulation of dead adipocytes, such as observed in models of 
specific deletion of PPARγ in WAT (lipodystrophy) (162).  
Because of the early role of PPARγ in the development of the adipose tissue, we set up an 
innovative in vitro model where the expression of PPARγ could be modulated at different moments 
with the help of the lentivirus-mediated gene knock-down by siRNA. This model helps the 
investigation of the involvement of PPARγ in mechanisms important in different aspects of the 
mature adipose tissue functions. Furthermore, it gives a highly flexible tool for the in vitro study of 
metabolic pathways not only in adipocytes but also in hepatocytes and myocytes giving  
 79 
INTRODUCTION-Role of PPARγ in the white adipose tissue 
 
us the opportunity to decipher their interconnection trough the adipokine and cytokine secretion. 
Indeed, we can readily imagine models in which the knock-down of a target gene in adipocytes will 
influence the adipokine secretion program having a direct effect on the metabolic pathway, such as 
insulin induced glucose sensitivity, glycolytic and lipolytic pathways in hepatic and muscle cells.  
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I. Deletion of one PPARγ allele affects the integrity of the adipose tissue and has further effects 
on the whole body metabolism 
 
I.1. Introductive remarks 
 
Adipose tissue integrity is one of the most important features of the whole body homeostasis. 
Deregulation of its functions, as observed in cases of obesity or lipodystrophy are linked to 
metabolic syndrome related diseases such as type 2 diabetes.  
PPARγ is an important player in WAT where it participates to adipocytes differentiation and 
maintenance and promotes lipid storage. PPARγ agonists are used as therapeutic drugs for –the 
treatment of type 2 diabetes. Interestingly, PPARγ  +/- mice treated with HFD were shown to be 
resistant to obesity and to be more sensitive to insulin then their wt counterparts (189,247). As a 
paradox, the PPARγ  +/- mice on HFD were as sensitive to insulin as wt mice on HFD treated with a 
PPARγ agonist, Rosiglitazone (246). Thus, unexpectedly, the activation of the receptor through 
agonist treatment or its inactivation trough genetic ablation of one of its allele has a positive 
outcome on the metabolism, particularly on the insulin sensitivity.  
Since PPARγ was shown to be highly and continuously expressed in WAT, and to be 
important for WAT integrity (162) we suspected that the lipid storage is not its only metabolic 
function. Previous studies, challenging the PPARγ +/- mice with a HFD, exacerbate the lipid storage 
function to the detriment of the other functions. We therefore choose to study the role of PPARγ in 
metabolism in normal conditions by using young adult male mice on SD. 
Taking advantage of our PPARγ +/- mouse model, we aimed at understanding how deletion 
of one allele of PPARγ, which significantly reduces the activity of the receptor via a gene dosage 
effect, would affect WAT function and whole body metabolism. Thus, our goal was to make an 
exhaustive comparison of the expression profile of genes in the white adipose tissue between wild 
type and PPARγ +/- mice aiming towards understanding the repercussion of deletion of one PPARγ 
allele on this tissue.  
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I.2. Results 
 
I.2.1. Abstract taken from the submitted publication 
 
Peroxisome proliferator-activated receptor γ (PPARγ) is an essential regulator of adipocyte 
differentiation, maintenance and survival. Deregulations of its functions are associated with 
metabolic diseases. Synthetic ligands of PPARγ, the thiazolidinediones (TZD) are used as insulin 
sensitizers in the treatment of type 2 diabetes. Deletion of one allele of PPARγ or partial inhibition 
of its activity in mice also improves insulin sensitivity. To better understand this paradox and reveal 
new roles of PPARγ in the white adipose tissue (WAT), we compared its gene expression profiles in 
wild type and PPARγ +/- mice. Deletion of one PPARγ allele not only affected lipid storage, but 
more surprisingly, also the expression of genes involved in glucose uptake and utilization, the 
pentose phosphate pathway, fatty acid synthesis, lipolysis and glycerol export, as well as in IR/IGF-
1 signaling. These deregulations led to an energy crisis in the WAT, reflected in a decrease to nearly 
half of its intracellular ATP concentrations. In addition, there was a decrease in the metabolic rate 
and physical activity of the PPARγ +/- mice, which was abolished by TZD treatment, thereby 
linking regulation of the metabolic rate and physical activity to PPARγ. It is likely that the 
PPARγ +/- phenotype was due to the observed WAT dysfunction, since the gene expression profiles 
associated with metabolic pathways were not affected either in the liver or the skeletal muscle. 
These findings highlight novel roles of PPARγ in the adipose tissue and underscore the multifaceted 
action of this receptor in the functional fine-tuning of a tissue that is crucial for maintaining the 
organism in good health. 
Personal contribution to this work 
 
This work represents the first author’s main research project. Thus, the conception as well as 
the majority of the experiments were design and conducted by the first author in collaboration with 
her thesis director, Professor Walter Wahli. The only exception being, the insulin measurements 
(conducted by Dr. Elodie Bedu), the microarray statistical analysis (conducted by  
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Celine Delucinge, from the Genomics Platform in Geneva) and the histology staining (conducted by 
Delphine Galaud, from the Phenotyping Laboratory, University of Lausanne). 
  
I.2.2. Manuscript submitted for publication1 
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Peroxisome proliferator-activated 
receptor γ (PPARγ) is an essential regulator of 
adipocyte differentiation, maintenance and 
survival. Deregulations of its functions are 
associated with metabolic diseases. Synthetic 
ligands of PPARγ, the thiazolidinediones 
(TZD) are used as insulin sensitizers in the 
treatment of type 2 diabetes. Deletion of one 
allele of PPARγ or partial inhibition of its 
activity in mice also improves insulin 
sensitivity. To better understand this paradox 
and reveal new roles of PPARγ in the white 
adipose tissue (WAT), we compared its gene 
expression profiles in wild type and 
PPARγ +/- mice. Deletion of one PPARγ allele 
not only affected lipid storage, but more 
surprisingly, also the expression of genes 
involved in glucose uptake and utilization, the 
pentose phosphate pathway, fatty acid 
synthesis, lipolysis and glycerol export, as well 
as in IR/IGF-1 signalling. These deregulations 
led to an energy crisis in the WAT, reflected 
in a decrease to nearly half of its intracellular 
ATP concentrations. In addition, there was a 
decrease in the metabolic rate and physical 
activity of the PPARγ +/- mice, which was 
abolished by TZD treatment, thereby linking 
regulation of the metabolic rate and physical 
activity to PPARγ. It is likely that the 
PPARγ +/- phenotype was due to the observed 
WAT dysfunction, since the gene expression 
profiles associated with metabolic pathways 
were not affected either in the liver or the 
skeletal muscle. These findings highlight novel 
roles of PPARγ in the adipose tissue and 
underscore the multifaceted action of this 
receptor in the functional fine-tuning of a 
tissue that is crucial for maintaining the 
organism in good health.  
 
White adipose tissue (WAT) plays a dual 
role in regulating energy homeostasis (1). 
Firstly, it is a tissue that responds to nutrient 
intake by storing excess energy in the form of 
triglycerides (TG), and to metabolic demands 
associated with fasting or exercise by releasing 
the stored TG as free fatty acids (FFAs) and 
glycerol (2). Secondly, WAT is an endocrine 
organ in addition to its energy reserve functions. 
In fact, it integrates metabolic signals and 
secretes molecules, called adipokines, which in 
turn impact on multiple target organs, such as 
the liver, muscle or brain. Therefore, it 
contributes significantly to the control of whole-
body energy homeostasis (3-5). 
Deregulation of WAT functions in 
obesity or lipodystrophy is often linked to 
metabolic disorders, such as dyslipidemia, 
atherosclerosis, hypertension, insulin resistance, 
glucose intolerance, as well as prothrombotic 
and proinflammatory states (6-10). Thus, WAT 
functional integrity is required for the balanced 
body metabolism of a healthy organism.  
A number of key transcription factors, 
among them the peroxisome proliferator-
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activated receptor γ (PPARγ ; NR1C3) (11), 
control WAT development and survival (12-15). 
PPARγ is a member of a sub-family of ligand-
activated nuclear receptors that includes its two 
relatives, PPARα (NR1C1) and PPARβ/δ 
(NR1C2). PPARγ forms heterodimers with the 
retinoid X receptor α (RXRα; NR2C1) and 
elicits transcriptional activation of target genes 
by binding directly to a DNA-specific sequence 
element called the peroxisome proliferator 
response element (PPRE) (16,17). PPARγ is 
highly expressed in the WAT, where it plays an 
important role in adipogenesis and in lipid 
metabolism (13,18,19). Suppression of PPARγ 
expression in preadipocytes impairs their 
differentiation (20,21). Furthermore, specific 
deletion of PPARγ in mature adipocytes causes 
their death, accompanied by macrophage 
infiltration in the affected WAT (12). Also, in 
humans, heterozygous PPARγ mutations are 
responsible for partial lipodystrophy, severe 
insulin resistance, steatosis and hypertension 
(22-26). Together, these findings underline the 
functions of PPARγ in adipocyte differentiation 
and survival, and underscore its role in WAT 
integrity and whole body homeostasis.  
The activation of PPARγ improves 
insulin sensitivity in humans and mice. Agonists 
of PPARγ, such as Pioglitazone (a member of a 
class of PPARγ agonists called 
thiazolidinediones, TZDs) are used clinically and 
are effective in reducing hyperglycemia, 
hyperinsulinemia and hyperlipidemia in patients 
suffering from type 2 diabetes (27-29). In 
addition to their beneficial effects on insulin 
sensitivity, TZDs are often associated with 
undesired secondary effects including water 
retention, weight gain and possibly heart 
problems, the latter being still debated  (30,31). 
Although the homozygous deletion of 
PPARγ in a mouse model was shown to be 
embryonic lethal, the survival of PPARγ -/- mice 
by inactivation of PPΑRγ in all tissues except 
the trophoblasts was successful. These animals 
suffered from lipodystrophy, insulin resistance 
and hypotension, most likely due to blood vessel 
relaxation (32). However, deletion of only one 
PPARγ allele had some intriguing effects 
(21,33). In  fact, PPARγ +/- mice were resistant 
to obesity induced by a high fat diet (HFD) and, 
under these conditions, remained more sensitive 
to insulin then their wt counterparts (34). 
Decreased PPARγ activity under HFD 
conditions has a positive outcome on the 
development of obesity and diabetes. Based on 
these observations, a novel approach in type 2 
diabetes therapy would include the use of 
PPARγ antagonists, potentially with fewer side 
effects compared to the present day synthetic 
agonists (TZDs). 
Taking advantage of our PPARγ +/- 
mouse model, we aimed at understanding how 
deletion of one allele of PPARγ, which 
significantly reduces the activity of the receptor 
via a gene dosage effect, would affect WAT 
function and whole body metabolism, when the 
mice are fed with a standard diet (SD), a 
condition which does not exacerbate the lipid 
storage function of the WAT. The results 
reported herein show that deletion of one PPARγ 
allele affects specifically the expression of genes 
associated with metabolic pathways in the WAT. 
These effects are not seen in the liver or skeletal 
muscle, where PPARγ expression is normally 
much lower. In addition to genes involved in 
lipid storage, genes involved in glycolysis, de 
novo fatty acid synthesis, and in lipolysis were 
also down-regulated in the PPARγ heterozygous 
mice, creating a strong energy deficit in these 
animals. These defects in WAT functions 
correlated with a lowering of the metabolic rate 
of the whole body and were accompanied by a 
reduction in physical activity. These results cast 
doubt on a potential long term use of PPARγ 
antagonists for the treatment of type 2 diabetes.  
 
Experimental Procedures 
 
In vivo animal study - Wild-type (wt) and 
PPARγ +/- male mice, of a mixed background 
Sv129/C56BL/6, were maintained at 23oC on a 
12-hour light-dark cycle. The animals studied 
were between 10 to 12 weeks of age. They had 
free access to water and to a SD, except during 
fasting when they had free access to water only, 
food being withdrawn for 24 hours. In some 
experiments, five to six week-old animals were 
fed with a SD containing 0.004% of Pioglitazone 
(wt/wt) for five weeks. The Pioglitazone 
treatment protocol was adapted from (21), a 
study that involved PPARγ +/- animals, too. 
Pioglitazone was kindly provided by Takeda 
Chemical Industries (Switzerland). The standard 
food pellets containing the Pioglitazone as well 
as the control pellets were produced by Provimi-
Kliba (Switzerland). For analysis, the animals 
were killed in the morning between 9:00 to 
11:00 AM by cervical dislocation and tissues 
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were rapidly frozen in liquid nitrogen. The 
animal experimentation protocols were approved 
by the Commission de surveillance de 
l’expérimention animale of the canton de Vaud 
(Switzerland). 
RNA preparation - The RNA from epidydymal 
WAT, gastrocnemius skeletal muscle and liver 
was extracted from the frozen tissues using the 
Trizol reagent (Invitrogen, Switzerland) 
according to the manufacturer’s instructions. The 
RNA for microarray analyses was further 
purified using the RNeasy kit (Qiagen, 
Switzerland). The RNA quality was assessed by 
capillary electrophoresis on a 2100 Bioanalyzer 
(Agilent Technologies, Switzerland). 
Microarray experiment and data processing -  
To minimize inter-individual variation due to the 
mixed background of the mouse strain, each 
PPARγ+/- animal had a wt counterpart coming 
from the same litter.  
Three independent sets of total RNA 
samples (three wt and three PPARγ +/- animals) 
from epidydymal WAT and gastrocnemius 
skeletal muscle were isolated as described in the 
section on RNA preparation and used as 
templates for target generation. cRNA was 
synthesized from 5 µg total RNA, according to 
the GeneChip Expression Analysis Technical 
Manual (Affymetrix), using the one-cycle target 
preparation kit (Affymetrix). After purification 
using a QIAGEN RNeasy column, aliquots of 20 
µg cRNA were fragmented. Each fragmented 
cRNA (15 µg) was then hybridized to an 
Affymetrix “Mouse Genome 430 2.0 Array” 
GeneChip microarray. Hybridization, washing 
and scanning were performed according to the 
Affymetrix manual. 
Data from the scanned chips were 
analyzed using the Affymetrix MAS 5.0 
software (35,36). This software calculates a 
signal value (robust average unaffected by 
outliers) after background correction and assigns 
a detection call (“present”, “marginal” or 
“absent”) for each probe set. 
To identify differentially expressed 
transcripts, pairwise comparison analyses were 
carried out with Affymetrix MAS 5.0. Each 
experimental sample was compared with each 
reference sample, resulting in nine pairwise 
comparisons. This approach, which is based on 
the Mann-Whitney pairwise comparison test, 
allows the ranking of results by concordance, as 
well as calculating the significance (p value) of 
each identified change in gene expression. 
Transcripts were considered to be differentially 
expressed if their levels changed in the same 
direction in seven out of nine comparisons. 
Further data-filtering and analyses were 
performed with the Genespring (Agilent) and 
Ingenuity Pathway Analysis 4.0 softwares. 
Quantitative RT-PCR - Single-stranded cDNA 
templates for quantitative real-time PCR (RT-
PCR) analysis were synthesized using 
Superscript II reverse transcriptase and random 
priming, starting from the same RNAs used for 
the microarray analysis, and from additional 
independent experiments as described above. 
Amplicons were designed using the Primer 
Express software (Applied Biosystems) with 
default parameters, which span exon junctions 
when possible. Amplicon sequences were 
checked by BLAST against the mouse genome 
to ensure that they were specific for the gene 
being assayed. 
Primer pairs were tested and efficiencies 
were measured using standard curves from serial 
dilutions of cDNA. Amplification efficiencies 
greater than 88% were judged acceptable for 
subsequent measurements. Specificity of 
amplification was further determined by 
examination of product melting curves. The list 
of primers is available on demand.  
Real-time PCR was carried out in optical 
384-well plates and labelled by using the SYBR 
green master mix (Applied Biosystems), and the 
fluorescence was quantified with a 7900HT SDS 
System (Applied Biosystems). Samples were 
analysed in triplicate and the raw data consisted 
of PCR cycle numbers required to reach a 
fluorescence threshold (Ct). Raw Ct values were 
obtained with the SDS 2.0 software (Applied 
Biosystems). The relative expression level of 
target genes was normalized according to 
geNorm using beta actin (actb), tubulin alpha 2 
(Tuba2), and hypoxanthine guanine 
phosphoribosyltransferase 1 (HPRT1) as 
references to determine the normalization factor 
(37). Fold-changes were calculated from the 
ratio of means of the normalized quantities. The 
statistical significance of fold-changes was 
determined by a paired Student’s t-test.  
ATP level measurements - Frozen WAT was 
weighed and pulverized with a mortar chilled 
with liquid nitrogen. The homogenate was 
transferred into a plastic tube and four volumes 
of HClO4 6% were added. Following 15 minutes 
centrifugation at 4oC and 10 000 rpm, the 
supernatant was recuperated and neutralized at a 
pH 7 with KOH 5.5 M. The supernatant was 
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further clarified by a 5-minute centrifugation at 
4oC and 5 000 rpm, transferred into a tube and 
stored on ice. The ATP concentration was 
measured with an ATP Determination Kit, a time 
stable assay from Biaffin GmbH&Co KG 
(Germany). The kit allows quantitative 
determination of small amounts of ATP by a 
bioluminescence assay involving the oxidation 
of the firefly luciferase depending on the ATP 
present in the extracts. The ATP concentration 
was derived according to the manufacturer’s 
instructions. 
Glycerol level measurement - 0.5 ml of Krebs 
buffer was added per 200 mg of frozen WAT 
and the tissues were homogenized on ice. The 
supernatant was purified by two rounds of 10-
minute centrifugation at 8 000 rpm and 4oC. The 
glycerol content was measured with a Glycerol 
measuring kit (Randox, France). Briefly, the 
glycerol present in the samples was converted 
into a coloured product, whose concentration 
could be measured at a wavelength of 520 nm. 
The glycerol concentration was then determined 
according to manufacturer’s instructions. 
Metabolic measurements - Metabolic cage 
studies were conducted in a Comprehensive Lab 
Animal Monitoring System (8-chamber CLAMS 
system, Columbus Instruments, Columbus, 
Ohio). The mice were adapted to powdered food 
for 24 hours before they were introduced into the 
metabolic cages where a 48-hour acclimation 
preceded the 24-hour recording time. 
Information was collected on the metabolic 
activity, food intake, water drinking and physical 
activity.  
Blood was collected from the orbital 
sinus between 9:00 to 11:00 AM, using 
heparinized microcapillary tubes, and 
immediately centrifuged. The serum fraction was 
frozen immediately. Depending on the 
experiment, the animals were either normally fed 
or fasted for 24h. 
The plasmatic concentrations of 
triglycerides (TGs), free fatty acids (FFAs), 
glycerol and ketone bodies were measured at the 
Mouse Clinic Institute (ICS; Strasbourg, France) 
on a Olympus AU-400 automated laboratory 
work station (Olympus-SA France, France) 
using commercial reagents (Olympus 
Diagnostica GmbH, Lismeehan, Ireland). 
The plasma glucose levels were 
measured with an Accu-Chek Sensor glucometer 
(Roche, Switzerland) and the plasma insulin 
concentrations were measured with an Ultra 
Mouse Insulin Elisa Kit (Mercodia SA, 
Switzerland). 
RESULTS 
 
Decreased metabolic rate in PPARγ +/- mice. In 
PPARγ +/- animals, PPARγ mRNA and protein 
levels were reduced by half compared to those of 
wt mice (38). This prompted us to explore the 
impact of this reduced PPARγ expression on 
whole-body metabolism in the absence of any 
excess energy challenge, as is usually done with 
HFD feeding in assessing the role of PPARγ  in 
lipid storage. Instead, the PPARγ +/- mice were 
fed with a SD. Metabolic parameters of the 
PPARγ +/- mice and their wt littermates were 
determined using metabolic cages. As expected, 
both mutated and wt animals consumed more O2 
and produced more CO2 during the dark cycle 
when they are generally more active (Fig 1A, 
left panels). Although the PPARγ +/- mice had 
the same weight and ate an equal amount of food 
(data not shown), they consumed less oxygen 
and produced less CO2 during both the light and 
dark cycles, when compared to their wt 
counterparts, a difference reflected in a decrease 
of 14 % in the metabolic rate (heat production) 
of PPARγ +/- animals (Fig 1A). This effect was 
clearly PPARγ-dependent, since a five-week 
treatment with SD food pellets containing the 
PPARγ agonist  Pioglitazone, at 0.004%, 
alleviated the metabolic rate difference between 
the two genotypes (Fig 1A, right panels). 
Moreover, there was a trend, not statistically 
significant, for increased O2 consumption, CO2 
production, and a higher metabolic rate in 
Pioglitazone-treated PPARγ +/- mice, while such 
a tendency was not observed in wt animals.  
 
Deletion of one PPARγ allele does not affect the 
carbohydrate to lipid ratio in metabolic fuel 
utilisation.  To determine whether the decrease 
in the metabolic rate of PPARγ +/- animals was 
associated with alterations in the use of 
carbohydrates versus lipids as fuel molecules, 
we measured the respiratory exchange ratio 
(RER). The RER (=VO2/VCO2) indicates 
whether lipids (RER=0.7) or carbohydrates 
(RER=1.0) are being oxidized to produce 
energy. Both genotypes consumed carbohydrates 
as the main energy source (Fig 1B, left panel). 
This result disagrees with the notion of a 
metabolic compensation through increased fat 
oxidation in PPARγ +/- mice (9). Moreover, the 
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Pioglitazone treatment had no significant effect 
on the choice of fuel type (Fig 1B, right panel). 
Decreased physical activity in PPARγ +/- mice. 
Since a decreased metabolic rate in the mutated 
animals may correlate with a change in 
behaviour, we measured their physical activity 
(horizontal and rearing movements). 
Interestingly, the PPARγ +/- mice presented a 
23% decrease in total activity (Fig 1C, left 
panel). The Pioglitazone treatment corrected this 
decrease suggesting an implication of PPARγ in 
the level of physical activity (Fig 1C, right 
panel). Thus, reduced PPARγ levels decreased 
the metabolic rate and the physical activity of 
mice without changing their fuel preference.   
 
PPARγ +/- and wt mice have similar plasmatic 
insulin and glucose profiles. Since a decreased 
metabolic rate might impact on glucose and lipid 
homeostasis, we analyzed the plasmatic profile 
of the wt and PPARγ +/- mice. The plasmatic 
insulin concentration was normal in 
unchallenged animals, and was decreased after a 
24-hour fast as expected, but no difference was 
observed between wt and mutant mice (Fig 2A). 
Moreover, the plasmatic glucose concentration 
was also normal in PPARγ +/- mice, which 
however had a significantly attenuated response 
to fasting (Fig 2B). In fact, the fasting glucose 
level was higher in the PPARγ +/- mice 
compared to that of the wt animals. Fasting for 
24 hours decreased the glucose level by 45% in 
wt mice, while it was decreased by only 30% in 
the PPARγ +/- animals. Thus, after fasting 
PPARγ +/- mice presented a less pronounced 
hypoglycaemia.  
 
The plasmatic lipid profile of PPARγ +/- mice 
reveals an alteration in lipolytic activity. In fed 
conditions, the plasmatic FFA concentrations 
were normal and no deregulation was observed 
in PPARγ +/- mice (Fig 2C). Wt animals 
responded normally to fasting by liberating 
FFAs from the WAT into the circulation, thus 
increasing the plasma FFA concentration.  
Remarkably, this increase was not observed in 
the PPARγ +/- mice, suggesting a deregulation 
of the lipolytic activity of the PPARγ +/- WAT. 
This defect was confirmed by measuring the 
circulating glycerol concentration. As for the 
FFAs, there was no difference in the fed glycerol 
concentration between wt and PPARγ +/- mice 
(Fig 2D). However, the PPARγ +/- mice 
responded less well to fasting since they 
increased their plasma glycerol concentration by 
only 32%, compared to the 62% monitored in wt 
mice. Given that the fasting glycerol and FFA 
concentrations are indicators of the lipolytic 
activity in the WAT, we concluded that 
PPARγ +/- mice might have a decreased lipolytic 
activity. This alteration should also be detectable 
in the WAT itself in which the free glycerol 
originates from two main sources, 
glyceroneogenesis (from glycolysis) and 
lipolysis. There was a 23% decrease in the 
glycerol content of the PPARγ +/- WAT, 
suggesting that at least one of the two above 
functions, or both, were impaired (Fig 3).  
Reduced circulating FFA levels should 
have consequences for ketone body synthesis in 
the liver, which depends on FFA availability. 
We measured ketone body concentration after 
fasting in both wt and PPARγ +/- mice (Fig 2E). 
PPARγ +/- mice were less efficient in producing 
ketone bodies as their plasma concentration of 
this peripheral organ fuel was 33% lower than in 
wt animals. Thus, this decreased supply in 
ketone bodies reflects the reduced availability of 
FFAs in PPARγ +/- mice. The triacylglycerol 
(TG) concentrations were increased by 38% after 
fasting in wt mice, which reflects the recycling 
to TG-VLDL by the liver of a portion of the FFA 
liberated by the WAT during fasting (Fig 2F). In 
agreement with the observations reported above, 
the plasma TG concentration was not increased 
in PPARγ +/- mice, in contrast to that measured 
in wt animals. 
The metabolic cage measurements 
reported above revealed that the PPARγ +/- mice 
displayed a reduced metabolic rate and 
decreased physical activity, while using the same 
proportion of fuel molecules (carbohydrate vs 
lipids) as their wt counterparts. The glycaemia, 
insulinemia, and lipid profile were shown to be 
normal under basal fed conditions. However, 
when the PPARγ +/- mice were challenged by 
fasting they presented an increased glycaemia 
and, more significantly, a deregulation of energy 
supply in the form of lipid was observed. Thus, 
we hypothesized that the PPARγ +/- mice 
decreased their metabolic rate and their physical 
activity to adapt to a diminished energy supply. 
Three organs, the liver, skeletal muscle, and 
WAT, are primarily involved in energy supply 
and consumption, which express low to high 
levels of PPARγ. Deletion of one PPARγ allele 
decreased its expression level as mentioned 
above (38), which might affect the expression 
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pattern of PPARγ target genes. This possibility 
was tested by assessing the expression of genes 
involved in metabolic pathways of the three key 
tissues mentioned above either by microarray 
analysis (WAT and skeletal muscle), and/or 
qRT-PCR (WAT and liver). The expression of 
genes not represented in the microarray was 
analyzed by qRT-PCR. 
 
The expression of metabolic genes is not affected 
in the liver of PPARγ +/- mice. The liver is one 
of the major organs responsible for whole-body 
energy balance. During fasting, it ensures plasma 
glucose homeostasis by stimulating 
glycogenolysis and gluconeogenesis, and it 
participates in the conversion of FFA into ketone 
bodies, which are used by peripheral tissues as a 
source of energy. PPARγ is expressed at low 
levels in the liver under normal conditions, but is 
increased in steatosis induced by HFD or other 
pathophysiological conditions (13,18,19). The 
expression pattern of several metabolic genes 
known to be transcriptionally regulated by 
PPARs was tested by qRT-PCR. We found that 
the expression of metabolic genes in the liver of 
PPARγ +/- animals fed a SD was not affected 
when compared to that of wt animals (Table 1). 
In the PPARγ +/- animals, genes involved in the 
glycolytic and FA oxidation pathways were 
expressed at levels comparable to those for wt 
mice. For instance, the expression of genes, such 
as very long chain acyl-CoA dehydrogenase 
(Acadvl), long chain acyl-CoA dehydrogenase 
(Acadl), and carnitine palmitoyltransferase 1 
(CPT1) was not deregulated in the PPARγ +/- 
mouse liver. Similarly, the gluconeogenic 
pathway was not affected, even during fasting 
(data not shown). In particular, known PPARs 
target genes, such as those encoding phospho 
enol pyruvate carboxykinase (PEPCK), glycerol-
3-phosphate dehydrogenase 1 (GPD1), glycerol 
kinase (Gyk), aquaporin 3 (Aqp3) and glucose-
6-phosphatase (G-6-Pase) were not deregulated. 
Since PPARα is the main regulator of these 
genes in liver, these results suggest that the 
PPARγ insufficiency did not induce a 
compensatory activation of PPARα. In addition, 
these results are in agreement with the RER 
measurements (Fig 1B, left panel), which 
showed no fuel source switch between 
PPARγ +/- and wt mice.  
We conclude that the liver of PPARγ +/- 
mice on SD is not the organ primarily 
responsible for the deficiency in energy supply, 
the lowering of the metabolic rate, and the 
reduction in physical activity of these animals.  
The expression of metabolic genes is not affected 
in skeletal muscle of PPARγ +/- mice. The 
skeletal muscle is a key site of energy 
consumption. PPARγ is weakly expressed in this 
organ and its selective deletion in skeletal 
muscle can affect insulin sensitivity of the liver 
(39), as well as muscle and WAT insulin 
sensitivity (40).  
In our study, deletion of one PPARγ 
allele did not affect the expression of metabolic 
genes in the gastrocnemius skeletal muscle. 
Large scale analysis of PPARγ +/- mice and their 
wt counterparts on SD showed that of the 39 000 
transcripts analyzed, only a few were 
deregulated in the PPARγ +/- mice (data not 
shown) and none of those was involved in 
metabolism (Table 1). Thus, it is worth noting  
that, at least at the mRNA expression level, there 
was no deregulation of the expression of 
glycogenolysis, glycolysis, and FA oxidation in 
the PPARγ +/- mice. In conclusion, the skeletal 
muscle is apparently not responsible for the 
energy deficit observed in the PPARγ +/- mice, 
which argues against a significant role of 
PPARγ in this tissue under SD conditions.  
 
The expression of metabolic genes is affected in 
PPARγ +/- WAT. As mentioned earlier, PPARγ 
is required for the development and maintenance 
of WAT. As shown by several groups, specific 
deletion of PPARγ in WAT causes lipodystrophy 
(12,41,42). On the contrary, deletion of one 
PPARγ allele, although provoking a decrease in 
WAT weight, does not induce this same defect 
(38). We analyzed the transcriptional profile of 
the PPARγ +/- and wt WAT. The majority of 
genes deregulated in PPARγ +/- WAT were 
classified into two major categories. Firstly, 
genes involved in cell stress, detoxification, and 
inflammatory pathways were up-regulated, and 
secondly, genes involved in metabolic and 
energy production pathways were down-
regulated (Fig 4). The present study concentrated 
on the second category only. 
Taken together, these results validated 
our hypothesis of a metabolic deregulation and 
energy production impairment in the PPARγ +/- 
WAT. 
 
 The insulin and IGF-1 signalling pathways are 
down-regulated in the PPARγ +/- WAT. The 
microarray analysis revealed that the insulin as 
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well as the insulin growth factor 1 (IGF-1) 
signalling pathways were down-regulated in 
PPARγ +/- WAT. Insulin is a key regulator of 
fuel metabolism, whereas IGF-1 is mostly 
involved in cell survival, growth and 
differentiation. However, much remains to be 
clarified since IGF-1 was also shown to control, 
at least in part, the expression of metabolic 
enzymes (43,44). IGF-1 expression was down- 
regulated by 46% in the PPARγ +/- WAT, a 
result that is in agreement with our previous 
work (Table 2) (38). The present analysis went 
further by showing that not only IGF-1 
expression was deregulated in PPARγ +/- WAT, 
but also several other genes in the activation 
cascade downstream from IGF-1, such as c-Jun, 
and 3-monooxygenase tryptophan 5-
monooxygenase activation protein gamma (14-3-
3-γ), along with the insulin-like growth factor 
binding proteins (IGBBP), which were down-
regulated by 39%, 36% and 46%, respectively 
(Table 2). Thus, processes activated by IGF-1 
were affected in the mutated WAT, namely 
adipocyte differentiation and survival, and 
stimulation of glucose and lipid uptake (45-48). 
One major actor in the insulin pathway 
is the insulin receptor substrate 1 (IRS1); its 
mRNA was down-regulated by 44% in the 
PPARγ +/- WAT (Table 2). Furthermore, the 
mRNAs of eukaryotic translation initiation 
factor 4E binding protein 1 (EIF4EBP1), 
phosphodiesterase 3B (PDE3B), and Rap 
guanine nucleotide exchange factor 1 
(RAPGEF1) belonging to the same pathway 
were also down-regulated by 41%, 40% and 
34%, respectively. These results extend those of 
a previous study, which showed that the 
expression of PDE3B, as well as its insulin-
induced activation, were decreased in the 
PPARγ +/- WAT (49). On the contrary, an 
inhibitor of the insulin pathway, called protein 
tyrosine phosphatase receptor-type F (PTPRF) 
was up regulated by two-fold in the PPARγ +/- 
WAT (Table 2).  
 
Glucose uptake and glycolysis are decreased in 
the PPARγ +/- WAT. Gene expression changes 
identified by microarray and/or assessed by 
qRT-PCR indicated that glucose uptake, 
glycolysis and its associated lipogenesis, which 
are controlled by insulin, were deregulated in the 
PPARγ +/- WAT (Table 2 and Fig 5). The 
expression of the insulin independent glucose 
transporter Glut1 was decreased by 65%, 
suggesting a decreased basal glucose entry into 
the adipocytes (Fig 5). In contrast, the 
expression of the glucose transporter Glut4 was 
not affected.  
Once taken up by the adipocytes, 
glucose is processed via three main pathways. In 
brief, 35% of the glucose is used for TG 
synthesis, 55% for lactate production and finally, 
15% is used for ATP production that provides 
the energy for adipocyte maintenance and 
survival (50). One of the main enzymes of the 
glycolytic pathway, hexokinase 2 (HK2), was 
down-regulated by 40% in PPARγ +/- WAT 
(Table 2, Fig 5). The level of this enzyme is 
stimulated by insulin via SREBP-1c (51,52) (Fig 
6). In line with this effect, fasting decreases and 
refeeding restores HK2 levels in different 
tissues, including WAT (52). Therefore, the 
decreased expression of HK2 in the PPARγ +/- 
WAT is consistent with impaired insulin 
signalling in the mutated animals. 
6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase (PFK-2/FBPase) is also part of 
the glycolytic pathway. Four genes encode PFK-
2/FBPase (PFKFB1–4) and it is PFKFB3 that 
was identified as the isoform that is probably 
responsible for the activation of glycolysis in 
adipocytes. PFKFB3 was down-regulated by 
40% in the PPARγ +/- WAT (Table 2). Data so 
far available support a role of this enzyme in TG 
synthesis in adipocytes (53).  
Based on these combined results, we 
conclude that glucose uptake as well as the 
glycolytic pathway are defective in the 
PPARγ +/- WAT (Fig 6).  
 
De novo fatty acid synthesis is down-regulated 
in the PPARγ +/- WAT. Acetyl CoA, which is 
produced by the glycolytic pathway discussed 
above, is used for FA synthesis (Fig. 6). 
Pyruvate carboxylase (PC), whose activity 
increases during adipocyte differentiation, is 
thought to have a lipogenic function by 
providing amounts of acetyl groups and NADPH 
for fatty acid synthesis. Its gene is a direct 
PPARγ target in adipose tissue (54). Consistent 
with this finding, expression of the PC gene was 
decreased by 32% in the PPARγ +/- WAT. An 
even higher down-regulation was observed for 
acetyl CoA caroboxylase (ACC), which 
carboxylates acetyl CoA to malonyl CoA, and 
for fatty acid synthase (FAS), which produces 
palmitate from malonyl CoA. Their levels were 
reduced by 47% and 39%, respectively (Table 2 
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and Fig 5). Interestingly and in line with our 
findings, the expression of these enzymes was 
previously shown to be increased by the PPARγ 
agonist, GW1929 (55).  
In addition to a carbon supply (acetyl 
CoA), the de novo production of fatty acids 
requires reducing power, in the form of NADPH. 
NADPH is generated by the oxidation of 
glucose-6-phosphate via an alternative pathway 
to glycolysis, the pentose phosphate pathway 
(Fig 6). Treatment of 3T3L1 adipocytes with the 
PPARγ agonist rosiglitazone was shown to up-
regulate the expression of enzymes involved in 
this pathway (56). It is regulated mainly by the 
activation of glucose 1 dehydrogenase (GDH), a 
deficiency of which results in a decrease of 
NADPH production (57). GDH expression was 
down-regulated by 41% in PPARγ +/- WAT. 
Transketolase (TKT) is another enzym e linking 
the pentose phosphate pathway to the glycolytic 
pathway. Its expression was down-regulated by 
49% in PPARγ +/- WAT (Table 2). TKT 
expression was shown to be decreased in insulin 
receptor knock-out mice, and TKT+/- mice 
suffer from growth retardation and preferential 
reduction of the WAT (50,58). Thus, any 
reduction in the expression of these two key 
enzymes reflects decreased FA synthesis in the 
PPARγ +/- WAT (Fig 6).  
 
Deletion of PPARγ decreases the expression of 
enzymes involved in lipid storage. It is thought 
that the major source of activated glycerol 
(glycerol-3-phosphate) used by the WAT to 
esterify FA is produced by the glycolytic 
pathway (59,60). The production of glycerol-3-
phosphate from glucose is called 
glyceroneogenesis, and is one of the most 
important pathways in the adipocytes. 
Glyceroneogenesis is controlled by two 
enzymes, PEPCK1 and GPD1. PEPCK 
regulation was shown to be exclusively 
transcriptional with a participation of PPARγ in 
WAT, and PPARα in the liver, through two 
PPRE sites present in the promoter (61,62). 
GPD1 was also shown to be a PPARγ target in 
WAT (63). The expression of these two enzymes 
was decreased in the PPARγ +/- WAT, by 45% 
and 29%, respectively (Table 2, Fig 5).  
Diacylglycerol acyltransferase 1 (Dgat1) 
catalyzes the terminal and only committed step 
in triacylglycerol esterification by using 
activated glycerol (glycerol-3-P) and fatty acyl 
CoA as substrates. Dgat1 is necessary for 
adipose tissue formation and essential for its 
survival (64). Dgat1 was showed to be up-
regulated by the PPARγ agonist GW1929 (55) 
and was consistently down-regulated by 29% in 
PPARγ +/- WAT.  
The reduction in the PEPCK, GPD1 and 
Dgat1 expression, as well as the decrease in 
glycerol content measured in PPARγ +/- WAT 
are in agreement with a reduced 
glyceroneogenesis and lipid storage in the 
mutant WAT. These results are in line with the 
role of PPARγ in lipid storage and with the 
smaller adipocytes with reduced TG content 
found in the WAT of PPARγ +/- mice (21). 
 
Reduced expression of genes encoding lipolytic 
enzymes in the PPARγ +/- WAT. Fasting induces 
a breakdown to FFA and glycerol of the lipids 
stored in the WAT through lipolysis. These 
products are released into the circulation by FFA 
and glycerol transporters. Both are used by 
peripheral tissues as an energy source, as 
discussed earlier. The expression of enzymes 
involved in lipolysis, such as the hormone 
sensitive lipase (HSL), which catalyzes the rate-
limiting step in adipose tissue lipolysis, and the 
glycerol transporter from adipocytes into 
circulation, aquaporine adipose (Aqp7), were 
decreased in PPARγ +/- WAT, by 47% and 39%, 
respectively (Table 2, Fig 5 and 6). The genes 
encoding these enzymes are known PPARγ 
target genes (63,65). Decreased lipolytic activity 
in PPARγ +/- WAT might be a mechanism for 
sparing the TG stocks.  
 
ATP crisis in PPARγ +/- WAT. The gene 
expression profile of PPARγ +/- WAT showed a 
global decrease in metabolic pathways. This 
deficit affects the use of glucose for de novo 
fatty acid synthesis and their subsequent storage. 
Glucose is also used by the adipocytes as the 
source of ATP that is required for their survival 
(66-68). Since the glycolytic pathway is down-
regulated in the PPARγ +/- WAT, we suspected 
an ATP deficit in this organ. Moreover, our 
microarray profile showed that genes of cell 
stress were up-regulated in the PPARγ +/- WAT 
(not shown), suggesting that an ATP deficit 
might be causing this cellular stress. Thus, we 
measured the ATP concentration in the wt and 
PPARγ +/- WAT. As expected by the gene 
expression profiles reported herein, it was 
decreased by 45% in the PPARγ +/- WAT, (Fig 
7). This result is in agreement with a known 
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PPARγ role in lymphocytes where it attenuates 
the decline in ATP levels (69). Finally, enzymes 
involved in FA β-oxidation were not deregulated 
in the mutant WAT. This is in agreement with 
the minor role of this pathway in the adipose 
tissue and argues against compensation by 
increased fat utilisation for the lack of energy 
due to decreased glycolytic activity. Clearly, the 
adipose tissue in PPARγ +/- mice suffers from a 
significant energy deficit due to decreased 
glycolytic activity.  
 
DISCUSSION 
 
Adipose tissue integrity is crucial for 
whole body energy homeostasis. Its functional 
deregulation, as observed in obesity or 
lipodystrophy, is linked to diseases, such as type 
2 diabetes, usually found associated with the 
metabolic syndrome. Among transcription 
factors, PPARγ occupies key functions in WAT, 
where it participates in adipocyte differentiation 
and maintenance, including promotion of lipid 
storage (70). In the absence of PPARγ, 
preadipocytes do not differentiate into 
adipocytes, and its deletion in mature adipocytes 
leads to their death (12). The prime role of 
PPARγ in the metabolic balance is also 
underscored by the fact that it is the molecular 
target of type 2 diabetes drugs, which directly 
bind to PPARγ. Interestingly, PPARγ +/- mice 
were shown to be resistant to HFD-induced 
obesity and more sensitive to insulin then their 
wt counterparts (21,33). Paradoxically, untreated 
PPARγ +/- mice on a HFD were as sensitive to 
insulin as wt mice on the same diet, but treated 
with a PPARγ agonist, the insulin sensitizer 
rosiglitazone (34).  
We aimed to understand the reasons for 
this paradox. We suspected that lipid storage is 
by far not the sole metabolic function of PPARγ. 
However, in previous studies, challenging the 
PPARγ+/- mice with a HFD most likely 
exacerbated the lipid storage function of PPARγ 
and therefore other key functions went 
unnoticed. For this very reason, we chose to 
study the metabolic role of PPARγ in the 
absence of any specific nutritional challenge by 
investigating young adult PPARγ +/-  male mice 
fed on a SD. 
The plasmatic analyses showed that if 
insulin and glucose concentrations were normal 
in basal feeding conditions, there was an 
alteration of the glycaemic control in the 
mutated mice during fasting. Interestingly, the 
plasmatic lipid profile of these animals, 
especially FFA and glycerol, suggested the 
possibility of an abnormal lipolysis. This 
presumption was strengthened by the fact that 
the plasmatic concentrations of ketone bodies, 
which are produced in the liver from FFA that 
are released by WAT during lipolysis, were low. 
Although this would designate the adipose tissue 
as the main culprit for these deregulations, we 
nevertheless extended our study to the liver and 
skeletal muscle. All three organs are either 
important consumers (skeletal muscle) or 
producers (WAT and liver) of energy. 
Furthermore, all three express PPARγ, although 
at different levels, WAT presenting by far the 
highest levels of this receptor. Based on their 
gene expression profiles, we concluded that liver 
and skeletal muscle in PPARγ +/- mice are most 
likely not involved in the metabolic deregulation 
of these animals when fed a SD. Of all the genes 
tested, which are involved in glycolysis and FA 
oxidation in both tissues, as well as in 
gluconeogenesis in the liver, none presented a 
modified expression in the PPARγ +/- mice. 
These results are in agreement with liver and 
muscle gene expression profiles in fatless mice 
or mice with an organ-specific deletion of 
PPARγ in skeletal muscle. In these studies, no 
modification was observed in the expression of 
genes involved in β-oxidation and 
gluconeogenesis (10,39,40,71). 
On the contrary, deletion of one PPARγ 
allele had unexpectedly profound effects on the 
expression of genes involved in WAT growth 
and energy production. The present study shows 
that genes involved in the IGF-1 signalling 
pathway, known to participate in adipocyte 
differentiation and growth (38,45-48), were 
down-regulated in PPARγ +/- WAT. This 
explains the resistance to growth hormone action 
and the smaller adipocyte size already observed 
by us and others in the PPARγ +/- WAT 
(21,38,72). In addition to the IGF-1 pathway, 
genes belonging to the insulin signalling 
pathway, which is an important activator of the 
glycolytic and lipogenic pathways in WAT, were 
also down-regulated.  
Unexpected at first sight, but in 
agreement with a down-regulation of the insulin 
pathway, basal glucose uptake and glycolysis 
were decreased in the mutant WAT. Glycolysis 
is thought to play three majors roles in WAT by 
(i) participating in the de novo synthesis of fatty 
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acids,  (ii) promoting their storage as fat and, 
finally, (iii) producing ATP for adipocyte 
survival. Firstly, the acetyl CoA and NADPH 
synthesized by the glycolytic and pentose 
phosphate pathways, respectively, were 
decreased in the PPARγ +/- WAT (Fig 6). As an 
immediate consequence, de novo fatty acid 
synthesis was decreased, an effect reinforced by 
the down-regulation of enzymes involved in this 
process. Secondly, storage was altered since 
glyceroneogenesis was affected in the 
PPARγ +/- WAT. In fact, the activated glycerol 
produced by glyceroneogenesis is used for fatty 
acid esterification into TG, the main form of 
lipid storage. Thirdly, glucose is required for 
adipocyte survival, and ATP production is an 
important feature of this process, deficiency of 
which affects the integrity of the cell. In this 
respect, we observed a significant decrease of 
the ATP levels in the WAT of the mutant mice. 
This result is in agreement with previous data 
from cell culture experiments where decreased 
ATP concentration in 3T3L1 or primary 
adipocytes interfered with insulin signalling and 
lipolysis. Glycolysis and FA oxidation are the 
major ATP producers, but no increase of β-
oxidation was observed in the mutant WAT to 
compensate for the energy deficit. Moreover, 
genes involved in the lipolytic activity as well as 
in the glycerol release were down-regulated in 
the PPARγ +/- WAT. Thus, PPARγ +/- WAT 
suffers from a generalized energy shortage 
probably due to the ATP crisis in the adipocytes, 
which we link to a deregulation of the glycolytic 
pathway. We have shown previously that tissue-
specific ablation of PPARγ in adipose tissue 
causes the death, within a few days of the 
PPARγ-deficient adipocytes (12). We observed a 
necrosis rather than apoptosis, which triggered 
an inflammatory response in the affected adipose 
tissue (12). Usually, necrosis is caused by a 
metabolic disruption and ATP depletion, 
whereas apoptosis requires ATP without a 
clearly defined point of no return (73). The 
phenotype of the PPARγ +/- adipocytes suggests 
that what caused PPARγ -/- adipocyte death was 
in fact a metabolic breakdown associated with a 
loss of ATP. 
To our knowledge and for the first time, 
the findings reported herein link PPARγ 
expression levels with the regulation of the 
systemic metabolic rate and physical activity. 
Although deletion of just one PPARγ allele 
decreased the metabolic rate and physical 
activity of the mice, we recorded no effect on the 
relative amounts of carbohydrates versus lipids 
used as fuel molecules. Evidence that this 
systemic effect is PPARγ-specific comes from 
the Pioglitazone treatment of the PPARγ +/- 
mice, which alleviated the deleterious effect of 
heterozygocity. Thus, endogenous ligands of 
PPARγ are most probably not abundant, or not 
efficient enough to compensate for the lower 
levels of PPARγ protein by significantly 
increasing its activity. This observation 
underscores the importance of the combined 
effects of receptor expression level and ligand 
availability to reach the optimal tuning of 
PPARγ activity and, in turn, of its target genes, 
especially in WAT. 
We speculate that the reduced level of 
both metabolic rate and physical activity are part 
of a  protective survival strategy in conditions of 
energy shortage. When faced with an energy 
crisis, animals employ various behavioural and 
physiological responses to reduce metabolism, 
which prolongs the period of time during which 
energy reserves can cover metabolic needs. Such 
behavioural responses can include a reduction in 
metabolic rate and spontaneous activity (74). 
Interestingly, some of the physiological 
characteristics of the PPARγ -/- mice resemble 
those of PPARα -/- animals during fasting, such 
as hypoketonemia and reduced activity (75).  
Food intake itself cannot explain the 
metabolic and activity phenotype since the 
PPARγ +/- mice ate the same amount of food 
and had the same weight as their wt 
counterparts. Therefore, the fate of the energy 
spared due to the metabolic and activity down-
regulation remains to be elucidated. PPARγ is 
involved in intestinal epithelial cell renewal and 
is expressed all along the digestive tract, 
especially in the absorptive part of the small 
intestine, where it is co-expressed with 
transporters of fatty acids such as FABP and 
CD36, known target genes of PPARγ (76−79). 
Therefore, it is possible that in addition to the 
dysfunctioning of WAT, the PPARγ +/- mice 
suffered from a putative absorption deficit that 
remains to be explored.  
Collectively, the data obtained by taking 
advantage of PPARγ +/- animals fed a SD, 
showed that PPARγ activity in WAT is not only 
important for fat storage, as previously showed. 
In fact, in the absence of any nutritional 
challenge, PPARγ controls IGF-1 and insulin 
signalling with effects on energy production via 
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the regulation of the glycolytic and lipolytic 
pathways. Most importantly, deregulation of 
these functions in WAT most likely influences 
the whole-body energetic balance with its 
impacts on metabolic rate and physical activity 
which appear to adapt to the available energy. 
These results do not support the potential use of 
PPARγ antagonists as possible future drugs to 
treat type 2 diabetes or obesity. However, they 
do suggest that the use of agonists may be 
beneficial when PPARγ variants occur with 
reduced activity, or in situations resulting in a 
strongly reduced expression level of an 
otherwise fully functional PPARγ. In this 
respect, there are similarities with the 
improvement of the PPARγ +/- phenotype by 
Pioglitazone treatment and the ameliorations 
observed in patients with acquired, genetic or 
disease-induced lipodystrophies after treatment 
with TZDs (70). Thus, the PPARγ +/- mice may 
represent an excellent animal model to study the 
mechanisms of action of currently used drugs, 
and the potential of novel compounds in the 
treatment of lipodystrophies. 
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FOOTNOTES 
 
The abbreviations used are : PPARγ: peroxisome proliferator-activated receptor γ; TZD: 
thiazolidinediones; WAT: white adipose tissue; TG: triglycerides; FFA: free fatty acid; RXR: retinoic 
X receptor; PPRE: peroxisome proliferator response element; HFD: high fat diet; SD: standard diet; 
RER: respiratory exchange ratio; VLDL: very low density lipoprotein; Acadvl: very long chain acyl-
CoA dehydrogenase; Acadl: long chain acyl-CoA dehydrogenase; CPT1: carnitine 
palmitoyltransferase 1; PEPCK: phosphoenol pyruvate carboxykinase; GPD1: glycerol-3-phosphate 
dehydrogenase 1; Gyk: glycerol kinase; Aqp3: aquaporin 3; G-6-Pase: glucose-6-phosphatase; IGF-1: 
insulin growth factor 1; IGFBP: insulin growth factor binding protein; IRS1: insulin receptor substrate 
1; EIF4EBP1: eukaryotic translation initiation factor 4E binding protein 1; PDE3B: phosphodiesterase 
3B; RAPGEF1: rap guanine nucleotide exchange factor 1; PTPRF: protein tyrosine phosphatase 
receptor-type F; Glut 1: glucose transporter 1; Glut 4: glucose transporter 4; HK2: hexokinase 2; 
SREBP-1c: sterol regulatory element binding protein-1c; PFKFB: 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase; PC: pyruvate carboxylase; ACC: acetyl CoA caroboxylase; FAS: fatty acid 
synthase; GDH: glucose 1 dehydrogenase; TKT: transketolase; Dgat1: diacylglycerol acyltransferase 
1; HSL: hormone sensitive lipase; Aqp7: aquaporin adipose. 
 
 
FIGURE AND TABLE LEGENDS 
 
Figure 1. Metabolic rate, fuel consumption and total physical activity in PPARγ +/- and control mice. 
A) Oxygen (O2) consumption, carbon dioxide (CO2) production and metabolic rate in the PPARγ +/- 
and control mice. O2 and CO2 were measured by indirect calorimetry, and expressed as average VO2 
and VCO2 per kg of body weight per hour during a 24-hour monitoring session (light/dark). Metabolic 
rate (heat) is calculated from the oxygen production and the respiratory exchange ratio (RER), and is 
expressed as average kcal per hour per kg of body weight during a 24-hour monitoring session 
(light/dark). B) The fuel consumption (RER), is the ratio of CO2 produced to the amount of O2 
consumed and serves as a guide of the fuel type consumption (carbohydrate: RER=1.0 or fat: RER= 
0.7). C) The total physical activity was measured as the horizontal and rearing movements during the 
24-hour monitoring period (total of light and dark movements). The activity is expressed as the 
average number of times a mouse crosses both the x and y axes at least twice. n = 12 (CTL 
experiments); n = 5 (Pioglitazone experiments); Values are expressed as mean ± S.E.; *, P ≤ 0.05  
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Figure 2. Plasmatic profile of PPARγ +/- and control mice. A) Plasmatic insulin concentrations. B) 
Plasmatic glucose concentrations. C) Free fatty acid (FFA) plasmatic levels. D) Plasmatic glycerol 
concentrations. E) Plasmatic ketone bodies concentrations. F) Plasmatic triglygerides (TG) 
concentrations. A to F) fed WT n = 7; fasted WT n = 11; fed PPARγ +/- n = 6; fasted PPARγ +/- n = 
6; Values are expressed as mean ± S.E.; *, P≤ 0.05 
 
Figure 3. Glycerol content in white adipose tissue of fed PPARγ +/- and wt mice.  
WT n = 11; PPARγ +/- n = 12; Values are expressed as mean ± S.E. ; *, P≤ 0.05 
 
Figure 4. Heat map representation of the microarray results on PPARγ +/- and wt white adipose tissue. 
 
Figure 5. Metabolic gene expression in fed PPARγ +/- and wt WAT. Transcript levels of indicated 
genes were analyzed by qRT-PCR performed on an isolated total RNA extract from WAT. The 
geometric mean expression of actb, Tuba2 and HPRT1 were used as an internal control. The qRT-
PCR included RNA samples used on the microarray experiment as well as additional RNA samples. n 
= 12; Values are expressed as mean ± S.E.(relative to the WT expression); *, P≤ 0.05 
 
Figure 6. Schematic representation of the metabolic pathways influenced by the deletion of one 
PPARγ allele in the WAT. The enzymes which were shown to be down-regulated in PPARγ +/- WAT 
either on the microarray experiment or by qRT-PCR, or both, are shown on the scheme. The enzymes 
already described as being regulated by PPARγ or by its ligands are in red and those shown to be 
regulated by the insulin pathway are in green.  
 
Figure 7. Effect of the deletion of one PPARγ allele on the ATP levels in the WAT. 
n = 9; Values are expressed as mean ± S.E.; *, P≤ 0.05. 
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     GeneBank Gene Name Symbol Muscle Liver 
 
Glycogenolysis 
 
NM_133198 
NM_011224 
NM_030678 
 
Glycolysis 
 
NM_009204 
NM_028121 
NM_013820 
NM_021514 
NM_011099 
 
Gluconeogenesis 
 
NM_067306 
NM_008797 
NM_001044 
NM_010294 
NM_010271 
NM_008904 
 
NM_016689 
 
Fatty Acid 
Oxidation 
 
NM_017366 
 
NM_017381 
 
NM_013495 
NM_016763 
 
NM_026444 
NM_009464 
NM_016774 
 
     NM_009942 
 
 
    
   Glycogen  Phosphorylase, liver 
Glycogen Phosphorylase, muscle 
Glycogen Synthase  1 
 
 
 
Glucose Transporter 4 
Glucokinase 
Hexokinase 2 
Phosphofructokinase 
Pyruvate kinase 
 
 
 
Glucose 6 Phosphatase 
Pyruvate Carboxylase 
Phosphoenol Pyruvate Carboxykinase 
Glycerol Kinase 
Glycerol 3 Phosphate Dehydrogenase 1 
Peroxisome Proliferator Activated  
Receptor, Coactivator 1 alpha 
Aquaporin 3 
 
 
 
 
Acyl-Coenzyme A Dehydrogenase,  
very long chain 
Acyl-Coenzyme A Dehydrogenase,  
long chain 
Carnitine Palmitoyltransferase 1 
Hydroxyacyl-Coenzyme A 
Dehydrogenase 
Citrate Synthase 
Uncoupling Protein 3 
ATP Synthase, H+ Transporting  
mitochondrial F1 complex 
Cytochrome c Oxidase, Subunit Vb 
 
 
 
Pygl 
Pygm 
Gys 1 
 
 
 
Glut 4 
Gk 
HK2 
PFK 
PK 
 
 
 
G6Pase 
PC 
PEPCK 
Gyk 
GPD 1 
PGC1α 
 
Aqp3 
 
 
  
 
Acadvl 
 
Acadl 
 
CPT 1 
HADH 
 
Cs   
UCP3 
ATP5b 
 
Cox5b 
 
 
 
 
x 
x 
 
 
 
x 
 
x 
x 
x 
 
 
 
 
 
 
 
 
x 
 
x 
 
 
 
 
x 
 
x 
 
 
x 
 
x 
x 
x 
 
x 
 
 
 
 
x 
 
 
 
 
 
 
x 
 
x 
x 
 
 
 
x 
x 
x 
x 
x 
x 
 
 
 
 
 
 
x 
 
x 
 
x 
 
 
 
Table 1. Metabolic pathways tested in skeletal muscle and liver isolated from fed animals. Gene 
expression was tested either by microarray in the skeletal muscle or by qRT-PCR in liver. X identifies 
the genes analysed; skeletal muscle n = 3; liver n = 6. 
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GeneBank                                  Gene Name                                 Symbol R* 
 
Glycolysis 
 
NM_013820 
NM_008792 
AK011810 
NM_133232 
NM_133198 
 
Pentose Phosphate 
pathway 
 
BC027358 
AV103412 
 
Glyceroneogenesis 
 
NM_011044  
AB056091 
NM_010271 
  
Lipid Synthesis 
 
NM_133366  
BC003717 
NM_007988  
 
Lipolysis 
 
NM_010719 
 
IGF-1 pathway 
 
AF440694 
NM_008344 
AI481026 
BF225802   
NM_018871 
 
 
Insulin pathway 
 
BB345784 
NM_007918  
 
AV270888 
BB339051 
 
BF235516            
                                          
                    
 
 
 
Hexokinase 2 
Pyruvate Carboxylase 
Pyruvate Dehydrogenase beta 
6 Phospho Fructo 2 Kinase 3 
Glycogen Phosphorylase 
 
 
 
 
Glucose 1 Dehydrogenase 
Transketolase 
 
 
 
Phosphoenol Pyruvate Carboxykinase 1 
Aquaporin Adipose 
Glycerol 3 Phosphate Dehydrogenase 1 
 
 
 
Acetyl CoA Carboxylase 
Diacylglycerol Acyltransferase 1 
Fatty Acid Synthase 
 
 
 
Hormone Sensitive Lipase 
 
 
 
Insulin-like Growth Factor 1 
Insulin-like Growth Factor Binding Protein 6 
Insulin-like Growth Factor Binding Protein 7 
Jun oncogene 
3 Monooxygenase Tryptophan 5-Monooxygenase                             
Activation Protein, gamma 
 
 
 
Insulin Receptor Substrate 1 
Eukaryotic Translation Initiation Factor 4E Binding 
Protein 1 
Phosphodiesterase 3B, cGMP inhibited 
Rap Guanine Nucleotide Exchange Factor 
(GEF)1 
Protein Tyrosine Phosphatase Receptor-type F 
 
 
 
HK2 
PC 
PDHB 
PFKFB3 
Pygl 
 
 
 
 
GDH1 
TKT 
 
 
 
PEPCK1 
Aqp7 
GPD1 
 
 
 
ACC 
Dgat1 
FAS 
 
 
 
HSL 
 
 
 
IGF-1 
IGFBP6 
IGFBP7 
c-Jun 
14-3-3-g 
 
 
 
 
IRS1 
EIF4EBP1 
 
PDE3B 
RAP6EF1 
 
PTPRF 
 
 
 
0.37 
0.52 
0.60 
0.75 
0.78 
 
 
 
 
0.59 
0.61 
 
 
 
0.55 
0.57 
0.71 
 
 
 
0.48 
0.53 
0.65 
 
 
 
0.53 
 
 
 
0.54 
0.54 
0.54 
0.61 
0.64 
 
 
 
 
0.56 
0.59 
 
0.60 
0.66 
 
2.12 
 
 
Table 2. Genes affected in WAT by the deletion of one PPARγ allele. Their expression reflects the 
decreased metabolic activity of the WAT (R*: fold change in heterozygous animals compared to wt 
mice, whose value is set to 1; threshold 1.3; validated result: reproducibility in 7 out of 9 
comparisons). n = 3. 
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I.3. Additional Preliminary Results 
 
The data shown in section Results I.2, demonstrate that PPARγ activity in WAT is not only 
important for fat storage, as previously showed. In fact, in the absence of any nutritional challenge, 
PPARγ controls IGF-1 and insulin signaling with effects on energy production via the regulation of 
the glycolytic and lipolytic pathways. Most importantly, deregulation of the glycolytic and lipolytic 
functions in WAT influences the whole-body energetic balance with its impacts on metabolic rate 
and physical activity that appears to adapt to the available energy. Besides the metabolic pathways, 
other functions involved in the maintenance of the tissue are affected by the PPARγ deletion. Our 
gene expression analysis of the PPARγ +/- WAT showed an important deregulation of genes 
involved in cell structure, growth and signaling, cell stress and detoxification and finally in cell 
inflammatory and immune reactions, Table 3.  
This information is important since, besides energy metabolism and protein synthesis 
represented by 45 % of the genes expressed in the white adipose tissue (21 % and 24 % 
respectively), 14 % of the genes expressed in WAT are involved in the defence of the cell and 
organism. This expression is more important than that of genes involved in lipid metabolism (10 %), 
which is known as one of the most important features of adipocytes (303). The relative high 
percentage of genes involved in cell and organism defence expressed in WAT extends the role 
played by this tissue in whole body homeostasis.  
 
I.3.1. Adipocyte differentiation 
 
Cytoskeleton, tight junction and cell adhesion reorganization are well known features of 
adipogenesis (224). The expression profile of different markers of adipocyte differentiation such as 
aP2, CD36 and SREBP1c, showed that PPARγ +/- adipocytes are less fully differentiated than their 
wild type counterparts (289).  
During adipogenesis, extracellular matrix (ECM) remodelling defines the onset of the 
differentiation process, characterized by the conversion from the fibronectin-rich stromal matrix  
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GenBank Gene Name Symbol R* 
 
Adipocyte differentiation 
 
Actin organization 
 
AF130364 
NM_019410 
NM_019671 
NM_021423 
 
Cell adhesion 
 
NM_018882 
NM_023061 
NM_022316 
 
NM_053082 
NM_008403 
 
Plasma membrane 
organization & Tight junction 
 
AF269062 
AK019164 
NM_013805 
NM_019769 
 
Calcium Homeostasis 
 
NM_016773 
NM_008037 
NM_007597 
NM_007589 
 
Cell cycle, growth & 
apoptosis 
 
NM_030750 
BQ176661 
NM_011641 
BI156044 
 
NM_009808 
NM_007913 
BC002076 
AV310588 
NM_019564 
 
Cell stress & detoxification 
 
NM_030143 
 
NM_008183 
NM_025569 
NM_008160 
AV261043 
 
 
 
 
 
 
Ankyrin 3 
Profilin 2 
Neuroepithelial Cell Transforming Gene 1 
SH3 Ankyrin Domain Gene 3 
 
 
 
G protein Coupled Receptor 56 
Melanoma Cell Adhesion Molecule 
SPARC Related Modular Calcium Binding 
1 
Transmembrane 4 Superfamily Member 7 
Integrin Cytoplasmic Domain Associated 
Protein 1 
 
 
 
Prominin 2 
Multiple PDZ Domain Protein 
Claudin 5 
Calcium Binding Protein P 22 
 
 
 
Nucleobindin 2 
Reticulocalbin 
Calnexin 
Calmodulin 2 
 
 
 
 
Shingosine 1 Phosphate Phosphatase 1 
Makorin 1 
Transformation Related Protein 63 
Growth Arrest and DNA Damage inducible 
45 gamma 
Early Growth Response 1 
Caspase 12 
Mesenchyme homeobox 2 
Cyclin D2 
Protease Serine 11 
 
 
 
Regulated in Development and DNA 
Damage Responses 1 
Glutathione S Transferase mu 6 
Microsomal Glutathione S Transferase 3 
Glutathione Peroxidase 1 
Superoxide Dismutase 
 
 
 
 
 
 
 
Ank 3 
Pfn 2 
Net 1 
Shank 3 
 
 
 
Gpr 56 
Mcam 
Smoc 1 
 
Tm4sf7 
Icap 1 
 
 
 
 
Prom 2 
Mpdz 
Cldn 5 
CHP 
 
 
 
Nucb 2 
Rcn 1 
Canx 
Calm 2 
 
 
 
 
Spp 1 
Mkrn 1 
p63 
Gadd45γ 
 
Egr 1 
Casp 12 
Meox 2 
Ccnd 2 
Prss 11 
 
 
 
Redd 1 
 
Gstm 6 
Mgst 3 
Gpx 1 
Sod 
 
 
 
 
 
 
2.60 
2.27 
0.51 
0.56 
 
 
 
1.70 
0.46 
0.54 
 
0.61 
0.65 
 
 
 
 
51.1 
0.58 
0.59 
0.63 
 
 
 
3.36 
2.32 
1.70 
1.40 
 
 
 
 
3.06 
2.63 
2.51 
0.50 
 
0.50 
0.51 
0.53 
0.53 
0.60 
 
 
 
2.31 
 
1.87 
0.56 
0.68 
0.72 
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GenBank Gene Name Symbol R* 
Immune reactions 
Inflammatory reactions 
 
NM_007402 
NM_010030 
NM_019511 
 
NM_013777 
NM_007388 
 
Macrophages & lymphocyte 
activation 
 
NM_007675 
NM_008522 
NM_010872 
NM_008604 
NM_011925 
 
Anti inflammatory reactions 
Glucocorticoid Pathway 
 
NM_0104013 
NM_010220 
NM_008288 
NM_008173.1 
 
 
 
 
A Desintegrin Metalloproteinase Domain 7 
Defensin β 2 
Receptor (Calcitonin) Activity Modifying 
Protein 3 
Aldo Keto reductase 1A 1 
Acid Phosphatase 5 
 
 
 
 
CEA related Cell Adhesion Molecule 10 
Lactotransferrin 
CD56 antigen 
Membrane Metallo Endopeptidase 
CD97 antigen 
 
 
 
 
Histone Deacetylase 6 
FK506 Binding Protein 5 
11-β-Hydroxysteroid Dehydrogenase type 1 
Glucocorticoid receptor 
 
 
 
Adam 7 
Defb 2 
Ramp 3 
 
Akr1 A1 
Acp 5 
 
 
 
 
Ceacam 10 
Ltf 
CD56 
Mme 
CD97 
 
 
 
 
Hdac 6 
FKBP 51 
Hsd11β1 
GR 
 
 
 
 
325 
57.1 
12.5 
 
2.07 
0.32 
 
 
 
 
14.7 
6.99 
2.97 
1.63 
1.50 
 
 
 
 
6.88 
3.36 
1.52 
1.00 
 
 
 
Table 3: Genes affected in WAT by the deletion of one PPARγ allele. Their expression reflects 
deregulation of adipocyte differentiation, cell stress and detoxification and finally of the cell 
inflammatory and innate immunity reactions, (R*: fold change in heterozygous animals 
compared to wt mice, whose value is set to 1; threshold 1.3; validated result: reproducibility in 7 out 
of 9 comparisons). n = 3. 
 
of the preadipocyte to the basement membrane of an adipocyte. The expression of ECM components 
is highly regulated during this process: types I and III collagen, fibronectin, and ß1-integrins are 
down-regulated, whereas type IV collagen and actin are up-regulated (304,305). During ECM 
remodelling, adipogenic cells release their cell-ECM adhesion and change their morphology and 
volume (306). The morphological and cytoskeletal reorganizations in the preadipocyte is required 
for the induction of the expression of lipogenic genes (307-309). Our microarray analysis showed 
that the expression of Ank 3, which is a component of the actin cytoskeleton known as being down-
regulated during adipogenesis (224), was increased in the PPARγ +/- WAT by 2.6 folds (Table 3). 
Besides Ank 3, the expression Pfn 2 which maintains actin in a non adipogenic permissive  
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monomeric form (310) was increased by 51 folds in the PPARγ +/- WAT. Furthermore, the 
expression of proteins controlling the actin skeleton dynamics such as Net 1, and Shank 3 were 
down-regulated by 2 and 1.8 folds respectively, indicating a destabilization of the actin cytoskeleton 
in the heterozygous WAT (Table 3)(310-313).  
As mentioned previously, proper adipocyte differentiation requires loss of the cellular 
adhesion (307). Our microarray analysis revealed a deregulation of genes involved in this function, 
(Table 3). Gpr 56 which is an important member of the adhesion family of G protein coupled 
receptors was up-regulated by 1.7 folds, whereas Icap 1 which is involved in the integrin dependent 
signals was down-regulated by 1.5 folds in the heterozygous WAT (314,315). The expression of 
Icap 1 was also confirmed by qRT-PCR analysis on additional RNA samples, (Fig 7). Other genes 
involved in these function are deregulated in PPARγ +/- WAT. However, their role in adipocyte 
differentiation is not completely understood. The deregulation of genes involved in the actin 
skeleton dynamics as well as in the cellular adhesion suggests retardation in the adipocyte 
differentiation process. 
Besides the morphological and cytoskeleton reorganizations, adipocyte differentiation 
requires changes in the plasma membrane composition such as a high increase in the caveolae 
composition and a reduction in the gap junctions (316-319). Claudin 6, which is a member of the 
claudin family involved in the tight junction, was shown to be required for adipocyte differentiation 
(317). Our microarray and qRT-PCR analysis showed a 1.7 folds down-regulation of another 
member of this family called Cldn 5, (Table 3, Fig 7). These results are in agreement with a 
retardation of the adipocyte differentiation in the PPARγ +/- WAT.  
Modulation of the calcium signaling is another feature of the adipocyte differentiation (320). 
The intracellular calcium concentration affects adipogenesis. In fact, high concentrations inhibit the 
early stages of adipocyte differentiation, while promoting both the late stage of differentiation and 
lipogenesis (321). Several calcium binding proteins such as Nucb 2, Rcn 1, calnexin and calmodulin 
2 were up-regulated in the heterozygous WAT by 3.4, 2.3, 1.7 and 1.4 folds respectively. However, 
their involvement in adipocyte differentiation is largely unknown. Calmodulin 2 might be involved 
in the inhibition of adipocyte differentiation trough activation of the calcium/calcineurin dependent 
pathway. Nerveless however, the precise mechanism remains obscure (322).   
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Figure 7. Expression levels of different genes involved in A. 
adipocyte differentiation, B. inflammatory and C. 
glucocorticoid signaling pathways in the white adipose tissue. 
Integrin Cytoplasmic Domain Associated Protein 1 (ICAP 1), 
Claudin 5 (Cldn 5); Interleukin 6 (Il-6), Monocyte Chemotactic 
Protein 1(MCP1), Tumour Necrosis Factor α (TNF-α); 11-β-
Hydroxysteroid Dehydrogenase type 1 (Hsd11β1), Glucocorticoid 
receptor (GR), FK506 Binding Protein 5 (FKBP51) n = 4 * p-
value ≤ 0.06  
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Adipocyte differentiation requires a growth arrest (224,323). Several genes involved in cell 
cycle control were deregulated in the PPARγ +/- WAT. However, their roles in adipogenesis have 
not been studied yet (Table 3). High expression of Spp 1, Mkrn 1 and p65 was shown to induce 
apoptosis in different cellular models (324-326) and were up-regulated in the heterozygous WAT by 
3.1, 2.6 and 2.5 folds, respectively. The tumour suppressor Prss 1 and the regulators of the cell cycle 
Meox 2 and Ccnd 2 were down-regulated in the heterozygous WAT by 1.7 and 1.9 folds 
respectively. Ccdn2 expression was shown to be increase during adipogenesis (224). These results 
show, that there is a deregulation of the cell cycle in the heterozygous WAT. However, further 
experiments are required to better understand this deregulation.  
Our histological analysis using hematoxylin and eosin staining showed, in agreement with 
published data (245), a 20% decrease of adipocytes size in PPARγ +/- mice WAT (Fig 8 C). These 
results are in agreement with retardation in adipocyte development.  
Our microarray and qRT-PCR analysis revealed important deregulations in the expression of 
genes involved in several aspects of adipocyte differentiation. These results are in agreement with a 
retardation of the adipogenic process. However, a better validation of this hypothesis requires a 
deeper characterization of the differentiation process. Since ECM remodelling during adipogenesis 
requires up-regulation of actin and collagen I and III expression as well as rearrangement of the 
actin skeleton from a monomeric to a polymerized form, we propose the characterization of the 
adipocyte cytoskeleton by immunofluoresence using antibodies against proteins of the ECM such as 
the actin and collagen I and III.  
 
I.3.2. Cell stress and detoxification 
 
Molecular oxygen (O2) is the premier biological electron acceptor that serves vital roles in 
fundamental cellular functions. However, with the beneficial properties of O2 comes the inadvertent 
formation of reactive oxygen species (ROS) such as superoxide (O2•−), hydrogen peroxide  (H2O2), 
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Figure 8. A. Histological analysis of the white adipose tissue. Black arrows represent adipocyte 
nucleus and red arrows represent the infiltrated inflammatory cells. B. Presence of inflammatory foci in 
the white adipose tissue. Black arrow represent the inflammatory foci (left picture).Black arrow 
represent inflammatory cell found in the inflammatory foci (right picture, higher magnitude). C. 
Measurement of the adipocyte size using the Image J program. D. Counting of the number of 
infiltrated inflammatory cells. A, B, C and D. Hematoxylin and Eosin Staining (H&E); n = 2 
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and hydroxyl radical (OH•). If unabated, ROS pose a serious threat causing cell death. To minimize 
the damaging effects of ROS, organisms evolved enzymatic antioxidant  defences. This includes 
enzymes such as superoxide dismutases (Sod), catalases (Cat), glutathione peroxidases (Gpx), and 
glutathione S-transferases (GST). Sod, Cat and Gpx protect cell integrity by directly scavenging 
superoxide radicals and hydrogen peroxide, converting them to less reactive species. Sod catalyze 
the dismutation of O2•−  to H2O2 and Cat and Gpx reduces H2O2 to 2H2O (327). Thus, the Sod and 
Cat/Gpx serve, in tandem, as a first front-line in the antioxidant defences (328). Glutathione S 
transferases (GST) are enzymes acting as a second line defence against the oxidative stress. These 
enzymes react with various electrophiles, physiological metabolites and xenobiotics to form 
mercapturates which can be safely degraded by the organism (329,330).  
14 % of the genes expressed in WAT are involved in cell and organism defences (303). 
Deregulation of this defence has been observed in metabolic syndrome diseases such as 
atherosclerosis, obesity and type 2 diabetes. The increase in the oxidative stress observed in these 
pathologies is due to a defective antioxidant system reflected by a decrease in the expression of Gpx, 
Cat and Sod as well as an increase in the expression of inflammatory molecules such as IL-6, MCP1 
and PAI1 (331). Observations on mouse and human adipocytes showed a correlation between 
increased ROS production and increased inflammatory reactions (332). Moreover, oxidative stress 
was shown to impair lipogenesis and glucose uptake as well as PPARγ expression in WAT (331). 
Impairment of lipogenesis and glucose uptake were observed in PPARγ +/- WAT (section Results 
I.2.). Our microarray analysis showed a deregulation of several genes involved in the first and 
second line of defence in the detoxification pathways in the PPARγ +/- WAT.  
As mentioned above, two of the enzymes involved in this first front-line antioxidant defence 
were down-regulated in the heterozygous WAT. The expression levels of Sod and Gpx1 were 
decreased by 1.4 and 1.7 folds respectively (Table 3).  Lower Gpx activity was observed in obese 
and diabetic rats and decreased Gpx expression was observed in several pathologies linked to 
oxidative stress (191,333). Gpx knock-out mice are sensitive to an increase in H2O2 concentrations 
(334), whereas Sod knock-out mice suffer from an increase in lipid peroxidation (335). These results 
suggest that the PPARγ +/- WAT suffers from an increase in the ROS concentrations. However, 
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further experiments measuring the ROS concentrations as well as the Sod and Gpx activities in 
WAT would allow a better analysis of this situation (336).  
A second line of defence in the antioxidant program is the activation of GST enzymes. These 
enzymes catalyze the nucleophilic attack by reduced glutathione (GSH) on nonpolar compounds 
containing an electrophilic carbon, nitrogen, or sulphur atom. Their substrates include metabolic 
derivatives such as oxidized lipids, DNA, protein, and carbohydrates as well as xenobiotics (327). 
GSTs were shown to participate to the synthesis of eicosanoids and prostanoids, to reduce fatty 
acids, cholesteryl and phospholipid hydroperoxides and to protect DNA against oxidative damage 
(327,337-339). Three major families of proteins that are widely distributed in nature exhibit 
glutathione transferase activity. Two of these, the cytosolic and mitochondrial GST, comprise 
soluble enzymes that are only distantly related. The third family comprises microsomal GST and is 
now referred to as membrane-associated proteins in eicosanoid and glutathione (MAPEG) 
metabolism (327).  
The glutathione S transferase mu 6 (Gstm6) is a cytosolic GST, participating to the 
elimination of oxidative stress molecules. Its overexpression was shown to protect against oxidative 
stress induced apoptosis, involving this enzyme in the adaptive response to cell stress (340,341). Its 
expression was up-regulated by 1.9 folds in PPARγ +/- WAT, suggesting that the heterozygous 
WAT needs an increased protection against the oxidative stress (Table 3). Measuring the levels of 
lipid peroxidation in WAT should sharpen this analysis and will definitely underline possible 
perturbations in the mechanism of protection against oxidative stress (336,342).  
The microsomal GSTs are membrane associated proteins involved essentially in the 
synthesis of leukotrienes, which are lipid mediators of the inflammatory response (343). Knock-out 
models of microsomal GSTs were shown to be deficient in leukotriene synthesis (344). The 
expression of Mgst3, one of the microsomal GSTs, was down-regulated by 1.8 folds in the 
PPARγ +/- WAT, (Table 3). Since this class of GSTs was associated to leukotriene synthesis, it is 
possible that their production is reduced in the heterozygous WAT implying that the adipose tissue 
is deficient in the anti-inflammatory response. Moreover, the expression of Redd1, a marker of 
oxidative stress up-regulated by cellular stress (345), was also increased by 2.3 folds in PPARγ +/- 
WAT, (Table 3).  
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When the cells undergo irreversible damages their apoptotic programme is activated leading 
to their apoptosis (346). Gadd45γ and Egr1, two inducers of apoptosis activated by DNA damage 
and cellular stress (347), were down-regulated by 2 folds in the PPARγ +/- WAT, (Table 3). Thus, 
the PPARγ +/- WAT suffers from cell stress and accumulation of undesired metabolites. In this 
context, down-regulation of the expression of pro-apoptotic proteins could be a protective 
mechanism against cellular death.  
The results presented above are in agreement with our previous results showing that deletion 
of one PPARγ allele in WAT interfere with several metabolic pathways in the white adipose tissue 
leading to a deficiency in the energy production, (section Results I.2.). Deregulation of these 
metabolic pathways as well as the energetic deficiency could indeed be responsible for the cellular 
stress depicted by our microarray results.  
 
I.3.3. Inflammation and immune reactions 
 
Metabolic syndrome related diseases such as obesity, lipodystrophy or type 2 diabetes are 
associated to immune mediated disorders such as inflammation or deregulation of the innate 
pathway (section Introduction II.3.). Several proteins produced by the adipose tissue are known to 
participate to the inflammatory reactions. Their production not only influences the inflammatory 
state of the tissue but also interferes with its metabolic functions. Besides adipocytes, which are 
participating in the inflammatory reactions, macrophages are also present and active in the adipose 
tissue. Together with adipocytes and other cell types present in WAT, it perpetuates a vicious cycle 
of macrophage recruitment and the production of pro-inflammatory adipokines and chemokines 
(section Introduction II.3.).  
Specific deletion of PPARγ in the WAT was shown to have deleterious effects on the fate of 
the tissue, being responsible for the lipodystrophy and the increased inflammatory reactions in the 
remaining WAT (sections Introduction III.8.1 and III.8.2.1.). Until now, the deletion of one PPARγ 
allele was thought to have a beneficial effect on HFD induced obesity and type 2 diabetes. In fact, 
PPARγ +/- mice treated with a HFD were shown to be resistant to obesity and to be more sensitive 
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to  insulin (246). However, our results showed that in normal feeding conditions, the PPARγ +/- 
WAT suffers from a deregulation of several metabolic pathways leading to an energy deficit, which 
we have shown to have a repercussion on the metabolic rate and physical activity (section Results 
I.2.). Moreover, the microarray analysis showed that the PPARγ +/- WAT might suffer from cell 
stress due to the deregulation of its detoxification pathway. Thus, our results argue against a positive 
general outcome of the deletion of one PPARγ allele in the adipose tissue and suggest that normal 
PPARγ expression in WAT is required for the integrity of the tissue. Furthermore, the results 
presented are in agreement with such a hypothesis since deletion of one PPARγ allele, affects 
specifically in WAT the expression of several molecules involved in the inflammatory reactions.  
Inflammation is one of the first responses of the immune system. It is stimulated by chemical 
factors released by injured cells that attract inflammatory cells such as leukocytes (neutrophils, 
macrophages, natural killers and many other) and lymphocytes to the site of injury (348).  
Our microarray analysis showed an increased inflammatory reaction in the PPARγ +/- WAT. 
Molecules participating actively in the inflammatory reaction such as Adam 7, Defb2, Ramp3 and 
Akr1A1 were up-regulated by 300, 57, 12.5 and 2.1 folds respectively in the mutant WAT, (Table 
3). Adam 7 is an adhesion protein participating actively in the immune response, its expression is 
not observed in the healthy WAT (349). Defb2 it is a small peptide having a broad spectrum of anti-
microbial activities, its expression is up-regulated during inflammation (349,350). Ramp3 
participates in the inflammatory reactions through active regulation of the calcitonin gene related 
peptide (CGRP), which was shown to play an important role during inflammation of the WAT 
(351). Finally, Akr1A1 is a mediator of the inflammatory signals (352). Acp5 whose down-
regulation was linked to an increase inflammatory reaction (353), was shown to be down-regulated 
by 3 folds in the PPARγ +/- WAT, suggesting an increased inflammatory reaction in the mutated 
WAT, (Table 3). Surprisingly, 24h fasting induces up-regulation of the expression of MCP1 in the 
PPARγ +/- WAT, (Fig 7). Although its expression did not meet our statistical expectancy, the same 
expression pattern was observed for IL-6 (Fig 7). IL-6 as well as MCP1 are inflammatory markers, 
produced by the injured adipocytes (section Introduction section II.3.). Interestingly, this 
deregulation was observed in WAT samples collected from fasted mice suggesting a link between  
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energy deficiency in WAT and inflammation. However, due to a high variability in the expression 
level of inflammatory molecules between animals of the same experimental group, further 
experiments with increasing number of animals are required.  
Besides an increase in the inflammatory reaction, our microarray analysis suggests an 
activation of macrophages and lymphocytes in the PPARγ +/- WAT. The expression of molecules 
involved in their activation was up-regulated in the mutant WAT, (Table 3). Ceacam10, CD56, 
CD97 and Mme whose expression was up-regulated in the mutant WAT (Table 3) were shown to 
participate to the leukocytes and lymphocytes activation (354-357). Ltf which participates to 
macrophage activation (358), was also up-regulated in the mutant WAT, (Table 3). As for Il-6 and 
MCP1, TNF-α, another inflammatory cytokine produced exclusively by activated macrophages 
(section Introduction II.3.) was also up-regulated by 2.8 folds in samples from fasted PPARγ +- 
WAT, (Fig 7).    
Histological analysis using H&E staining showed a 57% increase in the number of 
inflammatory cells in the mutant WAT, (Fig 8 A, B, D). Although the qRT-PCR and histological 
experiments as well as the samples number need to be ameliorated, these preliminary results suggest 
that inflammation does occur in PPARγ +/- WAT.  
During an immune and inflammatory response, the activation of the stress system 
(glucocorticoids) protects the organism from an overload of inflammatory reaction which can 
irreversibly damage the organ. Glucocorticoids are potent  anti-inflammatory molecules able to 
shape both the innate and the adaptive immune response, activating the macrophages phagocytosis 
of leukocytes undergoing apoptosis (359). Over the past decade, it became apparent that the 
important level of control over endogenous glucocorticoid action is exerted by the 11-β-
hydroxysteroid dehydrogenase enzymes (360). The type 1 enzyme, Hsd11β1, reduces the inert 
glucocorticoids into active forms, increasing the intracellular ligand availability for the 
glucocorticoid receptors (GRs) (198,361). Its up-regulation is linked to pathologies related to the 
adipose tissue such as obesity, lipodystrophy and type 2 diabetes which are known as being 
characterized  by a low grade inflammatory status of the WAT (210,362,363). Our microarray 
analysis showed a 1.5 folds up-regulation of Hsd11β1 expression in the mutant WAT, (Table 3). Its 
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up-regulation was specific to WAT since it was not observed in the liver or in the skeletal muscle 
(Fig 7 and Table 4). These results suggest a local increase in the glucocorticoid effect in the mutant 
WAT. Further microarray and qRT-PCR analysis showed that although the expression of GR is not 
deregulated in the mutant WAT (Table 3 and Fig 7), the expression of Hdac6, a deacetylase protein 
required for GR activation (364) as well of FKBP51 a target gene of the GR pathway (365,366), 
were up-regulated by 6.9 and 3.4 folds respectively in the mutant WAT (table 3 and Fig 7). These 
results are in agreement with an increase glucococrticoid activity in PPARγ +/- WAT. 
Although the adipose corticoid production is thought to have only a local action (301,367), 
we also observed 24 % and 53% increase in the plasmatic concentration of corticoids in the 
PPARγ +/- mice in fed and fasted conditions respectively, (Fig 9). This increased plasmatic 
concentration has a systemic effect since glucocorticoid target genes such as Gilz, Tilz3c and Sgk1 
were up-regulated in the skeletal muscle without any increase in the expression of Hsd11β1 in this 
tissue, (Table 4). Other organs, such as the liver should also be tested for glucocorticoid response. 
 
              
 
Figure 9. Plasmatic glucocorticoid concentrations in 11 weeks old, wt and PPARγ +/- male 
mice. n = 8, * p-value ≤ 0.05  
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GenBank Gene Name Symbol R* 
 
Glucocorticoid 
pathway 
 
NM_008403    
AF201289 
NM_019671 
NM_008288 
 
 
 
 
 
Glucocorticoid-Induced Leucine Zipper  
TSC22-Related Inducible Leucine Zipper 3c  
Serum Glucocorticoid Regulated Kinase   1 
11-β-Hydroxysteroid Dehydrogenase type 1 
 
 
 
 
 
Gilz 
Tilz3c  
Sgk1 
Hsd11β1 
 
 
 
 
 
1.67 
1.65 
1.63 
1.20 
 
 
Table 4: Deregulation of the glucocorticoid pathway in the PPARγ +/- skeletal muscle, (R*: 
fold change in heterozygous animals compared to wt mice, whose value is set to 1; threshold 1.3; 
validated result: reproducibility in 7 out of 9 comparisons). n = 3. 
 
The major site of corticoid production is the adrenal cortex, whereas the kidney followed by 
the liver are the major sites for the conversion of corticoids from an inactive to an active form (360). 
Thus, it is possible that deletion of one allele of PPARγ affects the conversion to active corticoids in 
other organs, such as the kidney or liver. However, we did not observe any deregulation in the 
Hsd11β1 expression in the liver, (Fig 7). Moreover, it is possible that the increased plasmatic 
corticoid concentration is due to a deregulation of Hsd11β1 in the kidney where PPARγ is also 
normally expressed. Measuring the expression level of Hsd11β1 in kidney as well as its conversion 
activity using biochemical in vitro methods (368) should verify our hypothesis.  
 
I.3.4. Additional Material and Methods 
 
Tissue preparation and staining: Epididymal white adipose tissue samples were fixed in 4% 
paraformaldehyde–PBS 1x, dehydrated, and embedded in paraffin according to the standard 
procedure. 3 µm sections were cut and processed for hematoxilin & eosin (H&E) staining using 
standard protocols.  
Measurement of the adipocyte size: Mature white adipocytes were identified by their 
characteristic multilocular appearance. Total areas of adipocytes were traced manually and analyzed 
with Image J. 
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Measurement of plasmatic glucocorticoid concentrations: The corticoid concentrations were 
measured at the Mouse Clinical Institute (MCI, Strasbourg, France) as described in “Material and 
Methods” (section Results I.2.). 
Quantitative RT-PCR: Quantitative RT-PCR were conducted as described in “Material and 
Methods” section Results II.2. The primers used are the fallowing: Icap1: f: 
CACTGTCGCCAGCCTCG and r: GTCTAAATTGCTGTTACTCTGTCCTGA; Cldn5: f: 
TCAGGGATTTCTATAACCCGTTG and r: AGCTCCCATCTCCCGCT, MCP1: f: 
TGGCTCAGCCAGATGCAGT and r: GATCATCTTGCTGGTGAATGA;   TNF-α: f: 
TTCCCAAATGGCCTCCCT and r: TCGAATTTTGAGAAGATGAGATGATGATCTGAGT; IL-
6: f: TGTTCTCTGGGAAATCGTGGA and r: AAGTGCATCATCGTTGTTCATACA; FKBP51: f: 
CGCAGGCTGCCATCGT and r: CGTGTACTTGCCTCCCTTGAA; GR: f: 
GACATCTTGCAGGATTTGGAGTT and r: GACCTCCAAGGACTCTCGTTTG; Hsd11β1 and 
house keeping genes: see “Material and Methods” section Results I.2. 
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I.4. Discussion and Perspectives 
 
Adipose tissue integrity is crucial for whole body energy homeostasis. Its functional 
deregulation, as observed in obesity or lipodystrophy, is linked to diseases, such as type 2 diabetes, 
usually found associated with the metabolic syndrome. PPARγ occupies key functions in WAT, 
where it participates in adipocyte differentiation and maintenance, including promotion of lipid 
storage (369). In the absence of PPARγ, preadipocytes do not differentiate into adipocytes, and its 
deletion in mature adipocytes leads to their death (162). The prime role of PPARγ in the metabolic 
balance is also underscored by the fact that it is the molecular target of type 2 diabetes drugs, which 
directly bind to PPARγ. Interestingly, PPARγ +/- mice were shown to be resistant to HFD-induced 
obesity and more sensitive to insulin then their wt counterparts (189,247). Paradoxically, untreated 
PPARγ +/- mice on a HFD were as sensitive to insulin as wt mice on the same diet, but treated with 
a PPARγ agonist, the insulin sensitizer Rosiglitazone (246).  
We aimed to understand the reasons for this paradox. We suspected that lipid storage is by 
far not the sole metabolic function of PPARγ. However, in previous studies, challenging the PPARγ 
+/- mice with a HFD most likely exacerbated the lipid storage function of PPARγ and therefore 
other key functions went unnoticed. For this reason, we chose to study the metabolic role of PPARγ 
in the absence of any specific nutritional challenge by investigating young adult PPARγ +/- male 
mice fed on a SD. 
The plasmatic analyses showed that if insulin and glucose concentrations were normal in 
basal feeding conditions, there was an alteration of the glycaemic control in the mutated mice during 
fasting. Interestingly, the plasmatic lipid profile of these animals, especially FFA and glycerol, 
suggested the possibility of an abnormal lipolysis. This presumption was strengthened by the fact 
that the plasmatic concentrations of ketone bodies were also low. Although this would designate the 
adipose tissue as the main culprit for these deregulations, we nevertheless extended our study to the 
liver and skeletal muscle. All three organs are either important consumers (skeletal muscle) or 
producers (WAT and liver) of energy. Furthermore, all three express PPARγ, although at different 
levels, WAT presenting by far the highest levels of this receptor. Based on their gene expression 
 125
RESULTS-PPARγ and adipose tissue integrity 
 
profiles, we concluded that liver and skeletal muscle in PPARγ +/- mice are most likely not involved 
in the metabolic deregulation of these animals when fed a SD. Of all the genes tested, which are 
involved in glycolysis and FA oxidation in both tissues, as well as in gluconeogenesis in the liver, 
none presented a modified expression in the PPARγ +/- mice. These results are in agreement with 
liver and muscle gene expression profiles in fatless mice or mice with an organ-specific deletion of 
PPARγ in skeletal muscle. In these studies, no modification was observed in the expression of genes 
involved in β-oxidation and gluconeogenesis (248,253,255,370). 
On the contrary, deletion of one PPARγ allele had unexpectedly profound effects on the 
expression of genes involved in WAT growth and energy production. The present study shows that 
genes involved in the IGF-1 signaling pathway, known to participate in adipocyte differentiation and 
growth (245,371-374) were down-regulated in PPARγ +/- WAT. This explains the resistance to 
growth hormone action and the smaller adipocyte size already observed by us and others in the 
PPARγ +/- WAT (189,245,289). In addition to the IGF-1 pathway, genes belonging to the insulin 
signaling pathway, which is an important activator of the glycolytic and lipogenic pathways in 
WAT, were also down-regulated.  
Unexpected at first sight, but in agreement with a down-regulation of the insulin pathway, 
basal glucose uptake and glycolysis were decreased in the mutant WAT. Glycolysis is thought to 
play three majors roles in WAT by (i) participating in the de novo synthesis of fatty acids,  (ii) 
promoting their storage as fat and, finally, (iii) producing ATP for adipocyte survival. Firstly, the 
acetyl CoA and NADPH synthesized by the glycolytic and pentose phosphate pathways, 
respectively, were decreased in the PPARγ +/- WAT. As an immediate consequence, de novo fatty 
acid synthesis was decreased, an effect reinforced by the down-regulation of enzymes involved in 
this process. Secondly, storage was altered since glyceroneogenesis was affected in the PPARγ +/- 
WAT. In fact, the activated glycerol produced by glyceroneogenesis is used for fatty acid 
esterification into TG, the main form of lipid storage. Thirdly, glucose is required for adipocyte 
survival, and ATP production is an important feature of this process, deficiency of which affects the 
integrity of the cell. In this respect, we observed a significant decrease of the ATP levels in the 
WAT of the mutant mice. This result is in agreement with previous data from cell culture 
experiments where decreased ATP concentration in 3T3L1 or primary adipocytes interfered with  
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insulin signaling and lipolysis. Glycolysis and FA oxidation are the major ATP producers, but no 
increase of β-oxidation was observed in the mutant WAT to compensate for the energy deficit. 
Moreover, genes involved in the lipolytic activity as well as in the glycerol release were down-
regulated in the PPARγ +/- WAT. Thus, PPARγ +/- WAT suffers from a generalized energy 
shortage probably due to the ATP crisis in the adipocytes, which we link to a deregulation of the 
glycolytic pathway.  
To our knowledge and for the first time, the findings reported herein link PPARγ expression 
levels with the regulation of the systemic metabolic rate and physical activity. Although deletion of 
just one PPARγ allele decreased the metabolic rate and physical activity of the mice, we recorded no 
effect on the relative amounts of carbohydrates versus lipids used as fuel molecules. Evidence that 
this systemic effect is PPARγ-specific comes from the Pioglitazone treatment of the PPARγ +/- 
mice, which alleviated the deleterious effect of heterozygocity.  
We speculate that the reduced level of both metabolic rate and physical activity are part of a 
protective survival strategy in conditions of energy shortage. When faced with an energy crisis, 
animals employ various behavioural and physiological responses to reduce metabolism, which 
prolongs the period of time during which energy reserves can cover metabolic needs. Such 
behavioural responses can include a reduction in metabolic rate and spontaneous activity.  
Collectively, the data obtained by taking advantage of PPARγ +/- animals fed a SD, showed 
that PPARγ activity in WAT is not only important for fat storage, as previously showed. In fact, in 
the absence of any nutritional challenge, PPARγ controls IGF-1 and insulin signaling with effects on 
energy production via the regulation of the glycolytic and lipolytic pathways. Most importantly, 
deregulation of these functions in WAT most likely influences the whole-body energetic balance 
with its impacts on metabolic rate and physical activity, which appear to adapt to the available 
energy.  
Furthermore, our results showed that deletion of one PPARγ allele affects the integrity of the 
white adipose tissue. Beside the delay in the adipocyte differentiation, several key proteins involved 
in the detoxification pathway were deregulated in the mutated WAT. This deregulation was 
accompanied by an increased inflammatory reaction. Proteins involved in the inflammatory reaction 
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as well as in macrophage activation were up-regulated in the PPARγ +/- WAT. Surprisingly the 
expression of some of these adipokines and chemokines was shown to be stimulated by fasting. This 
is an interesting observation since it makes the link between the inflammatory status of the mutant 
WAT and its energetic deficiency that we explored above.  
Measurements of the ROS and lipid peroxide concentrations in WAT but also in other organs 
such as the liver, should tell us more about the deregulation of the detoxification program. 
Moreover, extensive measurements of the expression of inflammatory molecules as well as 
histological analysis of inflammatory cells infiltration in WAT should clarify these observations.  
Thus, in normal conditions, PPARγ plays an important role not only in lipid storage but also 
participates in the metabolic regulation of the WAT as well as to its integrity. Deletion of only one 
PPARγ allele deregulates the WAT equilibrium and has a whole body systemic effect.  
These results shows for the first time that PPARγ is not only involved in the lipid uptake and 
storage as it was suggested by studies in models of diet induced obesity, but it also controls the 
general metabolism of the WAT, regulating the glycolytic and lipolytic status of the tissue as well as 
its energy production. Besides metabolism and energy production, we showed for the first time that 
normal PPARγ  expression levels are required for the integrity of adipocytes where its expression 
levels are important. The link between inflammation and energetic status of the tissue argue against 
the utilization of PPARγ antagonists as drug replacement therapy for the treatment of type 2 
diabetes. Moreover, it shows again that the metabolic integrity of the WAT is a prerequisite for an 
uninflamed tissue, deregulation of its metabolism either by obesity or lipodystrophy will stimulate 
the inflammatory reactions.  
In the line of our results, selective modulators of PPARγ are from far a better alternative 
since they are not ablating PPARγ activity, rather they seem to preferentially activate genes involved 
in insulin signaling without affecting genes involved in the lipid metabolism (195,375,376). 
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II. Setup of the small interference RNA (siRNA) technique for the knock-down of different 
molecules involved in the metabolic pathways using a lentivirus mediated system 
 
II.1. Introductive remarks 
 
Silencing of gene expression by RNA interference (siRNA) had become a powerful tool for 
functional genomics in mammalian cells. A systematic characterization of genes with unknown 
functions is a key challenge after the sequencing of the human genome and the genomes of many 
model organisms. High-throughput RNA interference screenings have become a widely used 
approach in invertebrate model organisms and promise to revolutionize cell biology in mammals. 
Genome-wide siRNA screens in Caenorhabditis elegans and Drosophila, and in a smaller scale in 
mammalian cells have proven to be a valuable and successful method for the dissection of diverse 
biological processes (377-379). 
siRNA is a diverse, natural and evolutionary conserved mechanism in eukaryotic cell, which 
inhibits the transcription and translation of target genes in a sequence-specific manner. It is triggered  
naturally by double strand RNA (dsRNA) that is converted to small regulatory siRNAs by the 
cytoplasmic RNase III, called Dicer or, it can be introduced artificially directly into the cells by 
transfection of an expression vector (380). One strand of the siRNA duplex is incorporated into the 
RNA-induced silencing complex (RISC), while the second is released and degraded. Once 
incorporated into RISC, the siRNA guides this protein complex to mRNAs bearing highly 
complementary target sites, which can be then cleaved and degraded, (Fig 10) (381).  
siRNA has rapidly emerged as a tool to interrogate the function of candidate genes and the 
creation of siRNA libraries has permitted the advance of genetic analysis of normal physiological 
and disease processes (382). siRNA technology facilitates the dissection of signaling pathways 
involved in metabolic related diseases such as obesity, insulin resistance and type 2 diabetes (383-
386). The development of stable expression vectors driving the expression of siRNAs such as the 
lentivirus vectors further expanded their application in primary cells, non dividing cells, tissues 
cultures as well as in animal models. 
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Figure 10. Schematic representation of the mode of action of siRNAs. Transfection of a vector 
coding for a specific siRNA under the control of a Polymerase III promoter, such as H1, allows its 
expression in a desired cell type. Once transcribed in the nucleus, the siRNA is translocated into the 
cytoplasm where it can be incorporated into the RNA induced silencing complex (RISC) where the 
strands are separated. The RISC containing the antisense strand seeks and binds to complementary 
mRNA sequences. The binding of the complex to the target mRNA induces its degradation.    
 
 
Using this powerful new technique, we aimed to a deeper understanding of the role of 
PPARβ and PPARγ in the adipocyte metabolism and differentiation as well as in other aspects of 
their functions such as their involvement in the embryonic development.  
 
 130 
RESULTS-siRNA:lentivirus mediated system 
 
II.2. Using a lentivirus system as a siRNA delivery source: pro and cons  
 
One of the major challenges using the siRNA platform is the delivery. To obtain efficient 
and long-lived gene silencing in cells and tissues, many groups have developed a variety of viral 
vectors facilitating siRNAs delivery both in vitro and in vivo (387).  
Viruses are evolved biological machines that efficiently gain access to host cells and exploit 
the cellular machinery to facilitate their replication. The ideal virus based vector keeps the efficient 
infection pathway but avoids the subsequent expression of viral genes leading to its replication and 
toxicity. This is achieved by deleting the sequence responsible of its replication and toxicity from 
the viral genome but leaving intact the sequences required for the viral packaging and integration 
into the host genome.    
The number of different viruses vectors that are under development is increasing, but at the 
present, five main classes of viral vectors derived from oncoretroviruses, lentiviruses, adenoviruses 
and adeno-associated viruses exist. Each of these classes is characterized by a set of different 
properties that makes them suitable for some applications and unsuitable for others (388).    
Lentiviruses are members of the retrovirus family. Lentivirus vectors have been derived from 
human immunodeficiency virus (HIV) and other non-human lentiviruses. Vectors that are based on 
HIV (such as the ones used in our laboratory) retain less then 5% of the parental genome, and 25% 
of the genome is incorporated into separate packaging constructs, which minimizes the possibility of 
the generation of replication competent HIV. By deleting a high portion of the viral genome, the 
retroviral vectors are able to deliver up to 8 kb of extra sequences into the target cells (389). 
Biosafety was further increased by the development of self inactivating (SIN) vectors that contain 
deletions of the regulatory elements in the downstream long terminal repeat (LTR), eliminating the 
transcription of the packaging signal that is required for the vector mobilization (390). Reverse 
transcription of the retroviral RNA genome occurs in the cytoplasm, and the cDNA complex with 
other viral factors is able to translocate across the nuclear membrane and transduce non dividing 
cells. The capacity to infect (transduce) non dividing cells is one of the strength of this class of 
vectors.  
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Natural infections with wild type virus are restricted to tissues that are accessible through the 
route of transmission, but recombinant vectors are not subject to the same physical limitations. One 
approach to increase the number of infected cell types has been to conjugate capsids with molecular 
adaptors with particular binding properties. This approach has been used to enhance the transduction 
potential of various cultured cell types using lentiviruses (391). Besides different cellular types, 
lentivirus vectors derived from HIV are able to transduce different animal species such as human, 
mouse and rat (392,393). The high number and variety of cell type and species that can be 
efficiently infected by lentiviruses is a strength of these vectors.  
One of the side effects of using virus vectors, especially in gene therapy, is the activation of 
the immune response of the host by the virus vectors, which are recognized as foreign particles. 
However, lentivirus vectors are the less immunogenic and are not known as being able to induce 
inflammatory and immune responses in host organisms. This feature is another strength of the 
lentivirus vectors.  
Although the permanent integration of the viral genome into the host genome is one of the 
strength of the system, its integration could increase the risk of modifying the expression of 
endogenous genes. Retroviral vectors integrate preferentially into transcriptional active genes found 
in the host genome and the risk of disrupting a cellular sequence connected to malignancy is 
relatively high (394-396).  Moreover, we have to keep in mind that cultured infected cells are a 
heterogeneous population of infected cells since in each cell the number of integrated virus as well 
the integration site can be different. Disruption of the host endogenous genes as well as the number 
of integrated viral particles represents the undesired side effects of the lentivirus infections (397).  
Thus, we can summarize the positive and negative points of using lentivirus vectors as 
following: the lentivirus vectors have a packaging capacity of 8 kb, have a high tropism, being able 
to infect a high variety of cell types and species, it integrates its material into the host genome which 
gives a persistent gene transfer in most of the tissues and cell types even during development. 
Moreover, it can infect non dividing cells and has a low inflammatory potential but the integration 
might induce oncogenesis or endogenous gene disruption in some conditions. 
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II.3. Results 
 
II.3.1. Setup of the siRNAs against PPARβ and PPARγ 
 
The 19 base pairs (bp) sequence used as siRNA against the target gene should be specific to 
the target gene only. Six different target sequences were chosen for each of the target genes. 
Moreover, when possible, we select sequences conserved between several species preferentially 
between mouse, human and rat. Only empirical rules help to select the right sequence. For instance, 
better efficiency was observed when the 19 bp sequence is flanked by AA at the 5’ and TT at the 3’. 
However, the TT is not mandatory. Moreover, the 19 bp sequence should be found preferably in the 
coding region, 100 bp from the start and termination of translation. AAA repeats should be avoided 
from the sequence, which should be rich in GC nucleotides preferably at more than 30%, (Fig 11 A). 
The sequences were inserted into a 64 nucleotides (nt) structure (64-mer) containing the sequence 
for the restriction enzyme BglII in 5’ and HindIII in 3’ as well as a “TTTT” transcription termination 
signal also in 3’, (Fig 11 B). The specific insert was designed such that it specifies a 19 nt sequence 
derived from the target transcript of 21 bp, separated by a short spacer from the reverse complement 
of the same 19 nt sequence. This construction allows the insertion of the dimerized 64-mer 
sequences into the expression vector pSuper, under the polymerase III H1-RNA gene promoter (Fig 
11 C). This expression vector contains unique BglII and HindIII, allowing the insertion of the 
synthetic DNA oligonucleotides encoding the 64-mer  siRNA sequence (398).  Moreover, the 
resulting expression cassette is flanked by several unique restriction enzyme sites that allow it to be 
readily moved into lentiviral vectors.  
In order to verify the efficiency of the siRNA sequences designed for each target gene, the 
pSuper-siRNA vectors were transfected in cell lines having a good transfection efficiency, 293T 
cells, along with vectors expressing the target gene (PPARβ or PPARγ) fused to green fluorescent 
protein (GFP). The efficiency of the gene knock-down was monitored by FACS. 
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Figure 11. Schematic representation of siRNA construction. A. Representation of the six mouse 
PPARβ and PPARγ 21 bp sequences used as potent target for the design of the 19 bp used as 
siRNA. In black, the six tested 21 bp sequences. In blue, the 19 bp sequences retained as efficient 
siRNAs. In red, specificity for different species. Nucleotide in red represents the nucleotide change 
between species.  B. Representation of a pair of 64-mer (forward and reverse) needed for siRNA 
construction; sequences in black and purple are invariable trough siRNAs. C. Schematic 
representation of the cloning strategy in pSuper vector. 
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From the six siPPARβ tested, one was efficient at more then 90% in the reduction of the 
expression of the transfected mouse PPARβGFP, (Fig 12 A). This siPPARβ recognize human and 
mouse PPARβ. Moroever, even if it has one nucleotide difference with the rat gene sequence it 
induces an efficient knock-down of the PPARβ rat gene, as will be showed bellow (Fig 11 A), and 
section Results II.3.3.  
 
 
Figure 12. Measuring the efficiency of the siPPARβ and siPPARγ in transient transfection 
assays. A. Measurement of the six siPPARβ efficiency by transient cotransfection of mPPARβGFP 
and each of the constructed siPPARβ in 293T cells. B. Measurement of the six siPPARγ efficiency 
by transient cotransfection of mPPARγGFP and each of the constructed siPPARγ in 293T cells. The 
GFP fluorescence was measured by FACS.  
 
Concerning the six siPPARγ, two of the six tested sequences had an efficiency of around 
70% in the reduction of the transfected mouse PPARγGFP (Fig 12 B). The first siPPARγ recognizes 
the mouse and rat sequences and has one nucleotide difference with the human sequence but still 
efficient in its knock-down of the human PPARγ (data not shown), whereas the second siPPARγ, 
recognizes mouse and rat sequence and has only one nucleotide difference with the human 
sequence, however its efficiency on the human PPARγ was not tested.    
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Figure 13. Transduction efficiency of the lentiviral system. A. Schematic representation of the 
LVTHsiRNAs constructs. B. Test of the infection potential of 3T3L1 fibroblast by FACS, using 
GFP fluorescence as an infection marker. C. 3T3L1 fibroblasts infected with 30 MOI of the 
lentivirus vector LVTH expressing GFP. 
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Having identified one or more effective siRNA for each target gene, the next step was to 
express the selected siRNAs in vectors allowing stable knock-down of the target genes. To this 
purpose, we choose to use the lentivirus expressing vectors derived from HIV. The lentivirus 
vectors, as mentioned in section Results II.2., can infect with high efficiency a large variety of cell 
types and tissue from several species such as mouse, human and rat. Moreover, it can infect non 
dividing and primary cells and can be expressed during differentiation, namely during adipocyte 
differentiation which is one of our main interests.  
Thus, the siRNAs cassette was digested by EcoRI, ClaI and introduced into the lentivirus 
vector pLVTH, (Fig 13 A) (399). The pLVTH vector carries a marker gene (GFP) downstream of an 
internal EF1-α promoter allowing an easy detection (or selection by FACS) of infected cells, (Fig 13 
B, C). The vectors can be readily generated at quite high titers (more than a million particles per ml) 
by cotransfection into 293T cells together with the relevant packaging vectors, pCMV-∆R8.91 and 
pMD2G-VSVG, encoding for the envelop and the packaging genes respectively, section Results 
II.2. and (399,400).  
siPPARβ as well as siPPARγ were already used successfully in our laboratory in 
collaboration with Dr Karim Nadra and Dr Jerôme Feige, sections Results II.3.3. Ongoing 
collaborations with the laboratories of Dr Vittorio Giusti in Lausanne, Dr Alexander Odermatt in 
Bern, as well as Dr André Tremblay in Montreal are taking advantage of our technique using 
siPPARβ and siPPARγ as a tool for the infection of different cells types such as the human 
immortalized pre adipocytes, 3T3L1 fibroblasts as well as of macrophages.  
 
II.3.2.  Material and Methods  
 
Vector construction: Vectors were constructed using standard cloning procedures. The 64-
mer oligonucleotides forward and reverse (Microsynth, Switzerland) containing the siRNAs 
sequences were annealed and phosphorylated and further cloned into pSuper vector (provided by 
Professor Didier Trono, Switzerland) previously digested by Bgl II and Hind III. The H1siRNA 
cassette was excised from the pSuper and introduced into pLVTH vector (provided by Professor 
Didier Trono, Switzerland) previously digested by EcoRI and Cla I. 
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Transient transfection of pSuper siRNA into 293T cells: The 293T cell line was cultured in 
Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (DMEM 10%). 
The subconfluent 293T cells were plated on 12-well plate (2 × 104 cells/well), and cotransfected by 
calcium phosphate precipitation with 0.25 µg of the plasmids encoding pEYFP-PPARβ or pEYFP-
PPARγ (185), and 2.5 µg of the pSuper siPPARβ or siPPARγ. After 16 h medium was changed, and 
the cells were harvested 24 h later. 
Analysis of siRNA efficiency by fluorescence-activated cell sorting (FACS): Cells were 
trypsinezed, harvest in PBS 1X, fixed in 1% paraformaldehyde solution, and analyzed with a 
FACSscan for green fluorescence (399). 
Lentivirus production: Subconfluent 293T cells were plated on 10 cm plates (2.5x106 cells/ 
plate) and cotransfected by calcium phosphate precipitation with 5 ug pMD2G (VSVG-envelope, 
provided by Professor Didier Trono, Switzerland), 15 ug p8.91 (Gag/Pol/Rev/tet, provided by 
Professor Didier Trono, Switzerland ) and 20 ug of pLVTH constructions. After 16 h medium was 
changed, and the media containing the virus particles was collected twice, at 48h and 72h after 
transfection. The viral supernatant collected at 48h was stored at four degrees and mixed with the 
supernatant collected at 72h. The viral particles were further concentrated by ultracentrifugation on 
a 20% sucrose gradient (in sterile PBS1X ) using a swinging bucket rotor and Beckman conical 
tubes (Beckman, Switzerland) at 16 degrees, at a speed of 26 000 rpm, during 90 minutes. The viral 
pellet was resuspended into 50 to 200 µl of DMEM 10%. The titer of the viral production (number 
of viral particles/ µl), was calculated by FACS using the GFP fluorescence. The volume of virus 
needed for an efficient cell infection is calculated as the multiplicity of infection (MOI). One MOI is 
the volume of virus needed to have one viral particle per cell (399).  
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II.3.3. Application of the small interference technology 
 
II.3.3.1. Differentiation of trophoblast giant cells and their metabolic functions are dependent 
on Peroxisome Proliferator Activated Receptor β/δ 
 
II.3.3.1.1. Abstract taken from the article published in Molecular Cell Biology 
 
Mutation of the nuclear receptor Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) 
severely affects placenta development, leading to the embryonic death at E9.5/E10.5 of most, but 
not all, PPARβ/δ-null mutant. While very little is known at present about the pathway governed by 
PPARβ/δ  in the developing placenta, this paper demonstrates that the main alteration of the 
placenta of PPARβ/δ-null embryos is found in the giant cell layer. PPARβ/δ activity is in fact 
essential for the differentiation of the Rcho-1 cells in giant cells, as shown by the severe inhibition 
of differentiation once PPARβ/δ is silenced. Conversely, exposure of Rcho-1 cells to a PPARβ/δ 
agonist triggers a massive differentiation via increased expression of PDK1 and ILK and subsequent 
phosphorylation of Akt. The links between PPARβ/δ activity in giant cells and its role on Akt 
activity is further strengthened by the remarkable pattern of phospho-Akt expression in vivo at E9.5, 
specifically in the nucleus of the giant cells. In addition to this PI3K/Akt main pathway, PPARβ/δ 
also induced giant cell differentiation via increased expression of I-mfa, an inhibitor of Mash-2 
activity. Finally, giant cell differentiation at E9.5 is accompanied by a PPARβ/δ-dependent 
accumulation of lipid droplets, and an increased expression of the adipose differentiation-related 
protein (ADRP, also called adipophilin), which may participate to lipid metabolism and/or 
steroidogenesis. Altogether, this important role of PPARβ/δ in placenta development and giant cell 
differentiation should be considered when contemplating the potency of PPARβ/δ agonist as 
therapeutic agents of broad application.  
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The second author, Silvia I Anghel setup the experiments involving the use of the lentivirus 
system containing the small interference RNA against PPARβ in the rat Rcho-1 trophoblast cells. 
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Differentiation of Trophoblast Giant Cells and Their
Metabolic Functions Are Dependent on Peroxisome
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Mutation of the nuclear receptor peroxisome proliferator-activated receptor / (PPAR/) severely affects
placenta development, leading to embryonic death at embryonic day 9.5 (E9.5) to E10.5 of most, but not all,
PPAR/-null mutant embryos. While very little is known at present about the pathway governed by PPAR/
in the developing placenta, this paper demonstrates that the main alteration of the placenta of PPAR/-null
embryos is found in the giant cell layer. PPAR/ activity is in fact essential for the differentiation of the
Rcho-1 cells in giant cells, as shown by the severe inhibition of differentiation once PPAR/ is silenced.
Conversely, exposure of Rcho-1 cells to a PPAR/ agonist triggers a massive differentiation via increased
expression of 3-phosphoinositide-dependent kinase 1 and integrin-linked kinase and subsequent phosphory-
lation of Akt. The links between PPAR/ activity in giant cells and its role on Akt activity are further
strengthened by the remarkable pattern of phospho-Akt expression in vivo at E9.5, specifically in the nucleus
of the giant cells. In addition to this phosphatidylinositol 3-kinase/Akt main pathway, PPAR/ also induced
giant cell differentiation via increased expression of I-mfa, an inhibitor of Mash-2 activity. Finally, giant cell
differentiation at E9.5 is accompanied by a PPAR/-dependent accumulation of lipid droplets and an
increased expression of the adipose differentiation-related protein (also called adipophilin), which may par-
ticipate to lipid metabolism and/or steroidogenesis. Altogether, this important role of PPAR/ in placenta
development and giant cell differentiation should be considered when contemplating the potency of PPAR/
agonist as therapeutic agents of broad application.
The earliest cell differentiation event in the mammalian em-
bryo is the formation of the trophectoderm, which consists of
two regions: the polar trophectoderm, directly adjacent to the
inner cell mass, and the mural trophectoderm surrounding the
blastocoelic cavity. In rodent placentas, the cells of the mural
trophectoderm differentiate into a limited number of nondi-
viding primary giant cells during implantation, whereas those
of the polar trophectoderm proliferate to form the ectoplacen-
tal cone and develop a multitude of secondary giant cells (20).
Trophoblast giant cells participate in a number of processes
essential to a successful pregnancy, including blastocyst im-
plantation, remodeling of the maternal deciduas, and secretion
of hormones that regulate the development of both the fetal
and maternal compartments of the placenta. In the early
stages, the inherent invasive properties of these cells appear to
be crucial for remodeling in the maternal uterine stroma. At
later stages, after embryonic day 9.5 (E9.5), the secondary
giant cells produce a number of placental hormones, particu-
larly members of the prolactin/growth hormone family of pro-
teins, which in mice includes placental lactogen I (PL-I), PL-II,
and proliferin (49). The expression of these trophoblast giant
cell functions coincides with a very critical period of placental
development, exemplified by the high incidence of embryonic
lethality at that stage. Paradoxically, very little is yet known
about the giant cell differentiation process.
Peroxisome proliferator-activated receptors (PPARs) are
lipid-activated transcription factors that belong to the nuclear
hormone receptor family. Three isotypes of PPARs have been
cloned: PPAR (NR1C1; Nuclear Receptor Nomenclature
Committee 1999), PPAR/ (NR1C2; also called NUC-1 or
FAAR and which will be hereafter referred to as PPAR), and
PPAR (NR1C3), all of which bind to DNA as heterodimers
with retinoid X receptor (RXR; NR2B) (10). While PPAR
and PPAR have clearly defined roles in controlling lipid and
glucose homeostasis (64), various physiological roles of
PPAR are still being investigated. PPAR has been linked to
embryo implantation (41, 42), myelination in the brain (51),
osteoclastic bone resorption (44), and skin wound healing (46,
58). Its role in lipid metabolism comprises diverse facets asso-
ciated with the preadipocyte clonal expansion (26, 29), fatty
acid oxidation in muscle (63), or lipoprotein homeostasis (50).
The nature of the endogenous PPAR ligands remains to be
ascertained. Similar to the other two PPARs, some polyunsat-
urated fatty acids have affinities for PPAR in the low micro-
molar range. More specifically, a number of eicosanoids, par-
ticularly prostacyclin, which is a cyclooxygenase 2 arachidonate
metabolite, was shown to activate PPAR (16, 35, 37).
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A crucial tool for understanding PPAR functions in an in
vivo and physiological context is the generation of strains of
mice carrying mutations in the PPAR genes. However, most of
the PPAR and all PPAR null embryos die at an early de-
velopmental stage because of placental defects (1, 2, 38) that
have so far been poorly characterized. In the present work, we
delineate a pivotal role of PPAR in the early events of pla-
cental development. Whereas deficiency of PPAR leads to
impaired vascularization (1, 38), deletion of the PPAR gene
causes a severe failure of the placenta to undergo proper
morphogenesis, leading to embryonic lethality at E9.5 to
E10.5. The trophoblast giant cell layer is the most affected, and
we demonstrate a direct involvement of PPAR in promoting
trophoblast cell differentiation toward giant cells. This effect is
dependent on phosphatidylinositol 3-kinase (PI3K) and Akt1
(also called protein kinase B) and is at least partly due to the
high expression levels of two kinases involved in Akt activation,
namely 3-phosphoinositide-dependent kinase 1 (PDK1) and
integrin-linked kinase (ILK). In addition, PPAR caused in-
creased expression of a non-helix-loop-helix (non-HLH) inhib-
itor of the myogenic basic HLH (bHLH) subfamily, I-mfa (7),
which contributes to the differentiation process. Finally, we
reveal that giant cells are the primary sites of lipid accumula-
tion in the placenta at an early stage, together with a PPAR-
dependent up-regulation of adipose differentiation-related
protein (ADRP) expression. Taken together, these cellular
and in vivo approaches unveil important new aspects of the
development and functions of the giant cell layer, which has a
major impact on placenta development.
MATERIALS AND METHODS
Targeted disruption of the mouse PPAR. (i) Construction of a replacement
vector for PPAR. Nine overlapping mouse PPAR genomic clones were iso-
lated from an Sv129 mouse embryonic stem (ES) cell genomic library (gift from
F. Conquet), and their restriction maps were established (Fig. 1). A targeting
vector was designed to delete the two exons encoding the DNA binding domain
(i.e., exons 4 and 5), according to the organization of the Xenopus PPAR gene.
The targeting vector (derived from TK-NEO-UMS, a vector comprised of the
thymidine kinase gene, neomycin resistance sequence, and upstream mouse
sequence; a gift from Charles Weissman [54]) contained 1.7 kb of homologous
sequence at the 5 end, 7 kb of homologous sequence at the 3 end, and a
phosphoglycerate kinase-neomycin (PGK-neo) cassette (Fig. 1A).
(ii) ES cell transfection. D3 ES cells (13) were cultured as previously described
(22), and electroporation was performed as previously reported (59). Twenty-
four hours after electroporation, positive selection by G418 at 350 g/ml (gene-
ticin) was performed for 9 days. Resistant clones were then transferred onto
48-well plates (Costar) and subsequently grown to confluence on duplicate 24-
well plates for either genomic analysis or storage of master plates at 80°C.
(iii) Genotyping. Genomic DNA was prepared from ES cells, yolk sacs of
embryos, or tail samples following the classical procedures. A first round of
genotyping was performed by two independent PCRs. Primers b19 (5-ATCCA
GAGTGTTCGTATGAC-3) and UMS1 (5-TCTTATGCTCCTGAAGTCCA
C-3) amplified a 2.2-kb fragment from the recombinant allele, whereas the
FIG. 1. Targeted disruption of the PPAR gene in mouse. The PPAR gene was disrupted in ES cells by homologous recombination with a
replacement-type vector, using an approach based on positive-negative selection (A). In this vector, PPAR genomic sequences containing the
exons encoding the DNA-binding domain of the receptor (exon 4 and part of exon 5) were replaced with a PGK-neo cassette. Homologous
recombination at the PPAR locus in ES cells led to the deletion of both exon 4 and part of exon 5 encoding the two zinc fingers of the
DNA-binding domain. ES cells carrying the mutant allele were confirmed by Southern blot analysis (B). Two independent positive ES cell clones
were injected into blastocysts to generate chimeras, and heterozygous mice were obtained from a germ line transmitter chimera. Panel A shows
the structure of the wt PPAR allele, targeting vector, and recombinant PPAR allele. The exons as well as locations of restriction sites and probes
for PCR and southern blot are indicated. B, BamHI; E, EcoRI; K, KpnI; N, NotI; X, XhoI. Panel B shows a Southern blot analysis of genomic
DNA digested with BamHI and KpnI from E9.5 embryos produced by a PPAR heterozygous intercross. (C) PCR analysis of yolk sac DNA
derived from E9.5 embryos. (D) Western blot analysis performed on nuclear extracts with a specific PPAR antibody. The nuclear protein c-Jun
was used as an internal control. In order to obtain a sufficient amount of material, the control at the protein level was performed on pups obtained
from homozygous matings.
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primers b3 (5-AGCCTCAACATGGAATGTCG-3) and b4 (5-GATCGCAC
TTCTCATACTCG-3) amplified a 1.6-kb product from the wild-type (wt) allele.
Five percent of the neomycin-resistant ES cell clones were positive for homol-
ogous recombination. All mutant clones and/or embryos or mice were subse-
quently confirmed by Southern analyses using a digoxigenin-labeled probe
(CDP-Star protocol; Boehringer Mannheim), located 160 bp upstream of the 5
homology region. Digested genomic DNA samples were blotted on a Zetaprobe
GT membrane and processed following the manufacturer’s protocol (Bio-Rad).
Probes, restriction digestion, and hybridized fragments from wt and recombinant
alleles are indicated in Fig. 1.
(iv) Generation of chimeric mice and germ line transmission. Positive D3
clones were microinjected into the blastocoel of 3.5-day-old embryos at the
blastocyst stage and isolated from C57BL/6 females (10 to 15 ES cells per
blastocyst). Between five and seven injected blastocysts were reimplanted into
each uterine horn of pseudopregnant foster mothers. Male chimeric animals
were mated for germ line transmission with Sv129 mice. One chimeric male
transmitted the mutation from which the colony of mice has been obtained.
Reagents and probes. The antibodies anti-Akt1, anti-PTEN, anti-ILK, phos-
pho-Akt (Thr308), and (Ser473) were obtained from Cell Signaling; anti-c-Jun
and anti-PPAR were from Affinity Bioreagents; anti-PDK1 was from Santa
Cruz Biotechnology; antitubulin was from Pharmingen; anti-ADRP was from
Progen; and anti-PL-I was from Chemicon.
The gene-specific probes for PL-I and Tpbpa were a kind gift of J. Rossant, and
Mash-2 was obtained from F. Guillemot. For preparing the probes, total RNAs
were obtained from E9.5 placenta. cDNAs were prepared by reverse transcrip-
tion, followed by PCR, using specific primers (primer sequences are available
upon request). The cDNA corresponding to the mouse PPAR and L27 were
subcloned into pGEM3Zf() (Promega). The cDNA corresponding to the
mouse PPAR, as well as gene-specific probes corresponding to PL-I, Id-2,
Hand1, I-mfa, ADRP, and aP2, was subcloned into pGEM-T Easy (Promega).
Gene-specific antisense and sense riboprobes were synthesized by in vitro tran-
scription with either T7 or Sp6 RNA polymerase (Ambion).
RPA. For all riboprobes, except L27, a ratio of 1:1 of [-32P]UTP to cold UTP
was used, whereas a ratio 1:20 was used for L27 probe. An RNase protection
assay (RPA) was carried out as described by the manufacturer (Ambion) with the
following modifications. Briefly, total RNA was isolated from cells or tissues with
Trizol reagent (Sigma, St. Louis, MO). Ten micrograms of total RNA was
incubated at 37°C with 1 ng of gene-specific riboprobes (109 cpm/g) and 10 ng
of the L27 probe (107 cpm/g). RNase digestion (10 U/ml RNase A; 400 U/ml
RNase T1) was carried out for all probes at 37°C for 20 min. After inactivation
of RNase with 20 l of 10% sodium dodecyl sulfate (SDS) and 10 l of 20 mg/ml
proteinase K for 20 min at 37°C, protected RNA was precipitated with 500 l
isopropanol, and RPA products were resolved in a 6% electrolyte-gradient
denaturing polyacrylamide gel. Gels were then dried and exposed to X-ray film
or to the phosphor screen of a StormImager 840 (Molecular Dynamics). Control
RPAs were performed using an L27 antisense probe, which has been de-
scribed previously (39). Quantitative analysis was performed by using IQuant
2.5 software.
In situ hybridization. Embryos and placentas were obtained by dissecting
pregnant females, with the appearance of a vaginal plug being counted as day 0.5
of pregnancy. Because of their close contact, particularly at E9.5 stage, both the
maternal decidua and the fetal part of the placenta were dissected as a whole.
Embryos and placentas were separately fixed overnight at 4°C in 4% parafor-
maldehyde in phosphate-buffered saline (PBS) and embedded in paraffin, and
7-m sections were cut. In situ hybridization was processed as described previ-
ously (5). Briefly, antisense and sense riboprobes for PPAR, Mash-2, Tpbpa (or
4311), and PL-I were generated by in vitro transcription of the corresponding
cDNA clones with SP6 or T7 RNA polymerase. Rehydrated sections were
washed in 2	 SSC (1	 SSC is 0.15 M NaCl plus 0.015 M sodium citrate) for 5
min, and hybridization was performed overnight at 70°C with 1 g/ml of a
digoxigenin-labeled probe in the following hybridization buffer: 50% formamide,
10% dextran sulfate, 1	 Denhardt’s solution, 1 mg/ml yeast RNA, 200 mM
NaCl, 1.1 mM Tris-base, 8.9 mM Tris-HCl, 5 mM Na2HPO4, and 1.25 mM
EDTA. Three washes of 30 min were done in 50% formamide, 1	 SSC, and
0.1% Tween 20 at 65°C, followed by two washes in MABT (100 mM maleic acid,
140 mM NaCl, 1% Tween 20, pH 7.5). Sections were then incubated for 90 min
in a blocking buffer consisting of 20% goat serum–2% blocking reagent (Boehr-
inger Mannheim) in MABT and then left overnight at room temperature in an
alkaline phosphatase-conjugated antidigoxigenin antibody (Boehringer Mann-
heim) at a dilution of 1:2,000 in a blocking buffer. Washes were done in MABT,
five times for 30 min each time. Sections were then washed for 5 min in NTMT
(100 mM NaCl, 100 mM Tris, 50 mM MgCl2, 1% Tween 20, pH 9.5), and a color
reaction assay was performed in the dark in nitroblue tetrazolium and 5-bromo-
4-chloro-3-indolyl phosphate (Roche) and 1 mM levamisole in NTMT.
Immunohistochemistry. Immunohistochemistry was carried out on sections
using the avidin-biotin-peroxidase method (Vector Laboratories) on 7-m sag-
ittal placental paraffin sections. Endogenous peroxidases were quenched by ex-
posing the sections to 3% H2O2 for 5 min, followed by a wash in PBS. Nonspe-
cific binding sites were blocked using 10% normal serum in 0.1% Triton-PBS for
1 h. Immediately after, the sections were incubated with the primary antibody for
1 h. After being washed in PBS, the slides were incubated with appropriate
biotinylated secondary antibodies (1:200; Vector Laboratories) for 45 min, fol-
lowed by 30 min in an avidin-biotin complex solution (Vector Laboratories) in
PBS. The sections were then stained with 3,3 diaminobenzidine (Sigma),
rinsed in water, and counterstained with a 0.1% methyl-green aqueous solu-
tion for 5 min.
Western blots. For the Western blot of Fig. 1, nuclear extracts were obtained
from the skin of mouse pups. Briefly, tissues were homogenized in 10 mM KCl,
1.5 mM MgCl2 10 mM HEPES, pH 7.9, 1 mM dithiothreitol, 1 mM Na3VO4, 10
g/ml leupeptin, 0.3 trypsin inhibitor units (TIU)/ml aprotinin, 1 M pepstatin
A, and 1 mM phenylmethylsulfonyl fluoride. The homogenate was centrifuged at
2,000	 g for 10 min, and the pellet was washed with the same buffer. The washed
pellet was resuspended in a buffer containing 420 mM NaCl, 10 mM KCl, 20 mM
HEPES, pH 7.9, 20% glycerol, 1 mM dithiothreitol, 1 mM Na3VO4, and the
protease inhibitors specified above.
For other experiments, Western blotting was performed on cells or tissues,
lysed in an ice-cold lysis buffer (20 mM Na2H2PO4, 250 mM NaCl, 1% Triton
100, 0.1% SDS) supplemented with complete protease inhibitors (Roche). After
Bradford quantification (Bio-Rad), 10 g of nuclear extracts or 30 g of total
protein was separated by SDS-polyacrylamide gel electrophoresis and trans-
ferred onto polyvinylidene difluoride membranes for Western blotting. The
membranes were processed in the following steps: (i) 1 h of saturation in Tris-
buffered saline (TBS)–0.1% Tween–5% nonfat milk at room temperature (RT),
(ii) overnight incubation with a primary antibody in TBS–0.1% Tween–5% non-
fat milk at 4°C, (iii) three washings in TBS–0.1% Tween at RT, (iv) exposure for
1 h to a secondary antibody in TBS–0.1% Tween–5% nonfat milk at RT, and (v)
three washings in TBS–0.1% Tween at RT as a final step. The signal was detected
using an ECL detection kit (Amersham Pharmacia Biotech), according to the
manufacturer’s instructions. Equal loading and transfer were verified by Coo-
massie blue staining of the membrane.
Rcho-1 trophoblast cell culture. Rcho-1 trophoblast cells were a kind gift from
M. Soares. They were routinely maintained in a subconfluent condition with an
RPMI 1640 culture medium supplemented with 10% fetal bovine serum (FBS),
50 M -mercaptoethanol, 1 mM sodium pyruvate, 2 mM glutamine, 100 U/ml
of penicillin, and 100 g/ml of streptomycin in a humidified incubator under 5%
CO2–95% air at 37°C. Differentiation was induced by growing the cells to con-
fluence and subsequently replacing the 10% FBS supplementation with 1% horse
serum. The change to differentiation medium is indicated as day 0.
Design and cloning of lentiviral siRNA vectors. (i) Vector construction. The
target sequence (19 nucleotides) was chosen in the mouse PPAR sequence
5-GCACATCTACAACGCCTAC-3. This sequence has identity in 18 of 19
residues with the rat PPAR sequence (the underlined residue in rat PPAR is
a T) and was also efficient in the Rcho-1 cells of rat origin. A BLAST search
ensured that the sequences would not target other RNAs, including PPAR
mRNAs, in a nonspecific manner. The short interfering RNA (siRNA) was
cloned in a lentivirus vector in which the mouse PPAR siRNA was under the
control of the polymerase III-dependent H1 promoter. In addition, an internal
cassette allowed the expression of the green fluorescent protein (GFP) marker
TABLE 1. Lethal stages of PPAR/ embryos
Stage na
No. of embryos or pups by genotype (%) No. of
resorbed
embryosb/ / /
E 9.5 259 71 (30) 119 (50) 50 (20) 19
E 10.5 47 12 (32) 20 (54) 5 (14) 10
E 12.5 54 10 (20) 38 (78) 1 (2) 5
E 14.5 21 6 (29) 15 (71) 0 0
P 21c 1820 626 (34) 1,165 (64) 29 (1.6)
a n, number of embryos or pups analyzed.
b Resorbed embryos were not genotyped and not counted for the evaluation of
the percentages of the different genotypes.
c P, postnatal day.
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FIG. 2. Defects in extra-embryonic tissues associated with the PPAR-null genotype. (A) Morphology of E9.5 and E10.5 embryos from wt (a
and c) and PPAR/ (b and d). (B) Hematoxylin-eosin-stained sections of wt (a to c and g to i) and PPAR-null (d to f and j to l) placentas.
Higher magnification views of PPAR-null placenta at E9.5 (e and f) and E10.5 (k and l) show a severe reduction of the giant cell layer in the
mutant. A, heart atrium; gi, trophoblast giant cells; L, limb; la, labyrinthine trophoblast; ma, maternal decidual tissue; V, heart ventricle; sp,
spongiotrophoblast. Bars 
 1 mm (A), 400 m (B, frames a, d, g, and j), and 100 m (B, frames b, c, e, f, h, i, k, and l).
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FIG. 3. Expression of trophoblast markers in wt and in PPARmutant placentas. (A) Spatial expression of PPARmRNA in E9.5 wt placenta.
Left, hematoxylin-eosin (HE) staining; middle, in situ hybridization with digoxigenin-labeled antisense riboprobe for PPAR; right, control with
sense riboprobe. Scale bar, 200 m. (B) Representative E9.5 placenta sections from one wt (a, d, g, and j), and two PPAR mutant KO1 (b, e,
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gene under the control of the EF-1 promoter. A full description of the vector
is given in by Wiznerowicz and Trono (65). In our study, the control vector, which
contains all the features but not the siRNA, was called LV-TH and the siRNA-
containing vector was named LV-THsiPPAR.
(ii) Lentivirus production. All recombinant lentiviruses were produced by
transient transfection of 293T cells according to standard protocols. Briefly,
subconfluent 293T cells were cotransfected with 20 g of the control vector
pLV-TH or the PPAR-targeted vector pLV-THsiPPAR, 15 g of pCMV-
R8.91, and 5 g of pMD2G-VSVG (where CMV is cytomegalovirus and VSVG
is vesicular stomatitis virus protein G) by calcium phosphate precipitation. The
medium was changed after 16 h, and recombinant lentiviruses were harvested
24 h later.
(iii) Controlling lentivirus infection and silencing efficiency. The efficiency of
the transduction was given by the percentage of GFP-expressing cells. At a
multiplicity of infection of 60, 90% of the Rcho-1 cells expressed GFP. The
efficiency of the siRNA on rat PPAR sequence was measured by transducing
Rcho-1 cells with LV-THsiPPAR or the control LV-TH vector at a multiplicity
of infection of 60. Forty-eight hours later, the cells were harvested, and total
RNA was extracted. The level of expression of PPAR was measured by RPA.
Oil red O staining. Cultured Rcho-1 cells or sagittal sections of mouse pla-
centa were washed in PBS and fixed in 4% paraformaldehyde for 10 min at 4°C.
A fresh working solution of oil red O (Sigma Chemical, St. Louis, MO) was
prepared by dilution of the oil red O stock solution (5 g/liter in 98% isopropanol)
in distilled water at a ratio of 3:2. The working solution was allowed to stand for
10 min after mixing and was filtered with a 0.45-m-pore-size filter. Subse-
quently, sections were stained in oil red O for 10 min, washed in tap water, and
counterstained with a 0.1% methyl-green aqueous solution for 5 min. The slides
were allowed to dry and were mounted with Vectashield mounting medium
(Vector Laboratories, Burlingame, CA).
RESULTS
Growth and lethality of PPAR/ embryos. To assess the
physiological role of PPAR in the whole organism, particu-
larly during development, the PPAR gene was disrupted in ES
cells by homologous recombination, following the strategy de-
scribed in Materials and Methods and in the legend of Fig. 1.
The PPAR/ mice (of mixed background C57BL6/Sv129)
were healthy, fertile, and displayed no obvious aberrant pheno-
type. However, heterozygote mating did not produce the ex-
pected Mendelian ratio of mutant animals (Table 1), as the
PPAR/ live animals were very rare (1.6% instead of the
expected 25%) while no perinatal death was observed. The sac-
rifice of gestating mice from heterozygote mating revealed
segregation ratios that were close to normal at E9.5 for the
disrupted PPAR alleles among embryos. Beyond this stage,
the number of live PPAR/ embryos decreased, and by
E14.5, no living PPAR/ embryos were detected in the
litters sacrificed, indicating that the homozygous disruption of
PPAR resulted in a highly penetrant embryonic lethality. The
E9.5 live PPAR/ mutant embryos presented various de-
grees of developmental retardation, with severe growth retar-
dation but in most cases no gross abnormalities (Fig. 2A).
Significantly, the placenta of PPAR/ concepti appeared
small and abnormal, as previously observed by Barak et al. (2).
Surprisingly, around 1% of the expected number of homozy-
gotes lived through birth. These rare PPAR-null progeny
exhibited growth retardation, which was overcome by the time
the animals reached adulthood. Because the rarity of live ho-
mozygous pups obtained from heterozygote mating precluded
the possibility of constituting experimental groups of sufficient
size, we intercrossed PPAR/ mice. Both male and female
mutants were subfertile, and the number of nonproductive
breeding pairs was elevated in the PPAR-null mice. However,
a PPAR/ mouse colony was established after selection of a
few successful breeding pairs, for which the total number of
pups born per productive breeding pair as well as the mean
litter size was significantly lower (4  2 pups) compared to
control heterozygous matings (7  2 pups). In parallel, we
designed a new distinct homologous recombination strategy
and generated a second, totally independent, PPAR mutant
mouse line. This second mutant line, which carries a deletion
of the exon 4 disrupting the open reading frame of the corre-
sponding mRNA, displayed exactly the same phenotype (early
embryonic lethality of high but not full penetrance) as the one
used in the present study (data not shown).
This reproducible phenotype pointed to a major role of
PPAR in regulating some cellular and tissular processes tak-
ing place during placental development and was thus subjected
to an in-depth analysis.
Defining the placenta alterations in PPAR/ concepti.
For histological inspection, only placentas obtained from fe-
tuses that were not dead in utero, as judged by a beating heart
and absence of necrosis signs, were analyzed in order to ex-
clude artifacts from postmortem placental alterations. At E9.5,
the placentas of PPAR/ embryos, compared to those of
PPAR/ littermate embryos, were reduced in size and very
compact (Fig. 2B). The three main placenta layers, i.e., the
trophoblast giant cells, the spongiotrophoblast, and the laby-
rinthine layers were altered. Similar defects were observed at
E10.5, showing that the defect was not merely a delay in placental
development (Fig. 2B). We also sacrificed homozygous females
mated with homozygous males at day 9.5 post coitum. At that
stage, the litter size was close to normal (between 7 and 10
embryos), but many concepti exhibited similar placental defects
as those seen in PPAR/ concepti from heterozygous mating
(see supplemental information at http://www.unil.ch/webdav/site
/cig/shared/desvergne/Nadra_et_al_supp_data.pdf). The nor-
mal litter size at E9.5, but reduced litter size at birth, indicated
that lethality also occurred in homozygous matings, as ex-
pected from histological studies of the placenta. These obser-
vations established that the defect was also present in homozy-
gous breeding, but the penetrance was somehow milder,
allowing the birth of approximately 30% of the PPAR/
pups. Thus, these histological observations indicated that in
PPAR/ placentas, the overall structure of the placenta is
affected. Further analyses were therefore required in order to
define the primary defect.
h, and k) and KO2 (c, f, i, and l) littermates. HE corresponds to standard staining with hematoxylin-eosin. Mash-2 is a marker for spongiotro-
phoblast and labyrinthine trophoblast cells; Tpbpa is a specific marker of spongiotrophoblast cells; PL-I specifically labels trophoblast giant cells.
Scale bars, 200 m (a to i) and 400 m (j to l). (C) Relative mRNA expression of PPAR, PL-I, and Id-2 in mouse placental tissues from E8.5,
E9.5, E10.5, and E16.5. L27 ribosomal protein mRNA was used for normalization. Three independent samples are shown per condition. Numbers
represent the relative increase (n-fold) with respect to the basal level evaluated at E8.5 time points. gi, trophoblast giant cells; la, labyrinthine
trophoblast; ma, maternal decidual tissue; sp, spongiotrophoblast.
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We first analyzed whether there was a spatial specificity of
PPAR expression in the E9.5 developing placentas. However,
in situ hybridization in wt placentas showed that PPAR
mRNA is ubiquitously expressed throughout the placenta in-
cluding the labyrinth, the spongiotrophoblast, and the giant
cells (Fig. 3A). We thus evaluated the different trophoblast
layers in the mutant placentas using a series of specific mark-
ers. The bHLH transcription factor Mash-2 is mainly expressed
in the trophoblast cells of the spongiotrophoblast and labyrinth
layer (23). In situ hybridization performed with a murine
Mash-2 probe showed that the labyrinthine layer expressing
Mash-2 was thinner in PPAR mutants (Fig. 3B). In parallel,
the spongiotrophoblast cell layer, characterized by the expres-
sion of the trophoblast-specific protein Tpbpa (also called 4311)
(40), was also reduced in PPAR mutant placentas, consistent
with the histological analysis described above (Fig. 3B) (see also
supplemental information at http://www.unil.ch/webdav/site/cig
/shared/desvergne/Nadra_et_al_supp_data.pdf). The expression
profile of PL-I is especially useful in characterizing early mo-
lecular events underlying trophoblast differentiation, since
transcription of this gene occurs exclusively in giant cells and
begins at the time of implantation (40, 47). Interestingly, we
consistently observed in PPAR mutant placenta the most
severe reduction in the thickness of the PL-I-expressing layer
(Fig. 3B). Thus, while all layers were affected, the marker
analyses underscore the severe alteration of the giant cell layer.
To examine the possibility of a relationship between PPAR
and trophoblast giant cell differentiation, we performed a
quantitative analysis of the temporal expression of PPAR,
PL-I, and Id-2 in wt placentas by RPA. Id-2 is an inhibitor of
bHLH transcription factors. It is highly expressed in tropho-
blast progenitor cell populations and is down-regulated upon
induction of giant cell differentiation (8) (48). RPA analysis
performed at E8.5, E9.5, E10.5, and E16.5 showed a parallel
expression between PPAR and PL-I, with a similar peak of
expression at E9.5 followed by a decrease at E10.5. Consis-
tently, Id-2 expression was maximal at E8.5 and decreased at
E9.5, remaining low but detectable (Fig. 3C). Thus, the com-
bination of the spatiotemporal expression pattern of PPAR
with that of several placenta markers indicates that PPAR
may act directly to regulate trophoblast giant cell differen-
tiation.
PPAR is required for trophoblastic giant cell differentia-
tion. The putative direct role of PPAR in affecting giant cell
differentiation was explored in the Rcho-1 trophoblast cell line,
which provides a reliable system for the molecular analysis of
the giant cell differentiation process (15, 25). When cultured in
a regular 10% FBS-containing medium, these cells remain in
proliferation and can be regularly subcultured while maintain-
ing an undifferentiated status. The change from 10% FBS to
1% horse serum causes the cells to cease their proliferation
and corresponds to the initiation of their differentiation into
trophoblast giant cells (time zero). To evaluate the role, if any,
of PPAR in this process, we exposed the cells from time zero
to the PPAR agonist L-165041 and used cell morphology and
PL-I expression as readouts of the differentiation status. At day
4 of the experiment, only a few control cells exhibited the
features of differentiated cells; this was expected since the full
differentiation process usually requires 6 to 8 days (25). Strik-
ingly, the addition into the medium from day 0 onwards of the
specific PPAR agonist L-165041 triggered a massive early
differentiation (Fig. 4A) accompanied by a major increase of
PL-I mRNA levels and severe reduction of Id-2 mRNA (Fig.
4B). Western blot analyses confirmed the very high levels of
PL-I expressed in these cells (Fig. 4C). Because Rcho-1 cells
expressed both PPAR and PPAR (Fig. 5A, top lines), the
specific PPAR ligand rosiglitazone (RSG) was also tested but
was found to have no effect on PL-I expression and giant cell
differentiation (Fig. 4C).
To demonstrate that PPAR is indeed required for tropho-
blast giant cell differentiation, we silenced PPAR gene ex-
pression in the Rcho-1 cells and then assessed their ability to
differentiate. Silencing was obtained via infection with a lenti-
virus expressing a PPAR siRNA (LV-THsiPPAR), as de-
scribed in Materials and Methods. Cells infected with a control
lentivirus (LV-TH; see Materials and Methods) or noninfected
cells were used as controls. RPA analyses showed that cells
transduced with LV-THsiPPAR had around 70% less
PPAR mRNA than the LV-TH control vector-infected cells
and noninfected cells, which displayed similarly high levels of
PPAR mRNA (Fig. 4D). As expected, the control cells re-
acted to the PPAR agonist by a massive differentiation. In
contrast, and at the same time point, only a few cells were
undergoing differentiation when infected with the siRNA-con-
taining lentivirus (Fig. 4E, right panels). RPA analyses also
confirmed the low level of PL-I expressed in these cells after 4
days of exposure to the PPAR ligand (Fig. 5C). This clearly
demonstrates that PPAR is required for the L165041-medi-
ated accelerated differentiation of Rcho-1 cells into tropho-
blastic giant cells. More importantly, we also analyzed the
behavior of Rcho-1 cells under the regular differentiation pro-
tocol, which we prolonged up to 15 days. Fifteen days after the
initiation of differentiation by serum replacement, noninfected
and control LV-TH-transduced cells exhibited the expected
features of differentiated cells, as evaluated by the increased
nuclear size. In contrast, the LV-THsiPPAR-infected cells
remained undifferentiated (Fig. 4F). These results clearly dem-
onstrate the strict requirement of PPAR expression for giant
cell differentiation.
PPAR acts on giant cell differentiation via the PI3K/Akt
signaling pathway and I-mfa expression. Among the factors
known to contribute to giant cell differentiation, Hand1 is a
bHLH transcription factor that promotes giant cell differenti-
ation in early postimplantation mouse embryos (53, 56). In
contrast, Mash-2, which is mainly expressed in the spongiotro-
phoblast and labyrinthine layers, as mentioned above, must be
inhibited for the differentiation to occur. This is in part per-
formed by I-mfa, a non-HLH inhibitor of the myogenic bHLH
subfamily, which inhibits the transcriptional activity of Mash-2
by preventing its nuclear localization (7, 36). Id-2 acts as a
negative regulator of bHLH transcription factors, and its
down-regulation is required for trophoblast development (8).
According to these elements, we first hypothesized that
PPAR might promote giant cell differentiation via induction
of Hand1 activity. However, the expression of Hand1 did not
change upon PPAR-mediated induction of Rcho-1 differen-
tiation into giant cells (Fig. 5A). In contrast, the alternative
mechanism, via inhibition of Mash-2 activity, is supported by
the diminished expression of Id-2 and an increased expression
of I-mfa that parallels PL-I induction (Fig. 5A).
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FIG. 4. PPAR-dependent differentiation of Rcho-1 cells in trophoblast giant cells. Rcho-1 cells were grown to 60% confluence. The change
to 1% horse serum-containing medium defines the time zero of the differentiation process. (A) Expression of PL-I in Rcho-1 cells after 4 days of
differentiation in the presence of dimethyl sulfoxide (DMSO) (0.05%) used as a vehicle, the PPAR agonist L-165041 (5 M), the PPAR agonist
and the PI3K inhibitor LY294002 (10 M). Scale bar, 80 m. (B) Temporal expression of PL-I and Id-2 in differentiating Rcho-1 cells cultured
in the presence of L-165041 or of its vehicle dimethyl sulfoxide (DMSO), as indicated. Numbers represent relative increase (n-fold) with respect
to basal level in the presence of dimethyl sulfoxide (0.05%) at time zero. (C) Effect of RSG (1 M) on PL-I expression after 4 days of treatment.
Two independent duplicates per condition are shown. (D) Silencing of PPAR in Rcho-1 cells. The Rcho-1 cells were noninfected or transduced
with a control lentivirus vector (LV-TH), or with a vector producing a PPAR-specific siRNA (LV-THsiPPAR). Silencing efficiency was
established by measuring the mRNA levels of PPAR after 15 days of the differentiation protocol. L27 ribosomal protein mRNA was used as an
internal control. (E) Differentiation of Rcho-1 cells either noninfected, transduced with LV-TH, or transduced with LV-THsiPPAR. In situ
hybridization with PL-I probe was used as a marker of giant cell differentiation at day 4 of differentiation in the presence of L-165041 (5 M) or
its vehicle (dimethyl sulfoxide). Red arrowheads show some of the differentiated cells that express PL-I. The nuclei were stained with a
methyl-green solution. (F) Bright-field images of Rcho-1 cells in culture after 15 days of differentiation. Ni, noninfected; Ci, LV-TH; Si,
LV-THsiPPAR/.
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Using the same Rcho-1 cellular model, Kamei et al. (33)
have described the role of the PI3K signaling pathway in giant
cell differentiation. To examine whether the PPAR-mediated
regulation of the different factors was dependent on the PI3K
pathway, Rcho-1 cells were treated with the PPAR ligand in
the presence of LY294002, a specific PI3K inhibitor. Remark-
ably, the addition of LY294002 efficiently prevented the PPAR-
mediated up-regulation of PL-I mRNAs (Fig. 5A) and protein
(Fig. 5B). This reduction of PPAR activity was also observed
with respect to Id-2 repression (Fig. 5A). In contrast, the PI3K
inhibitor did not affect the PPAR-induced expression of I-mfa.
However, I-mfa expression remains PPAR dependent since it
was abolished in PPAR siRNA-expressing cells (Fig. 5C).
Further downstream of PI3K activation is the phosphorylation
of Akt at the residues Ser473 and Thr308. Consistent with the
results described above, treatment of Rcho-I cells with the
PPAR ligand for 3 h resulted in the phosphorylation of Akt1
(Fig. 5D).
These observations indicate that PPAR activates Akt-1,
which subsequently triggers the giant cell differentiation. We
previously identified two kinases, namely, PDK1 and ILK,
which in wounded skin regulate the PI3K/Akt pathway and
which are direct PPAR target genes (11, 12). As shown in Fig.
5E, both kinases were well expressed in control Rcho-1 cells
FIG. 5. PPAR promoting giant cell differentiation requires an intact PI3K/Akt pathway. (A) mRNA expression levels of PPAR, PPAR,
PL-I, Id-2, Hand1 and I-mfa after 4 days of indicated treatments with L-165041 (5 M) and/or PI3K inhibitor (LY294002) (10 M). Two
independent duplicates per condition are shown. (B) Western blot analysis of PL-I production in Rcho-1 cells treated by PPAR ligand and/or
by LY294002. Two independent duplicates per condition are shown. The number of cells seeded in each plate was accurately quantified at the
beginning of the experiment, and all culture conditions were strictly comparable. (C) mRNA expression levels of PPAR, PL-I, and I-mfa in
Rcho-1 cells either noninfected (Ni), transduced with the LV-TH (Ci), or transduced with the LV-THsiPPAR (Si), after 4 days of differentiation
in the presence of either dimethyl sulfoxide, used as a vehicle, or 5 M PPAR ligand. L27 ribosomal protein mRNA was used as an internal
control. (D) Relative expression of phosphorylated Akt from Rcho-I trophoblast cells treated for 3 h with either vehicle or 5 M PPAR ligand.
Total cellular proteins from Rcho-1 cells were used for Western blot analysis. Two independent duplicates per condition are shown. (E) Relative
expression of PDK1, ILK, and PTEN in Rcho-1 cells either noninfected, transduced with the LV-TH, or transduced with the LV-THsiPPAR,
after 4 days of differentiation in the presence of either dimethyl sulfoxide, used as a vehicle, or 5 M PPAR ligand. Tubulin was used as an internal
control. The apparent molecular mass is indicated for each protein. Numbers represent relative increase (n-fold) with respect to the basal level
in the presence of dimethyl sulfoxide (0.05%) (A and B), to basal level to (Ni) in the presence of dimethyl sulfoxide (0.05%) (C and E) or to the
level at time zero in the presence of dimethyl sulfoxide (0.05%) (D). DMSO, dimethyl sulfoxide; Ni, noninfected; Ci, LV-TH; Si,
LV-THsiPPAR.
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treated with the PPAR agonist, whereas they were markedly
reduced in LV-THsiPPAR. We also measured the levels of
phosphatase and tensin homolog deleted on chromosome 10
(PTEN), which negatively regulates the PI3K-mediated path-
way by increasing the conversion from PiP3 to PiP2. Con-
versely, the loss of PTEN leads to Akt activation (21). PTEN
levels were diminished in control Rcho-1 cells exposed to
PPAR agonist but remained similar to those of the nondif-
ferentiated cells in PPAR siRNA-treated cells (Fig. 5E).
These results demonstrate that PPAR is essential for the
full differentiation of trophoblast giant cells through the acti-
vation of the PI3/Akt1 signaling pathway, in addition to a
PI3K-independent induction of I-mfa.
The pathways responsible for giant cell differentiation are
altered in PPAR mutant placenta. To demonstrate the rele-
vance of the observations obtained in the Rcho-1 culture sys-
tem, we biochemically characterized the trophoblastic giant
cell layer by quantifying the expression levels of PL-I, Hand1,
I-mfa, and Id-2 at E9.5 in control and PPAR mutant placen-
tas. Consistent with the results obtained in Rcho-1 cells, PL-I,
Hand1, and I-mfa mRNA levels were markedly reduced in
PPAR mutant placenta compared with wt placenta. These
decreased PL-I, Hand1, and I-mfa expressions were associated
with a moderate increase in Id-2 mRNA levels (Fig. 6A).
We also analyzed the PI3K/Akt pathway in these placentas.
The level of PDK1, as evaluated by Western blotting, was
dramatically lower in the E9.5 PPAR mutant placentas. Con-
sistently, whereas the total amount of Akt1 protein was similar
in wt and PPAR mutant placentas, the phosphorylated forms
of Akt at Ser473 and Thr308 were markedly reduced in the
PPAR mutant placentas compared to wt placentas (Fig. 6B).
Recent studies have shown that Akt1 is expressed in all types
of trophoblast cells and vessel endothelial cells in E14.5 wt
placenta (67), but little is known about Akt activity at earlier
stages. To further explore in vivo the relationship between Akt
activity and trophoblast giant cells, we performed immunohis-
tochemical staining with an antibody specifically recognizing
Thr308-phospho-Akt1 (Akt-Thr308-P) and studied its localiza-
tion in E9.5 wt placentas. Interestingly, Akt-Thr308-P was
strongly detected in the trophoblast giant cells, where it was
specifically located in the cell nucleus (Fig. 6C).
Together, these results demonstrate that the major role
played by PPAR in giant cell trophoblast differentiation
through activation of the PI3K/Akt1 pathway, which we char-
acterized in cell culture, also occurs in vivo.
PPAR, lipid metabolism, and ADRP expression in giant
cells. Placental fatty acid transfer is critical for normal fetal
development, particularly for membrane biosynthesis, energy
needs and storage, and synthesis of precursors of signaling
molecules. In that respect, the labyrinth zone exerts a crucial
role in regulating the bidirectional exchange between maternal
and fetal compartments, with a facilitated directional flux of
fatty acids from the mother to the fetus (28). Insufficient fatty
acid supply may indeed result in retarded fetal growth (9).
Little is yet known about the molecular mechanism of fatty
acid transfer, while even less is known about fatty acid metab-
olism in the placenta in the early stages, when the labyrinth is
not yet fully developed. The severe growth retardation ob-
served in the PPAR mutant embryos at E9.5 (Fig. 2) and the
role of PPAR in lipid metabolism (3, 17) led us to investigate
the lipid status in E9.5 placentas, in comparison with the situ-
ation observed at E16.5.
As a first step, we assessed the presence and location of lipid
droplets in the placenta, by oil red O staining of tissue sections
of placentas. Strikingly, lipid accumulation was already observed
at E9.5, remarkably pronounced in the giant cells (Fig. 7A,
frames a to d) and to a lesser extent in the labyrinth part. At
E16.5, the giant cells were no longer distinguishable, and lipid
droplets were abundantly found in both the maternal decidua
and the labyrinth, while they were undetectable in the spon-
giotrophoblast (Fig. 7A, frames e to h). This lipid accumula-
tion in the form of cytosolic droplets was paralleled by the
expression pattern of ADRP, a major lipid droplet-associated
protein that helps in packaging neutral lipids into discrete lipid
storage droplets in the cytoplasm (31). At E9.5, ADRP immu-
noreactivity was mainly localized in the cytoplasm of tropho-
blast giant cells (Fig. 7B, frames a to d). Higher magnification
revealed the particular pattern of ADRP protein localized as
brown rings around the lipid droplets (Fig. 7B, frame d). In the
labyrinthine trophoblast cells, ADRP was found toward the
apical surface of the cells and was concentrated along the fetal
vessels (Fig. 7B). At E16.5, ADRP was abundantly expressed
FIG. 6. Reduced Akt activity in PPAR/ embryos. (A) Expres-
sion profiles of PL-I, Hand1, I-mfa, and Id-2 at E9.5 in PPAR wt and
mutants. L27 ribosomal protein mRNA was used as an internal con-
trol. Three independent samples are shown per genotype. (B) Relative
expression of PDK1, Akt phosphorylated in Thr308 or in Ser473, and
total Akt in PPAR wt and mutant placenta at E9.5. Tubulin was used
as an internal control. Total cellular proteins from E9.5 placentas were
used for these Western blot analyses. The apparent molecular mass is
indicated for each protein. Two independent samples are shown per
genotype. (C) wt E9.5 placenta. Hematoxylin-eosin staining is shown in
frame a. Immunohistochemistry (b and c) reveals the Thr308-phos-
phorylated Akt (Akt-Thr308-P) in the nuclei of giant cells (red arrow-
heads). The red square in frame b indicates the region seen in frame
c at higher magnification. Numbers in panels A and B represent the
relative increase (n-fold) with respect to basal level to wt.
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FIG. 7. Lipid storage droplets accumulate in the mouse placenta. (A) Oil red O staining of sagittal sections of mouse placenta at E9.5 (a to
d) and E16.5 (e to h). Abundant small lipid droplets were observed inside the cytoplasm of trophoblast giant cells. As seen in frame d, the droplets
are particularly localized near the nucleus. Black arrowheads indicate some lipid droplets. Bars: 200 m (a and e), 40 m (b, c, and f), 20 m (g
and h), and 8 m (d). (B) Distribution of ADRP in mouse placenta at E9.5 (a to d) and E16.5 (g to j). Red arrowheads indicate some specific
labeling corresponding to ADRP protein. (C) Expression profile of ADRP mRNA in E9.5 placentas from PPAR wt and mutant concepti (left)
and from PPAR wt and mutant concepti (right). (D) Relative mRNA expression profiles of ADRP and PPAR in mouse placental tissues from
E8.5, E9.5, E10.5, and E16.5. L27 ribosomal protein mRNA was used for normalization. Numbers represent the relative increase (n-fold) with
respect to the basal level at E8.5 (D) or to wt (C). gi, trophoblast giant cells; la, labyrinthine trophoblast; ma, maternal decidual tissue; sp,
spongiotrophoblast.
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in the decidua and the labyrinth (Fig. 7B, frames e to h),
closely reproducing the lipid droplet pattern.
A quantitative evaluation of ADRP expression by RPA
showed that ADRP mRNA levels were very low at E8.5 and
continuously increased with time, reaching high levels at E16.5
(Fig. 7D). We then explored the respective roles of PPAR
and PPAR in regulating ADRP expression. For that purpose,
we took advantage of the targeted disruption of the PPAR
allele, described by Rieusset et al. (52), to compare ADRP
expression in PPAR null and PPAR null mutant placentas
at E9.5. Strikingly, ADRP mRNA levels were markedly re-
duced in PPAR mutant placentas (Fig. 7C), consistent with
the strong alteration of the giant cell layer. In contrast, PPAR
mutant placentas exhibited minimal changes, with a tendency
to an increase in ADRP mRNA levels (Fig. 7C), clearly dem-
onstrating that at this stage of placental development, ADRP
is mainly expressed in the giant cells and under the direct or
indirect control of PPAR but not of PPAR. No mutant
placentas could be obtained at E16.5, but at this stage, there is
a remarkable parallel in wt placentas between the intense laby-
rinth ADRP immunostaining, the high levels of ADRP mRNA,
and the high levels of PPAR mRNA (Fig. 7D). This suggests
that the expression of ADRP in the labyrinth at later stages
of placental development is under the control of PPAR.
Whereas this is consistent with a previous report showing a
PPAR-dependent increase in ADRP expression in human
trophoblast cells (4), the control of ADRP expression at the
late placental stage remains to be analyzed.
ADRP expression is associated to giant cell differentiation
and under the control of PPAR. To evaluate whether ADRP
expression and lipid droplet accumulation in the giant cells
were due to the placental environment or could be precisely
attributed to giant cell functions, we furthered our investiga-
tions in Rcho-1 cells. Amazingly, an increase in ADRP expres-
sion and the appearance of lipid droplets accompanied giant
cell differentiation, obtained either using the classical proce-
dure or by accelerated differentiation via exposure to a PPAR
ligand. In this context, PPAR ligand RSG provoked little if
any increased ADRP expression. The need for PPAR was
further shown in cells infected by LV-THsiPPAR, which
prevented the PPAR ligand-induced expression of ADRP
(Fig. 8A).
While a peroxisome response element (PPRE) has been
identified in the ADRP mouse promoter, suggesting a direct
transcriptional regulation of ADRP (6), the mechanism by
which PPAR increased ADRP expression during trophoblast
giant cell differentiation also relies on PPAR-dependent
PI3K activity. Indeed, in cells treated with the PI3K inhibitor,
the expression of ADRP dropped to the same extent as the
other giant cell markers (Fig. 8A). This emphasizes the fact
that control of ADRP expression cannot be dissociated from
the overall process of giant cell differentiation regulated by
PPAR. To assess whether ADRP is truly under the control
of PPAR, we evaluated its expression in adult tissues from
mutant mice. In the white adipose tissue of PPAR mutant
mice, ADRP expression decreased by twofold, whereas the
adipocyte fatty acid binding protein (aFABP/aP2), used as an
adipocyte marker, only decreased slightly (Fig. 8B). In con-
trast, the mRNA levels of ADRP and aP2 were unchanged in
the heart of PPAR mutants compared to wt (Fig. 8B). Thus,
ADRP expression is dependent on PPAR in some tissues,
and most remarkably in the E9.5 placenta giant cells.
In summary, our observations demonstrate the crucial role
of PPAR in the differentiation of the trophoblastic giant cell
layer via two overlapping molecular mechanisms which involve
a PPAR-mediated increased Akt1 activity and a direct posi-
tive regulation of the transcription factor I-mfa. We further
demonstrated that giant cells accumulate lipid, together with
the expression of the ADRP protein, conferring on the giant
cells an unexpected role in lipid metabolism.
DISCUSSION
The analysis of PPAR functions in the mouse placenta
provides important information. First, although PPAR and
PPAR are expressed in the three layers of the developing
placenta, functional redundancies or compensations between
them, if any, are not fully operative. Second, PPAR is a major
regulator of the differentiation of the secondary giant cells,
which play a critical role in the establishment of the placental
structure and fulfill an important endocrine function. Third, we
reveal that secondary giant cells are the prime site of lipid
accumulation in the developing placenta, an event which is also
under the control of PPAR.
FIG. 8. ADRP expression is associated to giant cell differentia-
tion. (A) Expression profile of ADRP in Rcho-1 cells after 4 days of
treatment with L-165041 (5 M), RSG (1 M), or PI3K inhibitor
(LY294002) (10 M) (left and bottom panels) and in cells either
noninfected (Ni), transduced with the LV-TH (Ci), or transduced with
the LV-THsiPPAR (Si) (right panel). Dimethyl sulfoxide (DMSO)
was used as a vehicle. (B) Relative mRNA expression profiles of
ADRP and aP2 in mouse placental tissues at E16.5, in white adipose
tissue (WAT), and in heart. L27 ribosomal protein mRNA was used
for normalization. Numbers represent the relative increase (n-fold)
with respect to basal level in the presence of dimethyl sulfoxide
(0.05%) (A) or to level in white adipose tissue (B).
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PPAR and embryonic lethality. Conflicting results con-
cerning the embryonic lethality of PPAR null mutant mice
appeared in two previous reports (51, 2). Indeed, Peters et al.
(51) observed no embryonic lethality on a pure C57BL/6N
background but a lower than expected number of newborn
homozygous pups on a mixed genetic background. In contrast,
Barak et al. (2) reported a severe embryonic lethality in either
Sv129 or C57BL/6J background. Our observations are closer to
those of Barak et al. (2), with a frequent embryonic lethality
between E9.5 and E10.5 due to an altered placenta formation.
An explanation of these discrepancies may lie in the mutation
performed on the PPAR gene, with a disruption of the DNA-
binding domain therein, as in Barak et al. (2), whereas the
mutation performed by Peters et al. (51) disrupted the last 60
amino acids of the ligand-binding domain. The latter approach
might have resulted in a hypomorph allele, retaining some
aporeceptor functions. A comparative analysis of these two
models of PPAR disruption in a congenic background might
reveal very interesting features of PPAR functions.
The fact that we were able to obtain some productive ho-
mozygous pairs, in which the defects in the placenta were still
present but less penetrant, is likely due to the presence of one
or more modifiers responsible for the higher survival rate of
PPAR/ embryos. However, while we have not been able so
far to improve the survival rate by enriching the mixed genetic
background toward Sv129 or toward C57BL/6 background, a
contribution of the genetic background to the observed phe-
notypes cannot be excluded. Large-scale and in-depth genetic
studies will be needed to identify the genes that are partners in
this complex trait.
PPAR promotes giant cell differentiation. We demonstrate
that deletion of PPAR leads to a dramatic decrease of the
trophoblast secondary giant cell layer in vivo and abolishes the
ability of Rcho-1 cells to differentiate into giant cells in cell
culture. Conversely, agonist activation of PPAR in a cell
culture model of trophoblast giant cell differentiation markedly
accelerates and increases the extent of differentiation.
Our studies contribute to identifying the factors involved in
the development and endocrine functions of the placenta.
Members of the bHLH factor family are involved in the control
of commitment, differentiation, and development of many dif-
ferent tissues and organs, including the placenta (23). Hand1
promotes the differentiation of trophoblast giant cells (53). In
contrast, Mash-2 has the opposite effect as it is required to
maintain the pool of precursors in the ectoplacental cone and
spongiotrophoblast, and its sustained expression precludes
their differentiation in giant cells (23). Id-2 belongs to a subset
of HLH proteins and acts as a dominant negative factor by
dimerizing and sequestering the heterodimerization partner of
bHLH transcription factors (48). In Rcho-1 cells, overexpres-
sion of a related protein (Id-1) inhibits their differentiation
into giant cells (8). This can be paralleled with the expression
of Id-2, which is undetectable in differentiated trophoblast
giant cells but remains expressed in the extra-embryonic ecto-
derm of the chorion (30). Finally, the bHLH-repressor protein
I-mfa is also required for the generation of trophoblast giant
cells, possibly acting as a direct inhibitor of the activity of
Mash-2 by preventing its nuclear import (36). In the present
study, we demonstrate that PPAR activation does not affect
Hand1 expression but increases I-mfa mRNA levels in a PI3K-
independent manner and decreases Id-2 expression in a PI3K-
dependent manner. As proposed in Fig. 9 and its legend, these
two likely independent mechanisms are converging in tropho-
blast cell differentiation. Interestingly, the I-mfa mutants ex-
hibit a generally similar phenotype to that of PPAR mutant
embryos, with an overall reduced size of the embryos, a lack of
trophoblast giant cells, and a lethality that occurs at mid-
gestation (36).
The full activity of PPAR in promoting giant cell differen-
tiation thus requires an intact PI3K pathway. We previously
demonstrated the ability of PPAR to reinforce Akt signaling
upon skin wound healing (11, 12). We now reveal that this
activity and regulation by PPAR are crucial for proper pla-
cental development, an observation which parallels the in-
volvement of the PI3K/Akt1 signaling pathway for the devel-
opment of differentiated trophoblast giant cells (reference 33
and the present study). Our present observations unravel a
highly specific pattern of phospho-Akt (P-Akt) in the nucleus
of giant cells. Activated Akt can indeed translocate into the
nucleus (45). Unfortunately, unlike the known pleiotropic role
of P-Akt in the cytoplasm, the role of its nuclear form has yet
to be defined. Recent studies using a differentiated thyroid
cancer cell line revealed that the ability of the invasive cells to
migrate was associated with nuclear localization of P-Akt and
that PI3K inhibitors reduced cell motility (60, 34). In the pla-
centa, the association of nuclear P-Akt with trophoblast giant
cells suggests a role of P-Akt in giant cell invasiveness. How-
ever, the specific events which take place downstream of Akt
activity remain to be clarified. Akt has been reported to repress
Id-2 expression in neuroblastoma cells (43). In addition, it has
been shown to regulate the assembly and activity of bHLH-
coactivator complexes in neuronal differentiation (61). Thus,
we can propose that the full activity of PPAR on giant cell
FIG. 9. PPAR plays a key role in trophoblast giant cell differen-
tiation via two converging mechanisms. Hand1 and Mash-2 are two
crucial transcription factors involved in promoting and inhibiting giant
cell differentiation, respectively. In addition, Id-2 acts as a dominant
negative factor by dimerizing and sequestering the heterodimerization
partner of bHLH transcription factors and must be down-regulated to
allow trophoblast giant cell differentiation. PPAR first acts by in-
creasing Akt activity, which leads to Id-2 down-regulation. The bHLH
transcription factor targeted by Id-2 in the trophoblast cells is not
ascertained but could include Hand1 (dotted line) or the heterodimer-
ization partner of Hand1, which in the giant cells is not yet identified
(56). The role of PPAR in directly regulating Hand1 is unclear since
Hand1 expression is not modified in the Rcho-1 cell model. Secondly,
PPAR also increases the expression of I-mfa, which acts as an inhib-
itor of Mash-2 activity, possibly by impairing its nuclear import. Fi-
nally, the subsequent differentiation is associated with ADRP expres-
sion and lipid accumulation, which also depends on PPAR and its
activity on Akt-1.
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differentiation involves (i) the PI3K-dependent inhibition of
Id-2 expression and the up-regulation of the activity of some
bHLH factors and (ii) the direct or indirect activation of I-mfa
expression (Fig. 9). While a bioinformatic analysis identified a
possible PPRE in the I-mfa promoter (data not shown), this
DNA element remains to be functionally characterized.
PPAR and lipid metabolism in the placenta. Our present
results strongly support two mechanisms, possibly indepen-
dent, of lipid storage and ADRP expression in the placenta. At
an early stage, when giant cells are forming the main interface
between the maternal and the fetal compartments, giant cells
are the major site of lipid accumulation, which is accompanied
by increased ADRP expression. Herein, we demonstrate that
this early ADRP increased expression is PPAR dependent.
At a later stage, upon major development of a functional
labyrinth structure, the labyrinth and the maternal decidua
become the main sites where lipid droplets are observed, and
a careful examination points to the major presence of lipids in
the cells that surround the fetal vessels. This labyrinth expres-
sion is possibly dependent on PPAR, as previously suggested
(1, 55).
These features are particularly remarkable since both
PPAR and PPAR are expressed throughout the three pla-
centa layers, suggesting that the specificity of their action must
depend on distinct activation processes, including ligand avail-
ability and/or target gene specificity. In mice and in humans,
ADRP is a known PPAR target gene, and a PPRE identified in
the ADRP promoter mediates its response to the PPAR
agonist GW501516 (6, 62) and also to PPAR and to PPAR
(24, 14, 57). In Rcho-1 cells, the full activity of PPAR to
increase the expression of ADRP requires an intact PI3K/Akt1
signaling pathway (Fig. 8) and a successful differentiation in
giant cells. Thus, the high level of ADRP mRNA in Rcho-1
differentiated cells is likely the result of two processes: direct
transcriptional activity of PPAR at the ADRP promoter and
indirect action of PPAR on differentiation via the PI3K/Akt1
pathway.
Although elucidation of its function is still in progress,
ADRP seems to be involved in the formation and stabilization
of lipid droplets (19). Recombinant expression of ADRP in
COS-7 cells demonstrated that this protein facilitates the
transport of long-chain free fatty acids and may function as a
fatty acid carrier protein (18). Our results raise the question as
to whether or not lipid accumulation in the giant cells during
the early stages of placental development fulfills the same role
as it does in the labyrinth cells at a later stage. In the latter, the
ADRP location in close proximity to the vessel walls suggests
a metabolic role in feto-maternal exchange. This nutritional
role in the giant cells cannot be excluded. However, ADRP not
only encircles droplets mainly composed of triglycerides, such
as those found in the lactating mammary gland, but also drop-
lets rich in cholesterol stored as steroid hormone precursors in
adrenocortical cells (27). In the rodent placentas, androgen
synthesis takes places within trophoblast giant cells (32).
Rcho-1 cells synthesize both progesterone and androstenedi-
one (66). Thus, lipid droplet accumulation and ADRP expres-
sion in trophoblast giant cells may rather contribute to the
production of steroid hormones. Therefore, PPAR null con-
cepti would suffer from both a low number of differentiated
giant cells and an additional alteration of their endocrine func-
tions via decreased levels of ADRP, consequently impairing
placenta and embryonic growth.
In conclusion, we have revealed some crucial regulatory
events in giant cell differentiation mediated by PPAR. These
results also bring to light the significant role of PPAR in
correlation with lipid accumulation, which may fulfill an endo-
crine function as well as contribute to nutrient exchange be-
tween the fetus and the mother. Collectively, these observa-
tions concerning PPAR null placentas emphasize the need to
carefully evaluate the effects of PPAR ligands on placenta
development and physiology when they are considered for use
as therapeutic drugs in chronic metabolic diseases, which may
also affect pregnant women.
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II.3.3.2. Phthalates are environmental pollutants acting as selective modulators of PPARγ 
activity 
 
II.3.3.2.1. Abstract taken from the submitted publication 
 
The ability of pollutants to affect human health is a major concern which has been widely 
demonstrated by the interference of endocrine disrupting chemicals with reproductive functions. 
However, much less is known about the mechanisms through which such compounds affect 
metabolic regulations. We analyzed the impact of phthalate plasticizers on the Peroxisome 
Proliferator-Activated Receptor (PPAR) γ, a nuclear receptor playing a central role in adipogenesis 
and insulin sensitivity. Mono-Ethyl-Hexyl-Phthalate (MEHP), the active metabolite of the Di-Ethyl-
Hexyl-Phthalate (DEHP) plasticizer, directly activates PPARγ and promotes adipogenesis, albeit to 
a lower extent than the full-agonist Rosiglitazone. Importantly, we demonstrate that MEHP induces 
a selective activation of different PPARγ target genes by inducing the recruitment of a specific 
subset of PPARγ coregulators both in the nucleoplasm of living cells and on PPARγ target 
promoters. Altogether, our study characterizes the molecular basis of selective PPARγ modulation 
by MEHP and demonstrates that PPARγ is a molecular target through which pollutants can interfere 
with metabolic regulations. 
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The ability of pollutants to affect human health 
is a major concern, justified by the wide 
demonstration that reproductive functions are 
altered by endocrine disrupting chemicals 
(EDCs). The definition of endocrine disruption 
is today extended to broader endocrine 
regulations, and includes activation of 
metabolic sensors, such as the Peroxisome 
Proliferator-Activated Receptors (PPARs). 
Toxicology approaches have demonstrated that 
phthalate plasticizers can directly influence 
PPAR activity. What is now missing is a 
detailed molecular understanding of the 
fundamental basis of EDC interference with 
PPAR signaling. We thus performed structural 
and functional analyses that demonstrate how 
Mono-Ethyl-Hexyl-Phthalate (MEHP) directly 
activates PPARγ and promotes adipogenesis, 
albeit to a lower extent than the full-agonist 
Rosiglitazone. Importantly, we demonstrate 
that MEHP induces a selective activation of 
different PPARγ target genes. Chromatin 
immuno-precipitation and fluorescence 
microscopy in living cells reveal that this 
selective activity correlates with the recruitment 
of a specific subset of PPARγ coregulators 
which includes Med1 and PGC-1α, but not 
p300 and SRC-1. These results highlight some 
key mechanisms in metabolic disruption but are 
also instrumental in the context of selective 
PPAR modulation, a promising field for new 
therapeutic development based on PPAR 
modulation. 
 
Exposure to endocrine disrupting chemicals 
(EDCs) can lead to detrimental effects in human 
and animal populations by promoting or inhibiting 
the synthesis, the elimination and the action of 
hormones (1,2). At the molecular level, these 
compounds act by activating or inhibiting 
enzymatic activities of hormone biosynthesis and 
by targeting nuclear receptors (NRs), a class of 
transcription factors that regulate gene expression 
programs in response to lipophilic hormones and 
mediators. In the past, research on endocrine 
disruption has focused on reproductive defects 
caused by interference with steroid signaling, 
largely linked to modulation of steroid NR activity 
(3). However, NRs constitute a large family of 
receptors regulating diverse physiological 
functions, out of which most members share the 
capacity to regulate gene expression in response to 
 1
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ligand binding. The concept of endocrine 
disruption is now being broadened to other 
receptors implicated in different aspects of 
homeostatic regulation (4). 
Given their central role in metabolic 
regulations (5,6), Peroxisome Proliferator-
Activated Receptors (PPARs) potentially 
constitute important targets for environmental 
factors. PPARs are lipid sensors which cooperate 
in different organs to adapt gene expression to a 
given metabolic status. PPARγ (NR1C3) controls 
fat storage in the adipose tissue by promoting the 
differentiation and the survival of adipocytes, but 
also plays major roles in the control of insulin 
sensitivity (7). At the molecular level, PPAR 
action relies on its constitutive association with the 
Retinoid X Receptor (RXR, NR2B) (8,9), which 
allows binding of the heterodimer to specific 
response elements located in target gene 
promoters. The unliganded receptors are engaged 
in large complexes of corepressors and 
coactivators which can promote repression and 
activation according to the promoter context, 
respectively (9-11). In order to induce full 
transcriptional activation, ligand binding enhances 
the recruitment of coactivators acting through the 
remodeling of the structure and epigenetic marking 
of chromatin and by contacting the basal 
transcriptional machinery (12). PPAR activity can 
be pharmacologically modulated to treat major 
metabolic disorders (13). Thiazolidinediones 
(TZDs) are PPARγ activating drugs clinically used 
as insulin sensitizers but PPARγ-targeted 
therapeutics suffer from important adverse effects 
(7). The hope of better pharmaceutical strategies 
arises from the identification of selective PPARγ 
modulators (SPPARγMs) capable of uncoupling 
the beneficial actions of current PPARγ agonists 
from their side-effects (13,14). 
The large PPAR ligand-binding pocket, 
which can accommodate a wide variety of ligands, 
raises the question of whether PPAR activity and 
PPAR-regulated pathways could be affected by an 
exposure to EDCs. Actually, PPARα was 
discovered as the receptor mediating hepatic 
peroxisome proliferation and carcinogenesis in 
rodents in response to a wide class of chemicals 
which include pesticides, industrial solvents and 
plasticizers (15,16). We have focused the present 
study on the interference of phthalate esters with 
PPAR regulated processes. Phthalates are widely 
used industrial chemicals which primarily serve as 
plasticizers to soften PVC but are also found in 
cosmetics, perfumes and certain drugs as well as in 
industrial paints and solvents. Di-Ethyl-Hexyl-
Phthalate (DEHP) is among the most abundantly 
used phthalate esters with an annual worldwide 
production estimated around 2 million tons 
according to Swiss authorities (Federal Office of 
Public Health, http://www.bag.admin.ch/themen/ 
chemikalien/00228/01378/). DEHP is incorporated 
non-covalently into flexible plastics used for 
manufacturing a wide variety of daily products 
including medical devices and food packaging and 
its propensity to leach can expose humans to high 
concentration of this compound (17). The 
biological effects of DEHP are hence of major 
concern but so far elusive. Upon ingestion, 
pancreatic lipases present in the intestine convert 
DEHP to its monoester equivalent Mono-Ethyl-
Hexyl-Phthalate (MEHP) which is preferentially 
absorbed (18). In addition, MEHP can also be 
produced by plasmatic and hepatic lipases, which 
transform DEHP directly reaching the blood 
through absorption or medical contamination. This 
metabolite activates the three PPAR isotypes and 
mediates the action of DEHP on hepatic 
peroxisome proliferation via PPARα (19-21). 
This study, aimed at going beyond the 
toxicology approach, focuses on the molecular 
mechanisms through which MEHP modulates 
PPARγ signaling. For that purpose, we use a 
combination of molecular and cellular assays to 
directly monitor the action of the receptor in living 
cells. We demonstrate that MEHP promotes 
PPARγ-dependent adipogenesis, albeit to a lower 
extent than the full agonist Rosiglitazone. MEHP 
induces the expression of a subset of PPARγ target 
genes required for adipogenesis when compared to 
Rosiglitazone. Interestingly, the binding modes of 
MEHP and Rosiglitazone to the ligand binding 
pocket of PPARγ seem similar. However, MEHP 
selectively modulates PPARγ activity according to 
the promoter context by promoting differential 
interactions with coregulators. Thus, in addition to 
understanding the molecular actions of MEHP 
beyond the toxicological observations, the 
combination of microscopy techniques and 
chromatin immuno-precipitation provides a strong 
 2
 at isrec bibliotheque on M
ay 29, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
158
molecular basis in living cells for the concept of 
selective PPARγ modulation. 
EXPERIMENTAL PROCEDURES 
Plasmid constructs – Mouse PPARs were 
expressed from pSG5 vectors (reporter assay) or 
from pEYFP -N1 or -C1 (imaging experiments) 
(8). The constructs for  GST-p3002-516 (22), GST-
hSRC-1617-1259 and GST-mNCoR2204-2453 (23) were 
previously described. GST-hMed1 and GST-
mPGC1α were constructed by cloning PCR 
fragments corresponding to amino acid residues 
550 to 716 and 1 to 442, respectively, in pGEX 
5X3 (Amersham). The plasmid encoding EYFP-
p300N-term was constructed by cloning bases 1 to 
1790 (residues 1 to 595) of the human p300 cDNA 
into pEYFP-C1 using HindIII and BamHI as 
restriction sites. The EYFP-Med1 receptor 
interacting domain (RID) construct was generated 
by cloning a PCR amplification product 
corresponding to residues 550 to 716 of Med1 into 
pEYFP-C1, using BglII and SalI. The YFP-NCoR 
construct was generated by cloning a PCR 
fragment corresponding to residues 2235 to 2301 
of mNCoR into pEYFP-N1 using XhoI and SacII 
restriction sites. 
Cell culture and transient transfection assays – 
Cos7, C2C12 and 3T3L1 cells from ATCC were 
maintained in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% fetal 
calf serum (Gibco). Transient transfection assays 
were performed using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s 
instructions. After transfection, cells were let to 
recover in medium supplemented with 10% fetal 
calf serum for 5 hours and then grown in serum-
free medium for 18 hours in the presence of ligand 
or vehicle only. Unless otherwise stated, 
Wy14,643 (Cayman Chemical Co.), L-165041 
(synthesized at custom in the laboratory), 
Rosiglitazone (Sigma), MEHP (ICI) and GW9662 
(synthesized at custom by Zydus Research Center, 
India) were used at respective final concentrations 
of 10-5 M, 5.10-6 M, 10-6 M, 10-4 M and 2.10-5 M. 
Reporter assay – PPAR activity was monitored on 
a (PPRE)3-Luciferase reporter construct kindly 
provided by Dr. Evans (San Diego, USA). 
Luciferase activity assays were performed with the 
Promega dual-reporter kit, according to the 
manufacturer’s instructions. Renilla luciferase 
encoded by the normalization vector phRLTK 
(Promega) was used as an internal control for 
firefly luciferase normalization. 
Adipocyte differentiation - 2-day post-confluent 
3T3L1 pre-adipocytes were induced to 
differentiate using two different protocols: a 10 
day treatment with 10µg/ml insulin and PPARγ 
ligands (Rosiglitazone or MEHP) or a 2-day 
treatment with a differentiation cocktail (10µg/ml 
insulin, 1µM dexamethasone, 0.5mM IBMX) 
followed by an 8-day treatment with 10µg/ml 
insulin only. In both cases, the medium was 
changed every 48h. After differentiation, cells 
were stained with Oil Red O for morphological 
analyses or RNA was extracted using 
phenol/chloroform (Trizol, Invitrogen) and 
purified with Qiagen columns. For RNA 
extractions, four independent cultures were 
performed per condition. To determine triglyceride 
content, 3T3L1 cultures differentiated as described 
above in a 10cm plate were lysed in 1500µl PBS 
0.1% NP40 with a dounce homogenizer and 
cytoplasmic extracts were collected. Relative 
triglyceride levels were evaluated by adding 100µl 
of cytoplasmic extract to 200µl of Infinity 
triglyceride reagent (Thermo Electron 
Corporation) and measuring the absorbance at 
500nm. The levels of triglyceride were normalized 
to protein levels measured with the Bradford 
reagent (BioRad) at 595nm. 
siRNA knock-down - An oligonucleotide 
(5’ GATCCCCAAAGCCAAGGCGAGGGCGATC
TTTTCAAGAGAAAGATCGCCCTCGCCTTGGC
TTTTTTTTGGAAA 3’) encoding a PPARγ siRNA 
(5’ AAAGCCAAGGCGAGGGCGATCTT 3’) as 
a hairpin was cloned into the pLVTH lentiviral 
vector as previously described (24). Viral 
production was performed according to (24) and 
3T3L1 cells were infected at a multiplicity of 
infection of 10. 
Quantitative RT-PCR - Reverse transcription was 
performed with random hexamers on 1µg of total 
RNA using the superscript first-strand synthesis 
system (Invitrogen) and the reaction was diluted 
100 times for amplification. PCR reactions were 
performed in triplicate in 384-well plates on an 
Applied Biosystems 7900HT cycler using 
commercial Taqman probes (Applied Biosystems; 
see supplementary table SI for references). Results 
were normalized to 3 house-keeping genes 
(TATA-box binding protein, eukaryotic translation 
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elongation factor 1 alpha 1 and ribosomal protein 
S9) and quantified using qBase (25). 
Micro-array experiments – The mouse cDNA 
microarrays used in this study consisted of roughly 
17,000 PCR products generated from cDNA 
clones and control DNAs spotted onto Nexterion 
AL slides (Schott). A complete description of the 
slides and their content can be obtained from the 
Lausanne DNA Array Facility 
(http://www.unil.ch/dafl). RNA quality was 
assessed using the RNA 6000 Nanochip assay 
(Agilent Technologies). A single round of 
amplification was performed with 3µg of total 
RNA using the MessageAmp aRNA Amplification 
Kit (Ambion) following the protocol provided. 5µg 
of amplified RNA was reverse transcribed with 
SuperScript II reverse transcriptase (Invitrogen) 
and random hexamers for 2 hours at 42°C, in the 
presence of either Cy3-dCTP or Cy5-dCTP (GE 
Healthcare). RNA was hydrolyzed by heating at 
65°C for 15 minutes in a basic environment. The 
solution was then neutralized and labeled cDNA 
was purified using a Qiagen MiniElute PCR 
Purification kit. The Cy3 and Cy5 labeled targets 
were combined, mixed with Cot 1 DNA 
(Invitrogen), polyadenylic acid (Sigma) and yeast 
tRNA (Sigma), and hybridized on custom glass 
microarrays at 64°C for 20h in 3X SSC / 0.4% 
SDS. Slides were then washed twice for 5 minutes 
in 2x SSC, 0.1% SDS, twice for 1 minute in 0.2x 
SSC, once for 1 minute in 0.1x SSC and once for 5 
minutes in 0.1x SSC, 0.1% Triton X-100. After 
drying, slides were scanned on a microarray 
scanner (Agilent Technologies) and the resulting 
TIFF images were analyzed using the GenePix Pro 
6.0 software (Molecular Devices). 
 Statistical analysis was performed with the R 
software packages sma (26) and limma (27) 
(http://www.r-project.org). Gene expression was 
quantified with the sma package using print tip 
group lowess normalization without background 
subtraction (26,28). The three treatments (V, 
Rosiglitazone and MEHP) were compared 
pairwise using a linear model. Differential 
expression was assessed by fitting the linear model 
for the effects of the two treatments considered and 
computing moderated t statistics and Benjamini 
and Hochberg false discovery rates with the limma 
package (27,29). 
Pull-down experiments - GST fusion proteins were 
expressed in Escherichia coli and purified on a 
glutathione affinity matrix (Pharmacia). mPPARγ 
was produced in vitro with reticulocyte lysates 
(Promega) and labeled with 35S-Methionine. 3µg 
of GST fusion proteins were then incubated with 
15µl of programmed reticulocyte lysate in 500µl 
of binding buffer (Tris-HCl pH7.4 25mM, EDTA 
1mM, NaCl 100mM, Triton X-100 0.1%, PMSF 
0.2mM, protease inhibitor cocktail (Roche)) 
supplemented with 0.5% dry milk, during 4 hours 
at 4°C, with either DMSO, 10µM Rosiglitazone or 
1000µM MEHP. Beads were washed 3 times with 
binding buffer and samples were boiled with 40 µl 
of 2X SDS-Page buffer (12,5mM Tris-HCl, 20% 
Glycerol, 0.002% Bromophenol Blue, 5% 
β-mercaptoethanol), separated on a 10% SDS-
PAGE gel, transferred onto a nitrocellulose 
membrane and exposed to a phosphoImager 
(Typhoon, Amersham). 
Chromatin immuno-precipitation (ChIP) 
experiments - After 10 days of treatment, cells 
were washed twice in PBS and cross-linked for 
10min at room temperature in 1% formaldehyde. 
Cross-linking was stopped by a 5min incubation in 
0.125M glycin and chromatin was subsequently 
extracted as previously described (30). Chromatin 
resuspended in 500 µl / 10cm cell culture dish was 
then sonicated on ice with a 24-channel multi-
sonicator (Sonics Vibra cell) set at 40% during 
120s in 5s sonication periods spaced by 10s. After 
centrifugation, sonicated supernatants from 10 
independent cultures performed were pooled in a 
final volume of 5ml and immunoprecipitations 
were performed in triplicate with 250 µl of 
sonicated lysate diluted 2.5-fold in IP buffer [2 
mM EDTA, 100 mM NaCl, 20 mM Tris-HCl (pH 
8.1), and 0.5%Triton X-100] after a 3 hr 
preclearing at 4°C with 5 µg sheared salmon sperm 
DNA, and 150 µl of a 50% protein A-Sepharose 
bead (Amersham Pharmacia Biosciences) slurry. 
Immunoprecipitations were performed overnight at 
4°C under rocking with 0.5 µg of anti-Pol II 
antibody (Upstate Biotechnology; Clone CTD4H8 
#05-623), 1 µg of anti-p300, anti-NCoR and anti-
PGC1 (Santa Cruz; #sc-584, #sc-1609, sc-13067, 
respectively) and 1.5 µg of anti-HA epitope, anti-
SRC1 and anti-TRAP220 (Santa Cruz; sc-805, #sc-
6096 or #sc-5335, respectively). Complexes were 
recovered after 3 hr incubation at 4°C with 2 µg of 
sheared salmon sperm DNA and 50 µl of protein 
A-Sepharose. Precipitates were then serially 
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washed, using 300 µl of Washing Buffers (WB), in 
combinations specific for each antibody: WBI [2 
mM EDTA, 20 mM Tris-HCl (pH 8.1), 0.1% SDS, 
1% Triton X-100, 150 mM NaCl], WB II [2 mM 
EDTA, 20 mM Tris-HCl (pH 8.1), 0.1% SDS, 1% 
Triton X-100, 500 mM or 250 mM NaCl], WB III 
[1 mM EDTA, 10 mM Tris-HCl (pH 8.1), 1% NP-
40, 1% Deoxycholate, 0.25 M LiCl] and then twice 
with 1 mM EDTA, 10 mM Tris-HCl (pH 8.1). 
Combinations were as follows: Pol II [WB I, WB II 
(500 mM NaCl), WB III]; CBP [WB I, WB II (500 
mM NaCl ), WB III x 2]; SRC1 [WB I, WB II (250 
mM NaCl) x 2]; TRAP220 [WB I, WB II (250 mM 
NaCl) x 2], NCoR [WB I, WB II (250 mM NaCl) x 
2]; and PGC1 [WB I, WB II (500 mM NaCl), WB 
III]. Precipitated complexes were removed from 
the beads through three sequential incubations of 
10 min with 50 µl of 1% SDS, 0.1 M NaHCO3. 
Cross-linking was reversed by an overnight 
incubation at 65°C. DNA was next purified with 
Qiaquick columns (Qiagen) and eluted in 10 µl 
H2O. 2 µl of Inputs and ChiP DNA were then 
assayed in real-time PCRs using a BioRad MyiQ 
apparatus and BioRad iQ SYBR Green supermix 
and 1 µM of primers (Proligo, France) indicated in 
Fig. S1. Results from three independent 
experiments were normalized to inputs using the 
∆/∆Ct method. 
FCS experiments - FCS was performed on a 
LSM510 ConfoCor2 (Zeiss) as previously 
described (8). Briefly, intensity fluctuations of the 
fluorescence collected between 505 and 550 nm, 
were detected using an avalanche photodiode and 
recorded at 5 spots in each nucleus, with a 
repetition of 10 measurements per spot. Using the 
Origin software, the autocorrelation curves were 
fitted to an anomalous diffusion model to derive 
diffusion times, which were subsequently 
converted to diffusion coefficients and averaged 
over at least 10 cells. 
FRET experiments - Sensitized-emission FRET 
was monitored at 37°C over at least 50 living cells 
using a TCS SP2 AOBS confocal microscope 
(Leica) as previously described (9,31). Briefly, 
fluorescence was recorded in three different 
settings: CFPex: 405 nm / CFPem: 465-485 nm; 
YFPex: 514 nm / YFPem: 525-545 nm; FRETex: 405 
nm / FRETem: 525-545 nm. Laser power and 
detector gain were adjusted in the different 
channels so that equimolar concentrations of CFP 
and YFP give equal intensities (equimolar 
concentrations of CFP and YFP were obtained by 
expressing a fusion protein of CFP and YFP 
spaced by 475 residues). Settings were kept 
unchanged for analysis of all samples. As the ratio 
of CFP spectral bleed-through into the FRET 
channel (SBTCFP=IFRET/ICFP) determined on cells 
expressing CFP alone has been previously 
observed to vary with CFP intensity, this variation 
was modeled using an exponential fit (31). In 
contrast, the ratio of YFP spectral bleed-through 
into the FRET channel (SBTYFP=IFRET/IYFP) 
determined on cells expressing YFP alone was a 
constant equal to the average ratio. FRET 
measured in co-expressing cells was then corrected 
for spectral bleed-throughs and normalized for 
expression levels according to the following 
formula (31): 
YFPCFP
YFPCFPCFP
I  I
b  I)gf  exp(I  (e  II
expNFRET ×
×−+×××−= )FRET
 where IFRET, ICFP and IYFP are the intensities 
measured with the FRET, CFP and YFP settings in 
the presence of both the donor and the acceptor, e, 
f and g are the constants determined by the fitting 
of the CFP SBT ratio in the presence of CFP only 
and b is the average YFP SBT ratio in the presence 
of YFP only. 
Structural modeling – Missing parameters for 
MEHP, for use in conjunction with the 
CHARMM22 (32) all atoms molecular mechanics 
force field, were derived from the Merck 
Molecular Force Field (MMFF (33)), by taking the 
dihedral angle term as is, but only the quadratic 
part of the bond and angle energy terms. The 
partial charges and van der Waals parameters of 
the ligand atoms were taken from the MMFF. The 
ligand was modeled with all hydrogens. 
To take account of a possible induced fit of the 
protein upon ligand complexation, the docking of 
MEHP to hPPARγ was realized based on two 
experimental X-ray structures of the hPPARγ LBD 
in complex with two different ligands. The first 
corresponds to the structure of the complex with 
the agonist AZ242 obtained at 2.35 Å resolution 
(code 1I7I (34) in the Protein DataBank (PDB; 
(35))). The second structure corresponds to the 
complex of hPPARγ with an alpha-
aryloxyphenylacetic acid partial agonist obtained 
at 2.5 Å resolution (code 1ZEO (36) in the PDB). 
The two structures differ in the conformation of 
residues Phe282 (H3), Gln286 (H3) and Phe363 
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(loop between H6 and H7). In 1ZEO, these 
residues - together with residues Ile281 (H3), 
Leu356 (H6), Phe360 (loop between H6 and H7), 
Leu453 (H11) and Leu465 (loop between H11 and 
H12) - form a hydrophobic pocket where the 
benzisoxazol group fits. This pocket is closed in 
the 1I7I structure due to an alternate positioning of 
Phe282, Gln286 and Phe363. Both ligands of the 
template complexes have a carboxylate function, 
like MEHP. They were removed from the binding 
site prior to MEHP docking.  
Four calculations were performed, corresponding 
to the docking of the R or S configurations of 
MEHP in the 1I7I or 1ZEO structures. The protein 
was held fixed in all cases, the protein flexibility 
being taken into account through the use of 
different experimental structures. The details of the 
calculations will be presented separately 
(Grosdidier et al., submitted). In brief, starting 
from a set of 250 randomly generated initial 
conformations, positions and orientations of 
MEHP inside the known binding site of hPPARγ, 
the coordinates of the ligand were refined using 
several operators, renewing 10% of the population 
at each generation. The thorough exploration of the 
accessible conformational space of the ligand 
relative to the protein surface was submitted 
during 400 generations to the evolutionary 
pressure of a scoring function that takes account of 
the solvent effect thanks to the GB-MV2 implicit 
solvent model (37). The lowest energy 
conformation was retained as the proposed binding 
mode. The accessible conformational space was 
defined as a 15 Å radius sphere centered on the 
center of mass of the AZ242 ligand. This region is 
large enough to explore possible pauses on the 
protein surface, out of the binding site. Actually, it 
has been observed that the pauses proposed by 
EADock for bad ligands are situated out of the 
known binding site of the targeted protein (data not 
shown). In all models of MEHP binding to PPARγ, 
the energetically most favorable calculated binding 
mode is situated inside the known binding site of 
the protein, consistent with the ability of MEHP to 
transactivate PPARγ. 
Statistical analyses – Data are represented as 
average +/- standard error of the mean. Statistical 
significance was determined using an ANOVA 
analysis followed by Tukey's post hoc test. 
 
RESULTS 
MEHP is a partial PPARγ agonist whose efficacy 
varies according to the cell type 
 MEHP was previously reported to activate 
PPARs in transactivation assays (19-21). However, 
the levels of activation varied between studies, 
possibly because of the use of different cell types, 
different reporter systems and of receptors from 
different species. In order to characterize the action 
of this phthalate monoester on full-length PPARs, 
we assessed the ability of MEHP to induce the 
transcription of a reporter construct containing 3 
PPREs upstream of the luciferase cDNA in the 
presence of the different PPAR isotypes. MEHP 
could activate mouse PPARα, PPARβ and 
PPARγ1, albeit to a generally lower extent than the 
reference agonists (Fig. 1A). PPAR activation was 
detected with doses as low as 3.2 µM and reached 
maximum levels at 100 µM. Maximal activation of 
PPAR by MEHP was approximately half of that 
achieved with Wy14643 and Rosiglitazone for 
PPARα and PPARγ, respectively, whereas the 
maximal levels of PPARβ activation achieved with 
MEHP and L165041 were comparable. Altogether, 
these experiments demonstrate that MEHP is a 
partial pan-PPAR agonist with reduced affinity and 
efficacy compared to full agonists. We decided to 
focus this study on the activation of PPARγ by 
MEHP and therefore evaluated potential species 
and isoform differences. Both the mouse and 
human PPARγ1 receptors where activated with 
similar affinity and efficacy in C2C12 cells 
(Fig. 1B). The additional 30 N-terminal residues of 
the PPARγ2 isoform only mildly affected the 
ability of MEHP to activate the receptor by slightly 
increasing the maximal level of activation without 
affecting affinity (Fig. 1C). Surprisingly, the 
ability of MEHP to activate PPARγ was cell type 
dependent (Fig. 1D). While the affinity of the 
compound for PPARγ was comparable in the three 
cell lines tested (EC50 around 30 µM), the efficacy 
of MEHP relative to the reference agonist clearly 
differed between cell lines, the high dose reaching 
80% of Rosiglitazone activation level in C2C12 
cells, but only 60% in Cos7 cells and 35% in HeLa 
cells. Altogether, these experiments 
demonstrate that MEHP is a partial pan-PPAR 
agonist with reduced affinity and efficacy 
compared to full agonists. 
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In order to characterize whether differences 
in binding mode could potentially account for the 
differences in PPARγ activation by MEHP and 
Rosiglitazone, we modeled the binding of MEHP 
to two reference structures (1I7I, (34); 1ZEO, (36)) 
of the PPARγ ligand binding pocket (LBD) and 
compared it to the binding of Rosiglitazone 
available from the crystal structure of the PPARγ 
LBD in complex with this agonist (38). The results 
obtained for the docking of MEHP in the 1I7I and 
1ZEO structures of hPPARγ are very similar and 
both the R- and the S-enantiomer of MEHP could 
fit in the PPARγ LBD (data not shown). Although 
explored by the ligand during the docking process, 
the additional pocket of 1ZEO was not used in the 
proposed binding mode (material and methods). 
MEHP contacted S289, H323, H367 and Y473 
(Fig. 2A), a set of residues important for the 
stabilization of the interaction between 
Rosiglitazone and the receptor ((38); Fig. 2B). 
Furthermore, the contact between the carboxylate 
function of the phtalic acid ring and Y473, a 
residue from helix 12 important for transcriptional 
activation, suggests that the activity of MEHP 
relies on the stabilization of helix 12. This 
observation supports the absence of activity of the 
DEHP parent compound (39) where this 
carboxylate is esterified by a bulky and 
hydrophobic chain. MEHP and Rosiglitazone bind 
to the PPARγ LBD in similar configurations where 
only one side of the T-shaped binding pocket is 
occupied and where similar residues are contacted. 
Thus, the difference in affinity and in efficacy 
between MEHP and Rosiglitazone most likely 
reflect subtle variations in differences in the 
binding mode which may lead to less productive 
conformational changes upon MEHP binding. 
However, the full-characterization of the 
differential changes in the three-dimensional 
structure of the LBD would require the 
crystallization of the PPARγ LBD in complex with 
MEHP. 
Selective recruitment of coregulators by MEHP 
 Coregulator recruitment is the major 
functional determinant which follows 
conformational changes of the nuclear receptor 
LBD in response to ligand binding. We thus 
compared how MEHP and Rosiglitazone modulate 
interactions with corepressors and coactivators, 
which assist PPARγ to regulate transcription. This 
experiment is classically assayed in vitro. 
However, many other factors in the nucleus of the 
living cell may also affect protein-protein 
interactions. Fluorescence correlation spectroscopy 
(FCS) is a technique measuring the diffusion of 
fluorescent molecules at high temporal resolution 
that can be used in the living cell. Using this 
technique, we previously showed that YFP-PPAR 
mobility in cells is reduced by ligand binding (8). 
Since this reduction in mobility is caused by the 
formation of large complexes through coactivator 
recruitment (9), we hypothesized that a selective 
recruitment of coactivators in response to MEHP 
compared to Rosiglitazone binding could 
potentially translate into different patterns of YFP-
PPARγ mobility. We thus compared YFP-PPARγ 
diffusion coefficients by FCS in COS7 cells in the 
presence and absence of Rosiglitazone and MEHP. 
Diffusion coefficients were indeed reduced from 8 
to 6.5 µm2/s in response to MEHP whereas they 
were further reduced to 5 µm2/s by Rosiglitazone 
(Fig. 3A). The sizes of PPARγ/coactivator 
complexes formed by MEHP binding, which are 
directly evaluated in living cells using this assay, 
are therefore smaller than those formed in response 
to Rosiglitazone and reflect different complex 
compositions. 
To identify the regulators recruited by 
Rosiglitazone and MEHP, we analyzed their 
respective ability to trigger corepressor release and 
coactivator recruitment. Interactions with 
individual coregulators were assessed in the native 
context of a living cell using fluorescence 
resonance energy transfer (FRET) imaging. The 
levels of energy transfer, which reflect direct 
interactions, were measured in living cells co-
transfected with CFP-tagged PPARγ and large 
coregulator domains tagged with YFP. 
Transfection conditions were optimized to ensure 
low and equimolar expression levels and the 
analyses were restricted to cells without aberrant 
localization seen upon high levels of expression 
(8). The strong interaction between PPARγ and 
NCoR observed in the absence of ligand was 
totally abolished in the presence of Rosiglitazone 
but MEHP had only a partial effect on this 
interaction (Fig. 3B). Using a similar assay, a basal 
interaction was detected between PPARγ and p300 
and the Med1 subunit of the mediator complex 
(also called TRAP220, DRIP205 and PBP) in the 
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absence of ligand (Fig. 3C-D). Rosiglitazone 
significantly enhanced the interaction with p300 
and Med1, while MEHP promoted the recruitment 
of Med1 but was totally inefficient in inducing the 
recruitment of p300. MEHP therefore selectively 
regulates interactions with coregulators in living 
cells both at the level of transcriptional complex 
size and of interactions with individual 
corepressors and coactivators. 
The interaction with PGC1α could not be 
evaluated by FRET as this construct gave no FRET 
signal with PPARγ, most probably because of 
inappropriate fluorophore spacing and orientation. 
We therefore confirmed our live-cell results and 
extended them to other coregulators using an in 
vitro pull-down assay where GST tagged 
coregulators were immobilized on beads and 35S-
mPPARγ1 recruitment was evaluated (Fig. 4A). In 
this assay, the binding of SRC-1 to PPARγ was 
very weak and was not influenced by ligand 
binding but consistent with our FRET assays, 
MEHP induced only a partial release of NCoR, 
and a strong recruitment of Med1, but not of p300. 
The PPARγ coactivator 1 α (PGC-1α) strongly 
interacted with PPARγ in the absence of ligand 
and this interaction was modestly enhanced by 
rosiglitazone but strongly enhanced by MEHP. We 
also took advantage of this in vitro assay to assess 
species- and isoform-specific effects in coregulator 
recruitment in response to MEHP. The profile of 
coregulator recruitment to human PPARγ1 and to 
the PPARγ2 isoform in response to MEHP was 
very similar to that observed with mouse PPARγ1 
(Fig. 4B).  
Altogether, these experiments demonstrate 
that when compared to the action of the full 
agonist rosiglitazone, MEHP induces a selective 
recruitment of PPARγ coregulators with stronger 
interactions with PGC-1α but a lack of p300 
recruitment. 
Selective recruitment of coregulators by DNA-
bound PPARγ in the presence of MEHP  
 FCS and FRET analyses cannot specifically 
assess the property of the complexes bound to 
DNA. We thus needed to establish whether the 
selective interactions in the nucleus of living cells 
also translate into selective recruitment of 
coregulators by DNA-bound PPARγ-containing 
complexes. Using specific antibody against each of 
the coregulators, we performed chromatin 
immunoprecipitation (ChIP) and assessed PPARγ 
target promoter occupancy, in the presence of 
either Rosiglitazone or MEHP (Fig 5). The 
promoter of the ribosomal protein P0 was used as a 
reference gene, not regulated by PPARγ, and 
precipitation with the unrelated HA antibody 
served as a negative control. A control experiment 
using a PPARγ antibody could not be reliably 
realized, likely due to the poor quality of the 
various antibodies tested (data not shown). As 
previously described, in the absence of PPARγ 
ligand, NCoR was associated with the glycerol 
kinase (GyK) and oxidized LDL receptor 1 
(OLR1) promoters, but not with the fatty acid 
binding protein 4 (FABP-4) / aP2 promoter, and 
this association disappeared with Rosiglitazone 
treatment (10,40). Consistent with our FRET and 
pull-down observations, MEHP induced a partial 
clearance of NCoR from these two PPARγ target 
promoters. The recruitment of coactivators is also 
consistent with our observation in the living cells. 
Unlike Rosiglitazone, MEHP did not promote the 
recruitment of p300 or SRC-1 on target promoters. 
However, it induced a recruitment of Med1 to 
slightly lower levels than those achieved by 
Rosiglitazone but a recruitment of PGC-1α at 
much higher levels.  
 Thus, the global pattern of promoter-specific 
and ligand-dependent co-regulator recruitment 
strikingly correlates with the interaction assays. 
MEHP promotes adipocyte differentiation through 
PPARγ 
 To investigate the action of MEHP on 
PPARγ regulated pathways at the cellular level, we 
studied the influence of MEHP on adipogenesis, a 
well-characterized PPARγ regulated function. As 
expected, a 10-day treatment of 3T3L1 pre-
adipocytes with the full PPARγ agonist 
Rosiglitazone in the presence of insulin strongly 
induced adipogenesis in a dose-dependent manner, 
as evidenced by Oil Red O staining at low 
(Fig. 6A) and high magnification (Fig. 6B). While 
insulin alone had only mild effects, the 
combination of insulin and MEHP also induced 
dose-dependent adipogenic effects whereas the 
DEHP parent compound was inefficient in 
inducing adipocyte differentiation. The ability of 
MEHP to promote adipogenesis appeared at a dose 
of 10 µM and was maximal at 100 µM, with no 
further enhancement at higher doses (data not 
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shown). However, the maximal effect induced by 
MEHP was lower than that induced by 
Rosiglitazone. The actions of both ligands on 
adipocyte differentiation were confirmed by 
quantification of cellular triglyceride contents 
which were strongly induced by Rosiglitazone but 
only partially induced by MEHP (Fig. 6C). Thus, 
although MEHP significantly induces adipocyte 
differentiation, this phthalate monoester has a 
reduced adipogenic potential compared to 
Rosiglitazone, most likely related to the selective 
modulation of its activity through differential 
coregulator recruitment. 
 To address whether the actions of MEHP on 
adipogenesis require PPARγ, we inhibited PPARγ 
either by antagonist treatment or by generating a 
3T3L1 cell line stably expressing an anti-PPARγ 
siRNA through lentiviral infection. Treatment with 
an excess of the GW9662 antagonist partially but 
significantly inhibited the adipogenic actions of 
MEHP and Rosiglitazone (Fig. 6D). Consistently, 
the effects of both compounds on adipocyte 
differentiation were significantly reduced in 
PPARγ siRNA cells whereas cells infected with a 
virus containing the empty pLVTH vector 
underwent similar differentiation as WT cells 
(Fig. 6E).  
MEHP induces selective transcriptional 
regulations during adipocyte differentiation 
 In order to characterize the differences in the 
adipogenic actions of MEHP and Rosiglitazone 
and the underlying molecular pathways, we 
performed gene expression array analyses on glass 
slides spotted at custom with a collection of 17,000 
mouse cDNAs. Expression levels from 
undifferentiated cells treated with insulin only and 
from cells differentiated with Rosiglitazone or 
MEHP in the presence of insulin were compared 
using a linear model allowing direct comparisons 
between the three conditions. The vast majority of 
the genes regulated by MEHP were also regulated 
by Rosiglitazone (Fig. 7A), again indicating that 
the adipogenic actions of MEHP are mediated by 
PPARγ. Consistent with their ability to promote 
adipocyte differentiation, both compounds had 
strong effects on genes implicated in metabolism 
and cell cycle according to gene ontology analyses 
(Fig. 7B). The metabolic genes regulated by 
Rosiglitazone and MEHP affected both catabolic 
and anabolic pathways (Table I). Several genes 
implicated in glucose uptake, glycolysis, β-
oxidation, citrate cycle and oxidative 
phosphorylation were upregulated, likely 
providing the cells with high energetic levels in 
order to fulfill anabolic functions. The treatments 
with MEHP and Rosiglitazone also induced genes 
required for the structure of lipid droplets (aP2 and 
ADRP) and the function of mature adipocytes 
(lipogenesis, triglyceride synthesis and 
adipokines). Interestingly, we also observed an 
upregulation of enzymes from the pentose 
phosphate pathway and from some intermediate 
steps of neoglucogenesis, which can potentially 
increase NADPH levels subsequently utilized for 
lipogenesis. 
 MEHP specifically regulated only a very 
low number of genes which could not be assigned 
to characterized adipocyte differentiation 
pathways. In contrast, Rosiglitazone had a broader 
action than MEHP since around 30% of the genes 
were specifically regulated by this full agonist 
(Fig. 7A). Thus, MEHP potentially acts as a 
selective PPAR modulator regulating only a subset 
of PPARγ target genes compared to a full agonist. 
This target gene specificity could potentially 
translate into selective functional actions. 
However, genes specifically regulated by 
Rosiglitazone were distributed within various 
pathways with no particular enrichment in a 
specific function (Fig. 7B and Table I). This 
observation precludes concluding on the respective 
selective biological functions of Rosiglitazone and 
MEHP. The physiological selectivity, if any, may 
therefore rather arise from a differential regulation 
of rate-limiting enzymes or of crucial proteins 
rather than an entire pathway. 
 In order to validate the concept of a selective 
modulation of PPARγ targets by MEHP, we 
analyzed the expression of well-described PPARγ 
target genes by qRT-PCR (Fig. 8 and table II). 
When differentiation was induced with 
Rosiglitazone, most genes were up-regulated, from 
around 2 fold for PPARγ itself up to 400 fold for 
OLR1 (Fig. 8B) whereas the expression of some 
described PPARγ targets remained unaffected 
(Table II). When MEHP was used as a PPARγ 
ligand, 8 out of 10 genes were similarly induced 
(PPARγ, FABP-4 / aP2, adiponectin (AdipoQ), 
CD36, Acyl-CoA Synthetase 1 (ACS-1), 
lipoprotein lipase (LPL), C/EBPα, and liver X 
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receptor α (LXRα)), whereas GyK and OLR1 
were significantly less induced, indicating that the 
efficacy of gene induction by MEHP depends on 
the promoter context. In addition, we confirmed 
new potential PPARγ targets from the microarray 
results by showing that expression of the lipogenic 
enzyme AcetylCoA Carboxylase β (ACCβ) is 
induced both by MEHP and rosiglitazone while 
that of Acyl-CoA Synthetase Bubblegum 1 
(ACSBG1) is induced to higher levels with 
Rosiglitazone than with MEHP. 
 In the experiment described above, PPAR 
ligands were added all along the differentiation 
process. Since the activity of PPARγ is 
intrinsically linked to adipocyte differentiation, it 
is therefore difficult to uncouple the direct 
induction of PPARγ target genes from their 
indirect activation via the global network of 
transcription factors controlling the adipogenic 
program. We hence performed the same gene 
expression analyses with 3T3L1 cells treated for 
48h with Rosiglitazone or MEHP, either before 
differentiation or after differentiation with a 
classical adipogenic cocktail, as described in the 
Material and Methods section (Fig 8A & C). 
Interestingly, the relative efficacy of MEHP 
compared to Rosiglitazone varied between 
promoters and, for a given promoter, was different 
between the three differentiation status (non-
differentiated, differentiated with a PPAR ligand 
or differentiated with a classical cocktail). When 
treatments were performed in differentiated 
adipocytes, target gene induction was globally 
reduced or alleviated (Fig. 8C), presumably 
because the expression of these genes was already 
high in differentiated cells. Nevertheless, genes 
such as GyK, OLR1, ACSBG1 and FABP-4 that 
could still be further induced, maintained an 
activation profile whose selectivity was similar to 
that obtained with treatments during 
differentiation. In contrast, FABP-4 and AdipoQ 
which were strongly activated to equal levels both 
by MEHP and Rosiglitazone in cells treated during 
differentiation, only responded to Rosiglitazone in 
non-differentiated cells (Fig. 8A).  
 Altogether, these results demonstrate that in 
the same cellular context, MEHP exerts a selective 
action on different PPARγ target genes which 
varies according to the differentiation status of the 
cell. Two different classes of genes must be 
distinguished. The first group includes genes such 
as GyK, OLR1 and ACSBG1 on which MEHP 
exerts a lower activity than rosiglitazone, 
independently of the differentiation status of the 
cell. A second group is exemplified by FABP-4 
and AdipoQ, which equally respond to MEHP and 
Rosiglitazone during differentiation but are 
principally induced by Rosiglitazone in 
undifferentiated cells.  
DISCUSSION  
MEHP induces adipogenesis by activating PPARγ 
 The activation of PPARγ by the phthalate 
monoester MEHP, a metabolite of the industrial 
pollutant DEHP, has been previously reported 
(20,21). However, these experiments, conducted in 
a toxicological perspective, did not address the 
molecular mechanisms of action as well as the 
physiological consequences of such an activation. 
We demonstrated herein that MEHP-dependent 
PPARγ activation promotes adipocyte 
differentiation while DEHP has no effect. Several 
lines of evidence suggest that the adipogenic 
properties of MEHP are mediated by PPARγ. First, 
MEHP concentrations required for minimal and 
maximal induction of adipogenesis parallel those 
required for PPARγ activation in transactivation 
assays. Second, the adipogenic actions of MEHP 
are reduced by knocking-down PPARγ or by 
inhibiting its activity with an antagonist, although 
the intricate link between PPARγ and adipogenesis 
does not totally rule out the possibility of a 
concomitant action of MEHP downstream of 
PPARγ. Third, when analyzed on a genome-wide 
basis, the majority of the genes regulated by 
MEHP during adipogenesis are also regulated by 
the full PPARγ agonist Rosiglitazone. Finally, 
MEHP can induce the expression of some PPARγ 
target genes important for adipocyte 
differentiation. Nevertheless, this compound 
differs from TZDs by reduced affinity and efficacy 
and by eliciting a partial adipogenic response 
compared to Rosiglitazone. 
MEHP selectively regulates PPARγ activity during 
adipogenesis 
 Modelisation of MEHP within the PPARγ 
LBD revealed a configuration very similar to 
Rosiglitazone. However, the conformational 
changes induced by both ligands or their ability to 
stabilize helix 12 in an active configuration are 
most likely different since MEHP promotes 
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interactions with only a subset of PPARγ 
coregulators. Indeed, using three independent 
tools, i.e. in vitro, in living cells and on PPARγ 
target promoters, we demonstrated that MEHP 
only partially induces corepressor release and 
promotes the recruitment of the coactivators Med1 
and PGC-1α but not of p300 and SRC-1. In 
addition, other coregulators may be selectively 
recruited by MEHP and Rosiglitazone. This is 
indeed reflected by the partial reduction of PPARγ 
mobility upon MEHP treatment in living cells 
where a full set of coactivators is present and 
where the reduction of PPAR mobility upon 
ligand-binding is governed by the engagement in 
large complexes of coregulators (8,9). 
 This selective recruitment of coregulators 
translates into a partial adipogenic program where 
only a subset of genes is regulated by MEHP 
compared to Rosiglitazone. The partial release of 
NCoR in response to MEHP seems sufficient to 
alleviate the inhibitory effects of this corepressor 
on most PPARγ targets in order to promote 
adipogenesis (41). Indeed, genes important for 
adipocyte differentiation (FABP-4, adiponectin, 
ACS and LPL among others) are fully induced. In 
contrast, other direct PPARγ targets such as GyK, 
OLR1 and ACSBG1 are only partially activated by 
MEHP. Interestingly, GyK and OLR1 are 
specifically silenced by corepressors during 
adipogenesis and require an exogenous PPARγ 
ligand for activation ((10,40) and Fig. 5). Thus, the 
low levels of PPARγ/NCoR interaction remaining 
upon MEHP binding could limit the maximal 
activation level of such genes. In contrast, genes 
such as FABP-4 whose promoter is never 
associated with corepressors are insensitive to the 
limited action of MEHP on corepressor release, 
thereby potentially explaining why such genes are 
equally activated by MEHP and Rosiglitazone. 
AdipoQ is also activated by MEHP and 
Rosiglitazone with equal efficacy. Amazingly, the 
persistence of NCoR on the AdipoQ promoter in 
the presence of MEHP, as well as in the presence 
of Rosiglitazone albeit to a lower level, has to be 
compensated by stronger levels of coactivator 
recruitment such as those observed on this 
promoter for PGC-1α. Τhe selective recruitment of 
coactivators may also play a role in the differential 
induction of target genes. Although we have not 
observed major promoter-specific differences in 
the association of the coactivators tested here, it is 
possible that subtle differences between promoters 
may explain differences in gene expression. In 
addition, the reduced adipogenic potential of 
MEHP compared to Rosiglitazone could also be 
linked to a reduced efficacy in the recruitment of 
some coactivators. Indeed, both in live cell FRET 
assay and in ChIP experiments, MEHP induced 
only a partial recruitment of Med1, a coactivator 
required for efficient adipocyte differentiation 
(42). 
Distinguishing selective PPARγ modulation from 
partial PPARγ activation 
 Using MEHP as a model, this study 
demonstrates the molecular basis of selective 
PPAR modulation and clearly establishes the 
difference between selective PPAR modulators 
and partial PPARγ agonists. SPPARMs are usually 
characterized by their molecular properties, i.e. the 
ability to induce selective coregulator recruitment 
(14). This is then related to a physiological output 
where a restricted PPARγ action is established. 
Between these two steps, the nature of the target 
gene regulation is however often under-evaluated. 
Indeed, when compared to full agonists, 
SPPARMs differ from partial agonists as they 
promote selective gene regulation by differentially 
affecting target gene transcription in a gene-
specific manner, with some genes induced to 
similar levels than those obtained with a full 
agonist while others exhibit restricted activation. 
In contrast, partial agonists exhibit a global 
decrease in the activation of all target genes. Thus, 
a bona fide SPPARM should induce 
conformational changes different than full-agonists 
that translate into selectivity in terms of 
coregulator interactions, target gene induction and 
ultimately physiological effects. At the molecular 
level, MEHP fulfills these conditions as the 
differential recruitment of coregulators translates 
into a restricted profile of gene regulation.  
 Our results also point to the importance of 
the cellular context regarding coregulator 
equipment, illustrated by the differences of PPARγ 
transactivation by MEHP according to the cell line 
analyzed. In addition, gene expression analyses on 
3T3L1 cells treated with PPARγ agonists before, 
during or after differentiation, suggest that both the 
level and the selectivity of target gene induction 
rely on the expression of distinct sets of 
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coregulators. Thus, PPARγ agonists may exert 
different effects on subpopulations of adipocytes 
and their progenitors in the adipose tissue, an 
aspect that should be taken into consideration in 
pharmacological strategies aimed at finding 
PPARγ modulators acting on adipocyte 
physiology.  
 The identification of SPPARMs which favor 
the beneficial pharmacological actions of TZDs 
over their adverse effects is a major challenge for 
pharmaceutical research on type 2 diabetes 
(13,43), for which some candidate compounds are 
starting to emerge (44-48). FK614 is a SPPARM 
causing impaired recruitment of CBP but retaining 
beneficial effects on insulin sensitivity in 
hyperglycemic mouse models (46,49,50). The 
inability of MEHP to promote interactions between 
PPARγ and p300, a coactivator highly homologous 
to CBP, and enhanced recruitment of PGC-1α 
would both potentially be compatible with a 
positive action of MEHP on insulin sensitivity 
(45,50). However, a metabolic study of phthalate 
exposure in animal models is required to 
understand how the molecular and cellular effects 
described herein potentially translate into the 
selective regulation of the physiological functions 
regulated by PPARγ. Whereas mice and rats are 
the models most often used for this type of 
metabolic studies, the occurrence of sustained 
hepatic peroxisome proliferation mediated by 
PPARα, which does not occur in humans, is likely 
to affect the final metabolic phenotype of these 
animals, and alternate models might have to be 
considered. 
MEHP is a potential metabolic disruptor. 
 Our results on the adipogenic action of 
MEHP strongly argue that in addition to an action 
on hepatic carcinogenesis through PPARα-
mediated peroxisome proliferation (51), the 
endocrine disrupting actions of DEHP through its 
MEHP metabolite should also be considered with 
respect to the development of obesity and 
associated metabolic disorders. We have observed 
that human PPARγ can be activated with similar 
affinities and efficacies than the mouse isotype, but 
we failed to detect the subtle differences in affinity 
described by other reports which may therefore be 
linked to the cellular context (20,21). In addition, 
MEHP induces the same pattern of coregulator 
recruitment with the mouse and human receptors, 
suggesting that the effects of MEHP on 
adipogenesis studied here in the context of the 
mouse receptor may translate into similar effects in 
humans if MEHP reaches the adipose tissue in 
sufficient concentration. Although the human 
exposure to DEHP is ubiquitous through daily 
products, plasmatic levels of both DEHP and 
MEHP generally remain low because of rapid 
urinary excretion (17). However, individuals 
requiring frequent blood transfusion or dialysis are 
subjected to repetitive acute exposures to high 
levels of DEHP because of the leaching of the 
compound from plastic bags and tubings in direct 
contact with biological fluids. Under such 
circumstances, the plasmatic levels of DEHP and 
MEHP can reach 50 µM in humans (17), a 
concentration at which we already observed strong 
although not maximal induction of adipogenesis. 
Although the concentration of MEHP in 
adipocytes is difficult to assess, DEHP is lipophilic 
and can accumulate in adipose tissue (52,53). 
Despite the absence of data available to our 
knowledge on MEHP accumulation in the adipose 
tissue or on the adipose tissue expression of lipases 
that metabolize DEHP into MEHP, our data 
combined to these observations urge the need to 
consider the actions of DEHP and MEHP in the 
patho-physiology of this tissue. Together with 
reports showing that other pollutants including 
different phthalate esters and organotins can also 
target PPARγ and promote adipogenesis in cellular 
models (20,21,54,55) and in vivo (56), our study 
suggests that the metabolic functions of PPARγ 
can be targeted by a sub-class of endocrine 
disruptors that we propose to define as metabolic 
disruptors. 
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LEGENDS TO TABLES AND FIGURES 
 
Table I: The metabolic actions of MEHP and Rosiglitazone during 3T3L1 differentiation. The table 
represents the fold induction of significantly regulated metabolic genes from the microarray analysis 
described in Fig. 3. Genes that are regulated by Rosiglitazone only are in red and genes regulated by both 
ligands with a statistically higher effect with Rosiglitazone are in green.  
 
Table II: MEHP selectively induces PPARγ target genes in a differentiation-dependent manner. The 
results from Fig. 4 are presented as fold inductions over vehicle treatment and extended to additional genes. 
  
Table SI: List of the Taqman probes used in this study.  
 
Figure 1: MEHP activates PPARs in transactivation assays. (A) C2C12 cells grown in 12-well plates 
were transfected with a PPRE-firefly luciferase reporter construct (600 ng/well), a normalization vector 
encoding renilla luciferase (5 ng/well) and an expression vector, either empty or coding for mouse PPARα, 
PPARβ or PPARγ1 (250 ng/well). After transfection, cells were treated with DMSO (1‰) or the indicated 
ligands for 18 hours (10µM Wy14,643, 5µM L-165041, 1µM Rosiglitazone and 1 / 3.2 / 10 / 32 / 100 and 
200µM MEHP). Firefly luciferase activity of 4 biological replicates was normalized to the corresponding 
renilla luciferase activity. Similar transactivation assays were then performed as in A with mouse or human 
PPARγ1 in C2C12 cells (B) and with human PPARγ1 or PPARγ2 in C2C12 cells (C) and with mouse 
PPARγ1 in different cell types (D). 
  
Figure 2: MEHP and Rosiglitazone bind similarly to the PPARγ ligand binding domain. The binding 
of the R enantiomer of MEHP to the human PPARγ LBD (structure 1I7I) was modeled as described in the 
material and methods section (A) and compared to the reported structure of the hPPARγ LBD complex with 
Rosiglitazone (B). Left panels represent interactions with key residues of the LBD. Middle panels describe 
the positioning in the LBD cavity where asterisks represent the two parts of the T-shaped ligand binding 
pocket. The right panels show the position of the ligand in the secondary structure of the receptor. Helixes 
contacting the ligand are colored as follows: H3, green; H5, orange; H11, red and H12, blue. Hydrogen 
atoms were included in the modeling of the binding mode of MEHP but these atoms were removed from the 
representation for clarity since Rosiglitazone hydrogens are not present in the structure from the database. 
 
Figure 3: MEHP induces selective interactions between PPARγ and coregulators in living cells. (A) 
Fluorescence Correlation Spectroscopy (FCS) assays in living cells. The diffusion of YFP-PPARγ was 
measured by FCS in living Cos-7 cells expressing very low levels of the fusion protein. Diffusion 
coefficients were calculated from diffusion times extracted by fitting autocorrelation curves to a model of 
anomalous diffusion. (B-D) Fluorescence Resonance Energy Transfer (FRET) assays in living cells. 
FRET was measured in living Cos-7 cells expressing equimolar amounts of PPARγ-CFP and YFP-
NCoR2235-2301 (B), YFP-p3001-595 (C) or YFP-Med1550-716 (D). The concentrations of Rosiglitazone and 
MEHP were 1 and 100 µM, respectively. * and ** indicate p-values smaller than 0.05 and 0.01 
respectively, according to an analysis of variance (ANOVA) followed by Tukey's post hoc test. 
. 
 
Figure 4: MEHP induces selective interactions between PPARγ and coregulators in vitro. (A) The 
recruitment of 35S-mPPARγ1 to GST-labeled corepressor or coactivators immobilized on sepharose beads 
was quantified by phosphoimager and values plotted as ratios to the values for vehicle (corepressor) or 
Med1+Rosi (coactivators). (B) GST pull-downs were performed as in (A) with 35S-hPPARγ1, 35S-
mPPARγ1and 35S-hPPARγ2 to compare species- and isoform-specific effects. The second band observed 
for PPARγ2 likely results from the use of the alternate PPARγ1 start codon during in vitro translation. 
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Figure 5: MEHP induces the selective recruitment of coregulators on PPARγ target promoters. 
3T3L1 cells, treated for 10 days with a combination of 10 µg/ml insulin and vehicle (DMSO 1‰), 
Rosiglitazone or MEHP at the indicated concentrations, were cross-linked and subjected to chromatin 
immuno-precipitation as described in the Material and Methods section. The DNA fragments immuno-
precipitated in 3 independent IPs by specific antibodies against coregulators or a control HA antibody were 
analyzed by qRT-PCR. 
 
Figure 6: MEHP induces adipogenesis through PPARγ. 2-day post-confluent 3T3L1 cells were treated 
for 10 days without insulin or with 10 µg/ml insulin with vehicle (V; DMSO 1‰), or the ligands at the 
indicated concentrations. After Oil Red O staining, the entire wells (A) or representative zones (B) were 
imaged. Triglyceride content was determined in cell lysates by colorimetric assay (500nm) and normalized 
to the total quantity of protein measured by a Bradford assay (595nm) (C). The same treatments were 
applied to WT cells in the presence of the PPARγ antagonist GW9662 (D) and to 3T3L1 cells stably 
expressing an empty vector or a vector encoding an siRNA against PPARγ (E). 
 
Figure 7: MEHP regulates only a subset of genes compared to Rosiglitazone. RNA from 2-day post-
confluent 3T3L1 cells treated for 10 days with 10 µg/ml insulin in combination with vehicle (V; DMSO 
1‰), 1 µM Rosiglitazone or 100 µM MEHP was subjected to a custom micro-array as described in the 
Material and Methods section. Genes were considered to be significantly regulated when the p-value was 
lower than 0.05 and the fold change was above 2. The regulation by Rosiglitazone and MEHP compared to 
the untreated control are summarized as Venn diagrams (A) and the significant gene ontology classes are 
represented for each condition (B). 
 
Figure 8: MEHP selectively induces PPARγ target genes in a differentiation-dependent manner. 
3T3L1 cells were treated with a combination of 10 µg/ml insulin and vehicle (V; DMSO 1‰), 
Rosiglitazone or MEHP at the indicated concentrations. The treatments were performed for 48h in growing 
non-differentiated cells (A), for 10 days in 2-day post confluent cells (B) and for 48h in cells initially 
differentiated during 10 days with an adipogenic cocktail devoid of PPARγ ligand as described in the 
Material and Methods section (C). Gene expression levels relative to three house-keeping genes were 
quantified by Taqman qRT-PCR. Abbreviations are: Gyk: glycerol kinase; OLR1: oxidized LDL receptor 1; 
FABP: fatty acid binding protein; AdipoQ: adiponectin; ACS: AcylCoA Synthetase; LPL: lipoprotein 
lipase. 
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Feige et al - Table I
Lipid metabolism Rosi vs V MEHP vs V
β-oxidation: (fold change) (fold change)
Acyl-CoA dehydrogenase, C-2 to C-3 short chain 3.5 2.8
Acyl-CoA déhydrogénase, medium chain fatty acid 2.9 2.4
Acyl-CoA dehydrogenase, long chain 3.0 3.1
Acyl-CoA dehydrogenase, very long chain 3.8 3.4
Carnitine palmitoyltransferase 1B 4.9 6.7
Carnitine palmitoyltransferase 2 2.9 3.4
Enoyl-CoA hydratase 1, peroxisomal 2.3 -
Enoyl Coenzyme A hydratase, short chain, 1, mitochondrial 2.2 2.3
Acyl-CoA oxidase 1 6.7 5.3
Acyl-CoA synthetase long-chain family member 1 10.0 9.2
Acyl-CoA synthetase long-chain family member 4 3.1 3.0
Acyl-CoA synthetase bubblegum family member 1 7.5 3.5
HADHA 3.9 3.4
Acetyl-CoA acetyltransferase 2 2.7 2.6
Lipogenesis
Acetyl-Coenzyme A carboxylase beta 6.1 5.6
Fatty acid synthase 2.1 2.4
Triglyceride synthesis
Glycerol-3-Phosphate-dehydrogenase 7.1 5.1
Glycerol Kinase 5.8 3.8
Phosphatidate phosphatase 2B -2.2 -2.5
Diacylglycerol O-acyltransferase homolog 1 5.1 3.7
Diacylglycerol O-acyltransferase homolog 2 2.7 2.8
Hydroxyacyl-CoA dehydrogenase 2.5 2.1
Adipokines and adipokine signaling:
Adipsin 2.1 -
Adiponectin 6.5 5.5
Adiponectin receptor 2 8.2 6.2
Visfatin (PBEF1) 3.9 3.9
Angiopoietin-like 4 (FIAF) 3.8 4.0
MCP-1 (CCL 13) -3.8 -3.7
Il-6 2.9 -
Malonyl CoA/AMPK signaling:
Malonyl-CoA decarboxylase 3.1 2.5
Others
Lipoprotein lipase (LPL) 4.1 3.7
CD36 10.2 10.0
Hormone-sensitive lipase (HSL) 7.4 5.7
Lipase, member H 2.4 -
Apolipoprotein C-II 2.1 -
Apolipoprotein B editing complex 1 (Apobec1) 2.6 2.5
Fatty acid desaturase 1 2.4 2.5
Low density lipoprotein receptor 2.6 2.9
Low density lipoprotein-related protein 1 2.9 2.6
Methylmalonyl-Coenzyme A mutase 2.2 2.2
Fatty acid binding protein 4, adipocyte (aP2) 10.1 9.4
Adipose differentiation-related protein (ADRP) 6.6 5.5
Nuclear receptor signaling
PPARa 2.2 -
RXRa 2.0 -
NCOR2 -2.3 -
PGC-1a 2.1 2.1
PGC-1b 6.8 5.8
LXRa 4.9 3.8
ERRa 2.6 2.3
NR2F1(COUP TF1) -3.3 -2.0
Citrate cycle
 aconitase 1, soluble 3.2 2.8
 aconitase 2, mitochondrial 3.7 3.1
 citrate synthase 5.1 4.6
 fumarate hydratase 2.4 2.2
 isocitrate dehydrogenase 3 (NAD+) alpha 6.8 6.2
 isocitrate dehydrogenase 3 (NAD+) gamma 2.4 2.2
 malate dehydrogenase 1, NAD (soluble) 4.2 3.7
 malate dehydrogenase 2, NAD (mitochondrial) 2.6 2.3
 oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) 2.9 2.6
 pyruvate carboxylase 4.3 4.6
 succinate dehydrogenase complex, subunit A 2.6 2.5
 succinate dehydrogenase complex, subunit B 2.2 2.2
 succinate dehydrogenase complex, subunit D 2.7 2.3
 succinate-CoA ligase, ADP-forming, beta subunit 2.8 2.7
 succinate-CoA ligase, GDP-forming, alpha subunit 2.8 2.6
Specifically regulated by Rosiglitazone
Regulated by Rosiglitazone and MEHP but at significantly higher levels by Rosiglitazone
HADHA= hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-
Coenzyme A thiolase/enoyl-Coenzyme A hydratase, alpha subunit
Ketone body metabolism
Carbohydrate metabolism Rosi vs V MEHP vs V
Glycolysis: (fold change) (fold change)
Hexokinase 2 7.2 6.8
Glucose phosphate isomerase 1 4.8 4.5
Phosphofructokinase 4.4 5.2
Fructose-bisphosphate Aldolase A 3.6 3.6
Fructose-bisphosphate Aldolase B 2.5 2.4
Fructose-bisphosphate Aldolase C 7.0 5.0
Triosephosphate isomerase 1 3.5 3.3
Phosphoglycerate mutase 2 3.0 2.9
Phosphopyruvate hydratase 2.2 2.0
Pyruvate kinase 2.2 2.1
Pyruvate dehydrogenase b 2.8 2.4
Pyruvate dehydrogenase kinase, isoenzyme 1 4.9 4.9
Pyruvate dehydrogenase kinase, isoenzyme 4 9.1 7.1
Phosphoglycerate kinase 4.3 4.2
Glyceraldehyde-3-P dehydrogenase 5.4 4.6
Neoglucogenesis:
PEPCK 1 20.4 18.8
Fructose-1,6-bisphosphatase 1 2.0 -
Fructose-1,6-bisphosphatase 2 2.1 2.1
Pyruvate carboxylase 3.5 3.4
Malate dehydrogenase 1 (soluble) 4.3 3.6
Malate dehydrogenase 1 (mitochondrial) 2.4 2.2
Glycerol-3-phosphate dehydrogenase 1 7.1 5.1
Pentoses phosphate pathway
Glucose-6-Phosphate dehydrogenase 2.1 2.1
Transketolase 2.6 2.4
Transketoalse like 1 2.2 -
Transaldolase I 3.4 2.9
Hexosamine biosynthetic pathway:
Glutamine-fructose-6-phosphate transaminase 1 3.0 2.4
Glucosamine-P N-acétyltransferase 1 2.3 2.9
Glutamine synthase 3.0 -
Insulin signaling:
IRS-2 4.1 3.4
IRS-4 7.5 6.0
Protein tyrosin phosphatase (NS1) 2.1 -
PI3KR1 (phosphoinositide-3-kinase, regulatory subunit 1) -2.1 -
PI3KR2 -2.1 -
AKT1 -2.3 -
Serum/Glucocorticoid regulated kinase -2.7 -2.2
PKC iota 2.1 -
Glut4 12.5 12.8
Synthaxin binding protein 4 -2.7 -
PKAb 4.8 4.5
Lipase hormono-sensible 5.8 7.4
 Oxidative phosphorylation
Complex I:
NADH dehydrogenase 1 alpha subcomplex 10 2.3 2.0
NADH dehydrogenase (ubiquinone) 1 beta subcomplex 9 2.6 2.4
NADH dehydrogenase (ubiquinone) 1 subcomplex 2 2.5 2.3
NADH dehydrogenase (ubiquinone) Fe-S protein 1 2.2 2.0
NADH dehydrogenase (ubiquinone) Fe-S protein 2 2.1 2.0
NADH dehydrogenase (ubiquinone) Fe-S protein 5 2.1 -
NADH dehydrogenase (ubiquinone) Fe-S protein 7 2.5 2.2
NADH dehydrogenase (ubiquinone) flavoprotein 1 2.8 2.6
NADH dehydrogenase (ubiquinone) flavoprotein 2 2.4 2.0
NADH dehydrogenase (ubiquinone) 1 beta subcomplex 5 2.3 2.0
Complex II:
Succinate dehydrogenase complex, subunit A 2.5 2.4
Succinate dehydrogenase complex, subunit B 2.1 2.1
Succinate dehydrogenase complex, subunit C 2.5 2.2
Complex III:
Cytochrome c-1 4.1 3.3
Ubiquinol-cytochrome c reductase core protein I 2.7 2.5
Ubiquinol-cytochrome c reductase core protein II 3.3 2.8
Ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 4.5 3.7
Ubiquinol-cytochrome c reductase hinge protein 2.5 2.1
Complex IV:
Cytochrome c oxidase subunit IV isoform 1 2.4 2.3
Cytochrome c oxidase subunit VIa polypeptide 1 2.6 2.2
Cytochrome c oxidase subunit Vib polypeptide 1 (ubiquitous) 2.3 -
Cytochrome c oxidase subunit VIIa polypeptide 2 (liver) 2.8 2.2
Cytochrome c oxidase subunit 8A (ubiquitous) 2.3 -
ATP synthase:
ATP5A1 2.1 -
ATP5B 2.9 2.7
ATP5C1 2.1 -
ATP5D 2.7 2.3
ATP5F1 2.0 2.0
ATP5G1 2.2 -
Pyrophosphatase (inorganic) 1 8.7 6.1
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Feige et al - Table II
100nM 1µM 10µM 100µM 100nM 1µM 10µM 100µM 100nM 1µM 10µM 100µM
PPARγ 1.0 1.0 1.1 1.0 2.2 2.6 1.6 2.9 0.5 0.5 0.9 0.6
GyK 1.4 1.9 1.0 1.7 13.2 10.7 1.6 6.5 3.9 4.5 1.1 2.2
OLR1 0.9 1.0 0.9 1.2 208.6 442.0 3.4 88.3 29.4 38.2 1.7 20.6
ACSBG1 7.4 12.2 1.8 4.7 15.1 27.5 2.3 6.5 7.4 12.2 1.8 4.7
FABP-4/aP2 9.9 23.1 1.2 8.2 22.6 23.8 2.5 20.6 1.9 1.9 1.1 1.8
AdipoQ 8.3 14.0 1.4 4.7 7.4 7.3 2.5 7.4 0.6 0.6 0.9 0.6
CD36/FAT 48.3 119.0 2.4 40.1 17.7 20.5 2.7 21.0 1.0 1.1 0.8 1.1
ACS-1 0.9 1.1 1.1 1.3 13.6 14.5 2.7 13.3 1.2 1.2 1.0 1.2
LPL 1.1 1.3 1.1 1.0 3.8 3.7 2.0 4.4 0.8 0.8 0.9 0.9
ACCβ 1.4 1.3 1.1 1.3 3.1 2.9 1.3 2.6 1.4 1.3 1.1 1.3
C/EBPα 1.4 1.7 1.2 1.5 6.2 6.4 1.9 5.7 N.D. N.D. N.D. N.D.
LXRα 1.8 3.0 1.0 2.1 5.4 6.5 2.4 5.7 0.8 0.8 0.8 0.7
SMRT 0.7 0.8 0.9 0.7 0.8 0.6 1.1 0.7 0.5 0.8 0.9 0.7
FATP 1.3 0.9 1.0 1.1 0.9 1.0 1.2 1.1 N.D. N.D. N.D. N.D.
1 Cells were differentiated with the indicated ligands in the presence of insulin
2 Cells were induced with a differentiation cocktail for 2 days (IBMX / Dexamethasone / Insulin), differentiated for 8 days with insulin and then treated with the indicated ligands
Genes only induced during 
differentiation and in a non-
selective manner
Others
Genes selectively induced during 
and after differentiation
Genes selectively induced before 
differentiation but non-selectively 
induced after differentiation
After differentiation 2
(fold induction over vehicle treatment)
Rosiglitazone MEHP
Before differentiation
(fold induction over vehicle treatment)
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Taqman Gene expression probes
Gene Abbreviation Gene name Species ABI assay ID
Acacb Acetyl-Coenzyme A carboxylase beta mouse Mm01204667_m1
ACS-1 Acyl-CoA synthetase long-chain family member 1 mouse Mm00484217_m1
Acsbg1 Acyl-CoA synthetase bubblegum family member 1 mouse Mm00547366_m1
AdipoQ Adiponectin mouse Mm00456425_m1
C/EBPα CCAAT/enhancer binding protein alpha mouse Mm00514283_s1
FABP-4 / aP2 Adipocyte fatty acid binding protein 4 / aP2 mouse Mm00445880_m1
FAT / CD36 CD36 antigen / fatty acid translocase mouse Mm00432403_m1
FATP / Slc27a1 Long-chain fatty acid transport protein 1 / Solute carrier family 27 member 1 mouse Mm00449511_m1
GyK Glycerol kinase mouse Mm00433907_m1
LPL Lipoprotein lipase mouse Mm00434764_m1
LXRα / NR1H3 Liver X receptor alpha / Nuclear receptor subfamily 1, group H, member 3 mouse Mm00443454_m1
OLR1 Oxidized low density lipoprotein receptor 1 / Lectin-like receptor 1 mouse Mm00454586_m1
PPARγ Peroxisome proliferator activated receptor gamma mouse Mm00440945_m1
SMRT Silencing mediator of retinoid and thyroid receptors/ Nuclear receptor co-repressor 2 mouse Mm00448796_m1
Promoter primers for ChIP
Gene Abbreviation Gene name Species Sequence (5'-> 3')
Forward TGCTGAATTATTGTCCTTACCC
Reverse TTCTCTACCAGAGCAAGAGATGG
Forward CATTTGCCTTCTTACTGGATCAGA
Reverse TGGGCTGTGACACTTCCACTAGT
Forward AATCCTAACCACATCTGAACTTTAGCA
Reverse GCTGTCCCGTTGGAATCTGA
Forward CTCTTTCCCCTGCTGTCTGTTT
Reverse CCAGTCATGCTTCATGACCTTTC
Forward ACACATCAGTAGGAAAGCAAGAAA
Reverse TTCCTTTCAAAACCTACATCTTCA
mouseP0
OLR1 Oxidized low density lipoprotein receptor 1 / Lectin-like receptor 1
mouse
GyK Glycerol kinase mouse
mouse
AdipoQ Adiponectin mouse
FABP-4 / aP2 Adipocyte fatty acid binding protein 4 / aP2 
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II.4. Discussion and Perspectives 
 
The lentivirus mediated small interference RNA technique is a valuable tool for the down- 
regulation of different target genes. This technique could be used as a high through put screening 
method for the investigation of protein involvement in different metabolic pathways.  
siRNA’s expression ensures an efficient and relatively easy knock-down of target genes 
without having any effect on other related proteins. Their use is particularly valuable in the absence 
of available knock-out cellular models or of specific inhibitors against the target protein. By their 
expression through lentivirus vectors, siRNAs can be used as a first step tools in the investigation of 
the role of a target protein in different pathways and cellular types. Indeed, by the use of lentivirus 
vectors we were able to transduce several cell types from different species such as mouse, human 
and finally rat. This is of high interest in our laboratory since very often experiments are conducted 
in at least two of the species mentioned above, giving us a certain flexibility in the choice of 
experimental models. Besides their tropism and high diversity in their ability to transduce different 
animal species, the lentivirus vectors ensure the permanent integration of siRNAs in the host 
genome, facilitating the creation of siRNAs expressing cell lines. Moreover, the expression of GFP 
proteins under the EF1α promoter by the same vector expressing the siRNAs, ensure the tracing of 
infected cells, their sorting when convenient and the measurement of the percentage of infected cells 
in a given populations. Furthermore, in contrast of other viral vectors, the lentivirus vectors were 
shown to be devoid of immunogenic potential for the host cells or organisms. However, we have to 
keep in mind that infection with lentivirus vectors gives populations of heterogeneous infected cells 
where the lentivirus genome can be integrated at different sites from one cell to another. Moreover, 
the number of integration sites might be also variable from one cell to another. The integration 
numbers can have a repercussion on the expression of endogenous genes, which served as 
integration site for the lentivirus. 
As shown here, the siPPARβ was used successfully to decipher the role of this receptor in 
the embryonic death observed in the PPARβ-/- mice. siPPARβ lentivirus mediated expression 
allows an efficient infection of the rat Rcho-1 trophoblast. Their infection with siPPARβ inhibits  
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their differentiation into giant cells, which play a major role in placental development. Moreover, 
the use of this cellular model allowed the exploration of the pathway by which PPARβ is involved 
in their differentiation. We were able to show that PPARβ is involved in the control of the activity 
of several proteins from the Akt pathway as well as the expression of adipose differentiation related 
protein (ADRP) important for the lipid droplet accumulation in giant cells. In the future, using 
siRNA mediated knock-down of these proteins we could point out their role in the giant cell 
differentiation. Besides, the knock-down of ADRP could give us a hint on the role of lipid droplet 
accumulation in the giant cells during embryogenesis.  
3T3L1 cells are often used as a suitable model for the in vitro adipocyte differentiation. The 
pertinence of this model was well proved during the last years. Infection of 3T3L1 cells with 
lentivirus vector expressing siPPARγ is an important tool when studying adipocyte differentiation. 
As showed in section Results II.3.3.2., the use of  siPPARγ in 3T3L1 cells proved that the 
adipogenic effect of phthalate plasticizers (such as Mono Ethyl Hexyl Phthalate and of its active 
metabolite Di Mono Ethyl Hexyl Phthalate) was PPARγ specific, since knock-down of this receptor 
blocked the adipocyte differentiation.  
Future experiments using this powerful technique will certainly allow us to decipher other 
pathways controlled by PPAR members in metabolism but also in other cellular functions such as 
cancer, angiogenesis, tissue repair, inflammation and many others.  
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The metabolic syndrome incorporates into a single entity, insulin resistance and its 
associate cluster of cardiovascular risk factors including type 2 diabetes, hypertension, 
dyslipidemia and central obesity. Various hypotheses have been used to explain the interaction 
between genetic, intrauterine and environmental factors leading to this syndrome. Current 
interest addresses the role of the white adipose tissue in the development of metabolic diseases. 
As shown in the introduction, the white adipose is not considered solely as a fat storage 
compartment anymore. In the past years, several studies have shown its involvement in the 
whole body homeostasis, especially in the development of the metabolic syndrome related 
diseases. Beside its role in fat storage, the WAT was shown to produce and secrete several 
hormones, called adipokines. These adipokines can regulate the metabolism in several target 
tissues such as the brain, the skeletal muscle, the liver or WAT itself. Deregulation of its 
functions, such as observed during obesity or lipodystrophy produces a low grade inflammatory 
state, which was shown to be highly responsible for many metabolic related diseases.  
PPARγ is involved in the development and survival of WAT. Moreover, PPARγ agonists 
such as the TZDs, are potent drugs against type 2 diabetes suggesting that modulation of its 
activity, especially in the white adipose tissue, could have a positive outcome on the treatment of 
type 2 diabetes and of related diseases. Confusion came from the observation that PPARγ +/- 
mice had a better sensitivity to insulin that their wild type counterparts when the mice were 
under a HFD. Several authors define this observation as the PPARγ paradox, where its activation 
or inhibition could have the same beneficial effects. The idea of using PPARγ inhibitors as 
therapeutic drugs lacking the secondary effects observed with the TZDs, emerged from these 
observations.  
Our observations on the PPARγ +/- mice are in disagreement with this proposal. PPARγ +/- male 
mice on SD feature a decrease in their metabolic rate and physical activity. This systemic 
metabolic deregulation was linked for the first time to a deregulation of several metabolic 
pathways in WAT and to PPARγ activity in the same tissue. To our surprise, not only the lipid 
storage was down-regulated by a decrease in PPARγ expression and activity. Moreover, genes 
implicated in the energy production such as those involved in glycolysis and lipolysis were 
down-regulated in the mutant WAT, creating an energetic deficit in this tissue. This deficiency 
had as a repercussion in the down-regulation of the systemic metabolic rate and of the physical 
activity.  
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Our experiments revealed for the first time the importance of a subtle regulation of 
PPARγ activity in WAT in normal diet conditions and questioned the use of PPARγ antagonist 
as target drugs for the treatment of metabolic related diseases. Our additional results are in 
agreement with these findings since down-regulation by half of PPARγ levels in WAT was 
linked to a deregulation of the detoxification pathway and an increase of the inflammatory 
reaction in this tissue. The low grade inflammation of WAT was already associated with 
metabolic disorders as described in the introduction. However, our results further demonstrate 
that not only the presence or absence of PPARγ could be involved in this inflammation, but the 
levels of its activity are also of high interest. Moreover, besides its role in metabolism of WAT, 
PPARγ  was also shown to be involved in the development of the adipose tissue. Our results 
showed that PPARγ +/- mice have smaller and less fully diferentiated adipocytes.  
However, several questions remain open. For instance, we cannot completely exclude the 
hypothesis that other organs such as the small intestine could be involved in the reduced physical 
activity and metabolic rate observed in the PPARγ +/- WAT. Moreover, it is possible that the 
metabolic deregulations observed in the PPARγ +/- WAT could be a consequence of an 
incomplete adipocyte differentiation, which was observed in the PPARγ +/- WAT. Specific 
deletion of one PPARγ allele in WAT using a Cre system under a mature adipocyte specific 
promoter (aP2) could help to address this question.  
Furthermore, the lentivirus mediated siRNA system, which was set up in our laboratory is 
a useful method to study the metabolic pathways in freshly isolated mature adipocytes. It can 
also be used in the future, to explore new aspects of the involvement of PPARγ (and of other 
PPAR isotypes) in different cellular types where PPARγ was shown to be involved, such as in 
hepatocytes, myocytes, macrophages, renal cells, intestinal derived cells and other. Furthermore, 
it can also be a powerful technique for the rapid screening of the effect of different specific 
PPARγ modulators (SPARγMs) on the metabolic pathways. We believe that SPARγMs 
utilisation should be a better alternative for the treatment of metabolic syndrome diseases. High 
throughput in vitro screening of their metabolic effect in different cell types in presence or 
absence of PPARγ could facilitate the 
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discovery of new molecules. Secondly, by using co-culture experiments of siPPARγ infected 
adipocytes with hepatocytes or muscle cells (in which we also can modulate PPARs expression), 
we can test whether  these alterations in the WAT metabolism affects directly  the physiological 
functions of liver and muscle and whether PPARs participate in these responses.  
 Thus, from the PPARγ action in WAT to its actions in other target tissues many aspects 
remains to be unveiled. 
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